

CITATION REPORT

List of articles citing

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

DOI: 10.1176/ajp.2006.163.11.1905

American Journal of Psychiatry, 2006, 163, 1905-17.

Source: <https://exaly.com/paper-pdf/41262666/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2280	Management commentary: What would Hippocrates do?. 269-277		
2279	Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. <i>American Journal of Psychiatry</i> , 2007 , 164, 739-52	11.9	246
2278	Treatment resistant depression--advances in somatic therapies. 2007 , 19, 279-87		58
2277	Keeping our depressed patients in the right treatment long enough for them to get better: some hopeful findings. <i>American Journal of Psychiatry</i> , 2007 , 164, 1136-9	11.9	1
2276	A randomized controlled clinical trial comparing "guideline exposed" and "guideline naive" physicians in respect to dosage selection and treatment outcome with doxepin in depressive disorders. 2007 , 40, 77-81		11
2275	Efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. 2007 , 2, 361-371		1
2274	Selegiline transdermal system in the treatment of depressive disorders. 2007 , 2, 601-611		1
2273	Obsessive-Compulsive Disorder: An Update for the Clinician. 2007 , 5, 299-313		2
2272	Rebuttal: Depression is Not a Brain Disease. 2007 , 52, 100-101		3
2271	Psychopharm Review: CME QUIZ. 2007 , 42, 50		1
2270	Regulation of corticolimbic reactivity via the 5-HT1Aautoreceptor in the pathophysiology and treatment of depression. 2007 , 2, 121-124		2
2269	What does Star*D tell us about ECT?. 2007 , 23, 1-2		4
2268	Help-seeking and access to mental health care in a university student population. 2007 , 45, 594-601		612
2267	Current world literature. Neonatology and perinatology. 2007 , 19, 230-7		
2266	The Use and Clinical Significance of Transcranial Magnetic Stimulation in the Treatment of Major Depression. 2007 , 42, 43-49		4
2265	Unraveling anxiety and depression. 2007 , 32, 28-36; CEU quiz 36-7		1
2264	STAR*D: what have we learned?. <i>American Journal of Psychiatry</i> , 2007 , 164, 201-4	11.9	250

2263	Medical treatment of opiate dependence: expanding treatment options. <i>American Journal of Psychiatry</i> , 2007 , 164, 702-4	11.9	4
2262	High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder. 2007 , 22 Suppl 2, S21-5		25
2261	Le destin de l' episode d' pressif. 2007 , 33, 709-712		1
2260	P.2.a.006 Korean medication algorithm for depressive disorder 2006(I). 2007 , 17, S314-S315		5
2259	P.2.a.007 Beta-adrenergic receptor responsiveness may predict treatment response in panic disorder. 2007 , 17, S315-S316		
2258	The road to recovery from depression--don't drive today with yesterday's map. 2007 , 76, 260-5		84
2257	Bipolar II disorder : epidemiology, diagnosis and management. 2007 , 21, 727-40		88
2256	Navigating the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study: practical outcomes and implications for depression treatment in primary care. 2007 , 34, 505-19, vi		40
2255	Somatic therapies for treatment-resistant depression: new neurotherapeutic interventions. 2007 , 30, 31-7		18
2254	Somatoform disorders and recent diagnostic controversies. 2007 , 30, 593-619		42
2253	Cognitive and behavioral therapies for depression: overview, new directions, and practical recommendations for dissemination. 2007 , 30, 39-50		32
2252	A critical overview of the pharmacologic management of treatment-resistant depression. 2007 , 30, 13-29		33
2251	Depressive disorder needs an evidence base commensurate with its public health importance. 2007 , 52, 543-4		2
2250	Augmentation strategies in the treatment of major depressive disorder. Recent findings and current status of augmentation strategies. 2007 , 12, 6-9		39
2249	An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. 2007 , 22, 986-91		43
2248	Is the Dx for welfare Rx?. 2007 , 81, 624-6		
2247	Sequential treatment of depression in primary care. 2007 , 61, 1719-29		5
2246	Stepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP) study: design and practical implications of an intervention for comorbid pain and depression. 2007 , 29, 506-17		73

2245	[Brain stimulation methods for resistance to therapy]. 2007 , 78 Suppl 3, 575-81; quiz 582-3	1
2244	The STAR*D Project results: a comprehensive review of findings. 2007 , 9, 449-59	443
2243	The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. 2007 , 9, 467-74	175
2242	STEP-BD and bipolar depression: what have we learned?. 2007 , 9, 497-503	37
2241	The history and future of deep brain stimulation. 2008 , 5, 3-13	81
2240	Mental health and well-being in a 6-year follow-up of patients with depression: assessments of patients and clinicians. 2008 , 43, 688-96	41
2239	Treatment-resistant depression: critique of current approaches. 2008 , 42, 751-62	42
2238	Bipolar disorder: candidate drug targets. 2008 , 75, 226-47	42
2237	Major depression: emerging therapeutics. 2008 , 75, 204-25	37
2236	Neurostimulatory therapeutics in management of treatment-resistant depression with focus on deep brain stimulation. 2008 , 75, 263-75	13
2235	Treatment options in depression: past, present and future. 2008 , 19, 9-10	
2234	Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. 2008 , 117, 253-9	95
2233	Acute and continuation therapy in unipolar depression: observations from the run-in phase of a maintenance trial. 2008 , 118, 123-9	3
2232	The implications of gene-environment interactions in depression: will cause inform cure?. 2008 , 13, 1070-8	109
2231	Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. 2008 , 7, 426-37	633
2230	Redefining affective disorders: relevance for drug development. 2008 , 14, 2-9	9
2229	Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. 2008 , 10, 957-68	98
2228	Upping the ante on antidepressants. 2008 , 10, 975-8	3

2227	Clinical problems in the long-term care of patients with chronic depression. 2008 , 62, 689-97	18
2226	Mood disorders: regulation by metabotropic glutamate receptors. 2008 , 75, 997-1006	152
2225	Does early response predict outcome in psychotherapy and combined therapy for major depression?. 2008 , 105, 261-5	28
2224	The effectiveness of carbamazepine in unipolar depression: a double-blind, randomized, placebo-controlled study. 2008 , 109, 91-7	19
2223	Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. 2008 , 110, 1-15	112
2222	Prospective assessment of stereotactic ablative surgery for intractable major depression. 2008 , 64, 449-54	74
2221	Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. 2008 , 8, 1787-97	13
2220	Use of antidepressants in late-life depression. 2008 , 25, 841-53	33
2219	Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. 2008 , 22, 343-96	341
2218	Impact of pain on the outcomes of depression treatment: results from the RESPECT trial. 2008 , 134, 209-15	112
2217	Aripiprazole as an adjunctive treatment for refractory unipolar depression. 2008 , 32, 744-50	19
2216	Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. 2008 , 13 Suppl 1, S1-29	161
2215	Methods for testing theory and evaluating impact in randomized field trials: intent-to-treat analyses for integrating the perspectives of person, place, and time. 2008 , 95 Suppl 1, S74-S104	140
2214	P.2.c.011 An open study of quetiapine augmentation in treatment resistant depression. 2008 , 18, S330-S331	
2213	P.2.c.012 Serotonin transporter promoter polymorphism does not influence treatment response to escitalopram in depression. 2008 , 18, S331	
2212	P.2.c.013 Comparative efficacy of the antidepressants agomelatine, venlafaxine and sertraline. 2008 , 18, S331-S332	5
2211	P.2.c.014 Tansospirone augmentation therapy is useful in depressed patients with inadequate response to SSRIs or SNRIs. 2008 , 18, S332	
2210	P.2.c.015 The effect of paroxetine on amygdala reactivity after emotional faces measured with fMRI. 2008 , 18, S332-S333	

2209	C.22.02 How have observational studies in bipolar disorder furthered the field?. 2008 , 18, S613	
2208	C.22.03 Long-term treatment of bipolar disorder: making sense of RCTs and observational studies. 2008 , 18, S613	
2207	C.23.01 Remission as the goal of antidepressant therapies: where are we today?. 2008 , 18, S613	
2206	C.23.02 Remission: the expectations of both doctors and patients. 2008 , 18, S613-S614	
2205	Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders. 2008 , 172, 213-30	35
2204	Riluzole in the treatment of mood and anxiety disorders. 2008 , 22, 761-86	121
2203	Paroxetine. 2008 , 9, 787-94	24
2202	What is functional about functional autonomy?. 2008 , 90, 412-20	3
2201	Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. 2008 , 40, 149-59	71
2200	Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms. 2008 , 37, 714-24	47
2199	Current Status and Future Prospects of Clinical Psychology: Toward a Scientifically Principled Approach to Mental and Behavioral Health Care. 2008 , 9, 67-103	196
2198	Craft and science in the treatment of traumatized people. 2008 , 9, 293-300	2
2197	Antidepressants and Cdk inhibitors: releasing the brake on neurogenesis?. 2008 , 7, 2321-6	11
2196	Mindfulness-based cognitive therapy for treatment-resistant depression: a pilot study. 2008 , 77, 319-20	108
2195	[Sailing against the wind]. 2008 , 15, 184-6	2
2194	Current evidence for aripiprazole as augmentation therapy in major depressive disorder. 2008 , 8, 1435-47	8
2193	Addressing circadian rhythm disturbances in depressed patients. 2008 , 22, 13-8	14
2192	Vagus nerve stimulation for depression: efficacy and safety in a European study. 2008 , 38, 651-61	139

2191	Management of depression in adults. 2008 , 336, 435-9		45
2190	Remission in depression--is it a realistic goal?. 2008 , 62, 421-2		1
2189	Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. 2008 , 33, 2810-9		89
2188	Depression and heart disease: therapeutic implications. 2008 , 111, 75-81		30
2187	Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. 2008 , 20, 209-18		45
2186	Continuation and maintenance use of antidepressants in recurrent depression. 2008 , 77, 17-26		90
2185	Treatment-emergent hypomania or mania with modafinil. <i>American Journal of Psychiatry</i> , 2008 , 165, 134-5; author reply 135	11.9	11
2184	Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. 2008 , 299, 901-913		422
2183	The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. 2008 , 28, 156-65		335
2182	Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype. 2008 , 11, 727-8		6
2181	The STAR*D trial: the 300 lb gorilla is in the room, but does it block all the light?. 2008 , 11, 97-9		4
2180	STAR*D: have we learned the right lessons?. <i>American Journal of Psychiatry</i> , 2008 , 165, 133; author reply 133-4	11.9	6
2179	Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. 2008 , 11, 685-99		46
2178	Estimating the potential savings with vagus nerve stimulation for treatment-resistant depression: a payer perspective. 2008 , 24, 2203-17		8
2177	Changing tides in neurosurgical interventions for treatment-resistant depression. <i>American Journal of Psychiatry</i> , 2008 , 165, 671-4	11.9	1
2176	Bringing a research base to psychiatry. 2008 , 178, 1257-60		1
2175	Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. <i>American Journal of Psychiatry</i> , 2008 , 165, 1136-47	11.9	146
2174	Developing the evidence for evidence-based practice. 2008 , 178, 1313-5		4

2173	Genetic regulation of behavioral and neuronal responses to fluoxetine. 2008 , 33, 1312-22	71
2172	Desvenlafaxine succinate for the treatment of major depressive disorder. 2008 , 9, 2129-36	5
2171	Etablir une base de recherche en psychiatrie. 2008 , 178, 1259-1260	78
2170	Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy. 2008 , 65, 447-55	28
2169	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. 2008 , 6, 104-119	
2168	Patient Management Exercise: Major Depressive Disorder and Suicide. 2008 , 6, 47-57	
2167	Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. 2008 , 76, 459-67	44
2166	Decreased usage of electroconvulsive therapy: implications. 2008 , 192, 476	6
2165	Triple reuptake inhibitors: the next generation of antidepressants. 2008 , 6, 338-43	47
2164	Dr. Rush Replies. <i>American Journal of Psychiatry</i> , 2008 , 165, 133-134	11.9 2
2163	Research on depression in the workplace: where do we go from here?. 2008 , 50, 492-500	13
2162	A holistic approach to severe depression: my story. 2008 , 22, 81-6	2
2161	An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. 2008 , 28, 631-7	384
2160	Neuromodulation. 2008 , 13, 370-378	
2159	Journal Club. 2008 , 15, 105-112	
2158	Augmentation treatment in major depressive disorder: focus on aripiprazole. 2008 , 4, 937-48	34
2157	Psychopharmacology. 2009 ,	
2156	Commentary. 2009 , 14, 8-8	3

2155	Introduction and Clinical Presentations. 2009 , 14, 4-6	4
2154	Deep brain stimulation: Methods, indications, locations, and efficacy. 556-572	
2153	Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. 2009 , 5, 369-83	13
2152	Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability. 2009 , 5, 897-910	21
2151	[Review of the guidelines of the Brazilian Medical Association for the treatment of depression (Complete version)]. 2009 , 31 Suppl 1, S7-17	48
2150	Managing depression in primary care: it's not only what you do it's the way that you do it. 2009 , 59, 76-8	5
2149	Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. 2009 , 4, e4824	129
2148	Handbook of Depression. 2009 ,	
2147	Commentary on STAR*D: a summary and UK perspective. 2009 , 23, 615-7; discussion 622-4	
2146	Commentary on STAR*D: a summary and UK perspective. 2009 , 23, 613-4; discussion 622-4	2
2145	Pharmacotherapy of postpartum depression. 2009 , 10, 2593-607	27
2144	Acid-sensing ion channel-1a in the amygdala, a novel therapeutic target in depression-related behavior. 2009 , 29, 5381-8	117
2143	Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. 2009 , 10, 2145-59	15
2142	On Chemical Imbalances, Antidepressants, and the Diagnosis of Depression. 2009 , 11, 199-214	4
2141	Brief intervention for anxiety in primary care patients. 2009 , 22, 175-86	31
2140	Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. 2009 , 59, 227-33	27
2139	Meta-Analysis of Antidepressant Augmentation: Piling on in the Absence of Evidence. 2009 , 11, 171-182	2
2138	Comparison of a phased experimental approach and a single randomized clinical trial for developing multicomponent behavioral interventions. 2009 , 6, 5-15	48

2137	Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder. 2009 , 43, 956-967		8
2136	A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. 2009 , 66, 966-975		259
2135	The Structure of the Lived Experience for Persons Having Undergone rTMS for Depression Treatment. 2009 , 15, 333-7		9
2134	The decline of pharmaceutical psychiatry and the increasing role of psychological medicine. 2009 , 78, 220-7		21
2133	Identifying risk for attrition during treatment for depression. 2009 , 78, 372-9		20
2132	Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression. 2009 , 12, 1033-44		35
2131	Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. 2009 , 29, 327-33		61
2130	The 5-HT1B receptor: a novel target for the pathophysiology of depression. 2009 , 10, 1118-38		63
2129	Impact of ovarian hormones on the modulation of the serotonin transporter by fluvoxamine. 2009 , 34, 555-64		33
2128	Publication bias and the efficacy of antidepressants. <i>American Journal of Psychiatry</i> , 2009 , 166, 140-5	11.9	46
2127	Treatment-resistant depression and mortality after acute coronary syndrome. <i>American Journal of Psychiatry</i> , 2009 , 166, 410-7	11.9	116
2126	Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. 2009 , 66, 729-37		184
2125	Psychiatrische Indikationen für die tiefe Hirnstimulation. 2009 , 36, S24-S26		
2124	Recent Advances in Pharmacotherapy. 2009 , 22, 446-466		
2123	NAPSAQ-1: National Patient Sleep Assessment Questionnaire in depression. 2009 , 13, 48-58		13
2122	Transcranial Magnetic Stimulation (TMS): An Entirely Novel Form of Treatment in Psychiatry and a Groundbreaking Opportunity for Psychiatric Mental Health Nursing. 2009 , 15, 299-302		0
2121	When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. 2009 , 34, 2227-36		70
2120	Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. 2009 , 301, 2099-110		311

2119	Report of the Indo-US health care summit 2009 - Mental health section. 2009 , 51, 292-301	3
2118	Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. <i>American Journal of Psychiatry</i> , 2009 , 166, 980-91	11.9 415
2117	New approaches to the pharmacological management of major depressive disorder. 2009 , 57, 347-79	11
2116	Commentary on STAR*D: a summary and UK perspective. 2009 , 23, 618-9; discussion 622-4	1
2115	STAR*D: has it taught us anything about the management of depression?. 2009 , 17, 360-4	5
2114	Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. 2009 , 14, 197-206	207
2113	Ketamine and the next generation of antidepressants with a rapid onset of action. 2009 , 123, 143-50	209
2112	Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. 2009 , 43, 215-29	142
2111	A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. 2009 , 43, 205-14	80
2110	Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. 2009 , 34, 1208-13	57
2109	Are guidelines in need of CPR? The development of clinical practice recommendations (CPR). 2009 , 119, 5-7	15
2108	Clinical practice recommendations for depression. 2009 , 119, 8-26	71
2107	Psychosocial stress and anxiety in musculoskeletal pain patients with and without depression. 2009 , 31, 116-22	43
2106	The Indiana Cancer Pain and Depression (INCPAD) trial Design of a telecare management intervention for cancer-related symptoms and baseline characteristics of study participants. 2009 , 31, 240-53	57
2105	Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?. 2009 , 115, 234-40	17
2104	Eighteen months of drug treatment for depression: predicting relapse and recovery. 2009 , 114, 263-70	24
2103	Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. 2009 , 115, 439-49	125
2102	What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. 2009 , 116, 4-11	194

2101	Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic. 2009 , 117, 18-23	24
2100	Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study. 2009 , 118, 94-100	40
2099	ETHICAL CONSIDERATIONS FOR COGNITIVE-BEHAVIORAL THERAPISTS IN PSYCHOTHERAPY RESEARCH TRIALS. 2009 , 16, 153-163	5
2098	Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. 2009 , 26, 83-97	76
2097	Antidepressants, Psychotherapy or their Combination: Weighing Options for Depression Treatments. 2009 , 39, 83-91	7
2096	Just How Effective are Antidepressant Medications? Results of a Major New Study. 2009 , 39, 93-100	2
2095	The Sequential Combination of Pharmacotherapy and Psychotherapy in Mood Disorders. 2009 , 39, 101-109	9
2094	Translating evidence to practice: two stories from the field. 2009 , 16, 47-57	21
2093	Does concomitant antidepressant therapy enhance response to electroconvulsive therapy?. 2009 , 11, 423-5	
2092	Changes in how health plans provide behavioral health services. 2009 , 36, 11-24	22
2091	Primary care physicians treat somatization. 2009 , 24, 829-32	36
2090	Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis. 2009 , 26, 346-68	57
2089	[Affective disorders. The significance of psychotherapeutic approaches]. 2009 , 80, 540, 542-4, 546-8 passim	9
2088	Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. 2009 , 206, 335-44	38
2087	Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder. 2009 , 18, 965-72	5
2086	Managing high-acuity-depressed adults in primary care. 2009 , 21, 362-70	2
2085	Lithium specificity in bipolar illness: a classic agent for the classic disorder. 2009 , 11 Suppl 2, 34-44	79
2084	CRH signaling. Molecular specificity for drug targeting in the CNS. 2009 , 1179, 106-19	49

2083	Physical exercise and depression. 2009 , 76, 204-14	51
2082	Treatment of depression with transcranial direct current stimulation (tDCS): a review. 2009 , 219, 14-9	332
2081	Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. 2009 , 219, 36-43	41
2080	Treatment resistant depression as a failure of brain homeostatic mechanisms: implications for deep brain stimulation. 2009 , 219, 44-52	80
2079	5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. 2009 , 167, 97-105	23
2078	Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. 2009 , 65, 267-75	661
2077	Escitalopram in the treatment of major depressive disorder: a meta-analysis. 2009 , 25, 161-75	100
2076	The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis. 2009 , 32, 1159-73	27
2075	Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials. 2009 , 78, 172-81	131
2074	Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. 2009 , 34, 522-34	219
2073	Determinants of direct cost differences among US employees with major depressive disorders using antidepressants. 2009 , 27, 507-17	22
2072	Utility of atypical antipsychotics in the treatment of resistant unipolar depression. 2009 , 23, 369-77	34
2071	STAR*D: revising conventional wisdom. 2009 , 23, 627-47	172
2070	Antidepressant treatment patterns and costs among US employees. 2009 , 12, 36-45	2
2069	The role of efficacy and effectiveness trials. 2009 , 8, 34-5	5
2068	The primacy of mania: a reconsideration of mood disorders. 2009 , 24, 125-34	41
2067	P.2.c.044 Developing guidelines for the treatment of resistant unipolar depression across primary and secondary care. 2009 , 19, S428-S429	
2066	P.2.c.045 Outcome of escitalopram treatment based on baseline severity of depression. 2009 , 19, S429	

2065	Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. 2009 , 48, 186-95	124
2064	Predictors of attrition during one year of depression treatment: a roadmap to personalized intervention. 2009 , 15, 113-24	22
2063	Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. 2009 , 24, 133-8	72
2062	The role of L-methylfolate in depressive disorders. 2009 , 14, 2-7	36
2061	[Diagnosis and therapy of depression in family practice]. 2009 , 150, 1684-93	3
2060	Long-term management of depression: tips for adjusting the treatment plan as the patient's needs change. 2009 , 70 Suppl 6, 32-7	5
2059	Future drugs for the treatment of depression: the need to look beyond monoamine systems. 2009 , 14, 14-6	4
2058	Continuation-phase cognitive therapy's effects on remission and recovery from depression. 2009 , 77, 367-71	26
2057	Prescriptive authority and psychology: a status report. 2009 , 64, 257-68	20
2056	Catatonia: a syndrome appears, disappears, and is rediscovered. 2009 , 54, 437-45	44
2055	Screening for depression in adult patients in primary care settings: a systematic evidence review. 2009 , 151, 793-803	174
2054	Novel treatments for major depressive disorder. 2009 , 14, 11-3	6
2053	Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. 2009 , 14, 299-313	101
2052	The role of residual symptoms in nonadherence to treatment. 2009 , 14, 3-5	2
2051	Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. 2009 , 194, 252-9	150
2050	Opiates as antidepressants. 2009 , 15, 1612-22	82
2049	Childhood sexual abuse is associated with physical illness burden and functioning in psychiatric patients 50 years of age and older. 2009 , 71, 417-22	39
2048	Expectancy and the Treatment of Depression: A Review of Experimental Methodology and Effects on Patient Outcome. 2010 , 6, 1-10	86

2047	Two-year outcome of vagus nerve stimulation in treatment-resistant depression. 2010 , 30, 273-81	110
2046	The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. 2010 , 55, 126-35	199
2045	Atypical antipsychotics may be useful as adjuncts to antidepressant therapy in treatment-resistant depression. 2010 , 26, 17-20	
2044	S-adenosyl methionine (SAME) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. <i>American Journal of Psychiatry</i> , 2010 , 167, 942-8	11.9 229
2043	Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. 2010 , 30, 135-44	79
2042	Transcranial Magnetic Stimulation for the Treatment of Major Depression. 2010 , 45, 57-66	2
2041	A comparison of desipramine response in younger and older women. 2010 , 30, 80-2	2
2040	Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States. 2010 , 52, 115-24	12
2039	Antidepressants work, sort of--our system of care does not. 2010 , 30, 101-4	6
2038	Escitalopram versus placebo in the treatment of dysthymic disorder. 2010 , 25, 143-8	8
2037	MRP1 polymorphisms associated with citalopram response in patients with major depression. 2010 , 30, 116-25	28
2036	Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression. 2010 , 30, 748-51	19
2035	Transcranial Magnetic Stimulation for the Treatment of Major Depression. 2010 , 45, 25-30	3
2034	Transcranial Magnetic Stimulation for the Treatment of Major Depression. 2010 , 45, 32	
2033	A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole. 2010 , 30, 300-5	11
2032	Treatment response in major depression: effects of personality dysfunction and prior depression. 2010 , 196, 139-42	51
2031	Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. 2010 , 15, 79-94	28
2030	Antenatal depression and anxiety affect postpartum parenting stress: a longitudinal, prospective study. 2010 , 55, 222-8	71

2029	Diabetes and Depression: Management in Ordinary Clinical Conditions. 2010 , 109-141	1
2028	Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials. 2010 , 8, 570-582	2
2027	Separating hope from hype: some ethical implications of the development of deep brain stimulation in psychiatric research and treatment. 2010 , 15, 285-7	21
2026	Autonomous and controlled motivation and interpersonal therapy for depression: moderating role of recurrent depression. 2010 , 49, 529-45	27
2025	[The development of deep brain stimulation as a putative treatment for resistant psychiatric disorders]. 2010 , 81, 696-701	4
2024	[Evidence-based therapy of depression: S3 guidelines on unipolar depression]. 2010 , 81, 1049-68	28
2023	A critical review of human endotoxin administration as an experimental paradigm of depression. 2010 , 34, 130-43	124
2022	Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. 2010 , 260, 145-50	27
2021	Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. 2010 , 260, 25-39	31
2020	Pharmakotherapie der Depression bei Menschen mit Diabetes. 2010 , 6, 280-286	
2019	Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. 2010 , 44, 32-41	55
2018	Update on deep brain stimulation for neuropsychiatric disorders. 2010 , 38, 346-53	52
2017	[Impact of morbidity, resource use and costs on maintenance of remission of major depression in Spain: a longitudinal study in a population setting]. 2010 , 24, 13-9	20
2016	Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. 2010 , 120, 133-40	30
2015	History of suicide attempts among patients with depression in the GENDEP project. 2010 , 123, 131-7	16
2014	Relationship between TSH levels in the normal range and short-term duloxetine efficacy. 2010 , 123, 312-6	5
2013	Relief of chronic or resistant depression (Re-ChORD): a pragmatic, randomized, open-treatment trial of an integrative program intervention for chronic depression. 2010 , 123, 243-8	16
2012	Unveiling patterns of affective responses in daily life may improve outcome prediction in depression: a momentary assessment study. 2010 , 124, 191-5	107

2011	Predictors of efficacy in lithium augmentation for treatment-resistant depression. 2010 , 125, 165-8	24
2010	Impairment in psychosocial functioning associated with dysthymic disorder in the NESARC study. 2010 , 127, 84-8	25
2009	Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression?. 2010 , 127, 10-8	65
2008	Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. 2010 , 27, 78-89	257
2007	Major depression: the importance of clinical characteristics and treatment response to prognosis. 2010 , 27, 19-26	67
2006	Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. 2010 , 27, 12-8	40
2005	Randomised controlled trial of the clinical and cost effectiveness of a specialist team for managing refractory unipolar depressive disorder. 2010 , 10, 100	13
2004	The B-VITAGE trial: a randomized trial of homocysteine lowering treatment of depression in later life. 2010 , 11, 8	11
2003	Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. 2010 , 15, 501-11	328
2002	Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. 2010 , 16, 1393-5	133
2001	From BALANCE to DSM-5: taking lithium seriously. 2010 , 12, 673-7	9
2000	. 2010 ,	11
1999	Identifying phenotypes in psychiatry. 2010 , 1, 141	3
1998	The Impact of Residual Symptoms in Major Depression. 2010 , 3, 2426-2440	29
1997	Neuromodulation approaches for the treatment of major depression: challenges and recommendations from a working group meeting. 2010 , 68, 433-51	52
1996	Treatment of Depression in Patients with Diabetes: Efficacy, Effectiveness and Maintenance Trials, and New Service Models. 2010 , 81-107	8
1995	Electroconvulsive Therapy in the General Hospital. 2010 , 433-440	
1994	[Histone acetylation, gene regulation and depression]. 2010 , 26, 465-7	4

1993	Effect of telecare management on pain and depression in patients with cancer: a randomized trial. 2010 , 304, 163-71	219
1992	The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties. 2010 , 335, 762-70	23
1991	Association between repeated unpredictable chronic mild stress (UCMS) procedures with a high fat diet: a model of fluoxetine resistance in mice. 2010 , 5, e10404	141
1990	Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression. 2010 , 40, 415-24	46
1989	Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. 2010 , 26, 223-7	100
1988	Mind, Medications & Mental Disorders. 2010 , 27, 76-83	1
1987	Bases Clínicas para un Nuevo Modelo de Atención a las Psicosis. 2010 , 21, 299-318	
1986	Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. 2010 , 67, 507-16	644
1985	The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. 2010 , 71, 1645-56	72
1984	Antidepressant study design affects patient expectancy: a pilot study. 2010 , 40, 781-8	17
1983	Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences. 2010 , 26, 2757-64	9
1982	Paroxetine mesylate: comparable to paroxetine hydrochloride?. 2010 , 11, 185-93	8
1981	The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. 2010 , 24, 537-46	17
1980	Revoking serotonin's auto license. 2010 , 3, 137-137	1
1979	Therapeutic potential of new second generation antipsychotics for major depressive disorder. 2010 , 19, 1527-44	11
1978	Therapy-resistant depression. 2010 , 10, 77-86	34
1977	Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression. 2010 , 10, 651-70	15
1976	Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder. 2010 , 3, 3522-3542	6

1975	Lithium: a regeneration of interest. 2010 , 31, 753-4		0
1974	Physical exercise as psychotherapeutic strategy: how long? What will it take?. 2010 , 31, 153-4		3
1973	Catch 22: a case of mutually denied chronic depression. 2010 , 18, 238-46		
1972	The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission. 2010 , 24, 21-6		21
1971	Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. 2010 , 13, 71-82		197
1970	Telephone-based mutual peer support for depression: a pilot study. 2010 , 6, 183-91		17
1969	Differential effects of serotonergic and noradrenergic antidepressants on brain activity during a cognitive control task and neurofunctional prediction of treatment outcome in patients with depression. 2010 , 35, 247-57		66
1968	Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. 2011 , 68, 351-60		99
1967	Efficacy and effectiveness of antidepressants: current status of research. 2010 , 79, 267-79		225
1966	Advances in the Management of Treatment-Resistant Depression. 2010 , 8, 488-500		11
1965	Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. <i>American Journal of Psychiatry</i> , 2010 , 167, 782-91	11.9	130
1964	Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats. 2010 , 35, 752-63		109
1963	Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. 2010 , 122, 125-38		6
1962	Deep brain stimulation for treatment-resistant depression. <i>American Journal of Psychiatry</i> , 2010 , 167, 1437-44	11.9	57
1961	Ketamine for Chronic Pain and Treatment Resistant Depression: A Mechanistic Hypothesis. 2010 , 5, 229-249		
1960	Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects. 2010 , 5, 263-6		6
1959	Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. 2010 , 26, 2475-84		76
1958	Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. 2010 , 122, 39-48		128

- 1957 Therapeutic armamentarium for treating depression. **2010**, 122, 66-93 11
- 1956 A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy. **2010**, 85, 538-50 35
- 1955 La terapia elettroconvulsivante nel trattamento della depressione maggiore resistente. **2010**, 29, 140-145
- 1954 La neurostimolazione vagale in Neurologia e Psichiatria. **2010**, 29, 146-157
- 1953 Bilateral epidural prefrontal cortical stimulation for treatment-resistant depression. **2010**, 67, 101-9 76
- 1952 Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. **2010**, 67, 110-6 582
- 1951 Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. **2010**, 68, 785-94 363
- 1950 Therapeutic options for treatment-resistant depression. **2010**, 24, 131-61 141
- 1949 Cost-effectiveness of improved primary care treatment of depression in women in Chile. **2010**, 197, 291-6 12
- 1948 ¿Predice la mejoría precoz inducida por los antidepresivos la respuesta/remisión? Análisis de los datos de un estudio naturalista en una muestra a gran escala de pacientes hospitalizados con depresión mayor. **2010**, 17, 45-53
- 1947 Negative association of concomitant physical symptoms with the course of major depressive disorder: a systematic review. **2010**, 68, 511-9 31
- 1946 Linking the cytokine and neurocircuitry hypotheses of depression: a translational framework for discovery and development of novel anti-depressants. **2010**, 24, 515-24 40
- 1945 Integrating depression and chronic disease care among patients with diabetes and/or coronary heart disease: the design of the TEAMcare study. **2010**, 31, 312-22 82
- 1944 Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. **2010**, 34, 308-12 35
- 1943 Accelerating response to antidepressant treatment in depression: a possible role for atypical antipsychotics. **2010**, 34, 434; author reply 435-6 1
- 1942 Quetiapine XR: current status for the treatment of major depressive disorder. **2010**, 34, 1165-73 37
- 1941 Pramipexole for stage 2 treatment-resistant major depression: an open study. **2010**, 34, 1446-9 28
- 1940 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. **2010**, 65, 40-52 311

1939	From synapse to nucleus: novel targets for treating depression. 2010 , 58, 683-93	79
1938	Correlation between patient and clinician assessments of depression severity in the PREVENT study. 2010 , 177, 177-83	33
1937	P.1.024 Depressive disorder moderates the effect of fat mass and obesity-associated gene (FTO) on body mass index (BMI). 2010 , 20, S21-S22	
1936	P.1.025 Molecular imaging of beta-2 subunit containing nicotinic acetylcholine receptors in major depressive disorder. 2010 , 20, S22	
1935	C.01.01 Bipolar depression: managing hard to treat symptoms. 2010 , 20, S637	
1934	C.01.02 Disease severity and treatment-resistance: unraveling the treatment options in depression. 2010 , 20, S637	
1933	[Major depressive disorder: factors of risk, vulnerability and protection]. 2010 , 36 Suppl 5, S117-22	3
1932	Self-rated residual symptoms do not predict 1-year recurrence of depression. 2010 , 25, 52-7	6
1931	Outcomes of 1014 naturalistically treated inpatients with major depressive episode. 2010 , 20, 346-55	61
1930	Antidepressant Compounds: A Critical Review. 2010 , 1-19	5
1929	An assigned teaching resident rotation. 2010 , 34, 263-8	11
1928	The promise and reality of pharmacogenetics in psychiatry. 2010 , 33, 181-224	24
1927	The diagnosis of mental disorders: the problem of reification. 2010 , 6, 155-79	584
1926	Pharmacogenetic considerations in the treatment of psychiatric disorders. 2010 , 11, 423-39	22
1925	Antidepressant monotherapy and combination of antidepressants in the treatment of resistant depression in current clinical practice: A retrospective study. 2010 , 14, 303-8	3
1924	Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. 2010 , 24, 245-62	20
1923	Translating biomarkers to clinical practice. 2011 , 16, 1076-87	89
1922	Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. 2011 , 25, 109-27	62

1921	Miracle drug, poison, or placebo: patients' experiences with antidepressant medications as described in postings on an online message board. 2011 , 46, 922-30	2
1920	Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. 2011 , 41, 151-62	87
1919	Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. 2011 , 1, 81-7	29
1918	Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. 2011 , 108, 9262-7	216
1917	Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. 2011 , 45, 441-51	15
1916	Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders. 2011 , 27, 1815-26	3
1915	La risposta subottimale al trattamento antidepressivo: definizione e implicazioni cliniche. 2011 , 30, 58-64	
1914	La depressione maggiore resistente: update delle strategie di trattamento farmacologico. 2011 , 30, 106-114	
1913	Work Therapy: Welfare Reform and Mental Health in California. 2011 , 85, 109-133	
1912	Deep-Brain Stimulation for Basal Ganglia Disorders. 2011 , 1, 65-77	58
1911	Convergent animal and human evidence suggests a role of PPM1A gene in response to antidepressants. 2011 , 69, 360-5	28
1910	Mood-linked responses in medial prefrontal cortex predict relapse in patients with recurrent unipolar depression. 2011 , 70, 366-72	89
1909	A critical review of pharmacotherapy for major depressive disorder. 2011 , 14, 1417-31	37
1908	Agomelatine for the treatment of major depressive disorder. 2011 , 12, 2411-9	25
1907	Escitalopram modulates neuron-remodelling proteins in a rat gene-environment interaction model of depression as revealed by proteomics. Part I: genetic background. 2011 , 14, 796-833	19
1906	Deep brain stimulation for psychiatric disorders. 2011 , 34, 289-307	189
1905	Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study. 2011 , 31, 385-405	8
1904	Trigeminal nerve stimulation: seminal animal and human studies for epilepsy and depression. 2011 , 22, 449-56, v	36

1903	The depression market. 2011 , 10, 809-10	17
1902	Management of depression in patients with coronary heart disease: association, mechanisms, and treatment implications for depressed cardiac patients. 2011 , 12, 85-98	21
1901	Electrophysiological Recording Techniques. 2011 ,	6
1900	Sertraline vs. ELectrical Current Therapy for Treating Depression Clinical Trial--SELECT TDCS: design, rationale and objectives. 2011 , 32, 90-8	51
1899	Targeting remission by 8 weeks: when should supplementation be considered in patients with major depression treated with a specific serotonin reuptake inhibitor?. 2011 , 52, 9-16	1
1898	5-HT and depression: is the glass half-full?. 2011 , 11, 45-51	69
1897	Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot study. 2011 , 86, 129-33	32
1896	[Switch antidepressants: when? How? Why?]. 2011 , 37 Suppl 1, S50-7	1
1895	Trigeminal nerve stimulation in major depressive disorder: first proof of concept in an open pilot trial. 2011 , 22, 475-8	55
1894	Stuck in a rut: rethinking depression and its treatment. 2011 , 34, 1-9	252
1893	The mechanisms of tolerance in antidepressant action. 2011 , 35, 1593-602	97
1892	Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. 2011 , 35, 1155-9	135
1891	Mindfulness based cognitive therapy for psychiatric disorders: a systematic review and meta-analysis. 2011 , 187, 441-53	436
1890	[Antidepressants in bipolar disorder]. 2011 , 37 Suppl 3, S196-202	4
1889	C.14.03 A review of recent advances in evidencebased medicine in MDD: strategies for the unresponsive patient. 2011 , 21, S638-S639	
1888	C.14.04 Translating MDD trial-based evidence into clinical practice. 2011 , 21, S639	
1887	A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. 2011 , 12, 501-15	29
1886	Adjunctive medication strategies for treatment-resistant depression. 2011 , 56, 315-6	

1885	Depression drug disappoints. 2011 , 479, 278	10
1884	Retrospective chart review of a referenced EEG database in assisting medication selection for treatment of depression in patients with eating disorders. 2011 , 7, 529-41	6
1883	Cognitive Behavioral Analysis System of Psychotherapy (CBASP): A Disorder-Oriented, Theory-Driven Psychotherapy Method from the Third Generation of Behavior Therapy Models, Designed for the Treatment of Chronic Depression. 2011 ,	2
1882	Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. 2011 , 7, 303-12	31
1881	Polypharmacy or medication washout: an old tool revisited. 2011 , 7, 639-48	14
1880	Electroconvulsive Therapy. 2011 , 522-526	
1879	Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. 2011 , 2, 159	59
1878	A new anti-depressive strategy for the elderly: ablation of FKBP5/FKBP51. 2011 , 6, e24840	82
1877	Depresyon Tedavisinde Karşılanmamış İhtiyaçlar: Erişkinlerde Anksiyete ve Yaklaşım. 2011 , 21, S10-S19	1
1876	Blick in internationale Zeitschriften. 2011 , 57, 210-214	
1875	The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. 2011 , 10, 119-32	45
1874	Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. 2011 , 31, 563-8	19
1873	A primary care focus on the diagnosis and treatment of major depressive disorder in adults. 2011 , 17, 340-50	10
1872	Ketamine Treatment for Major Depression. 2011 , 46, 89-96	1
1871	Ketamine Treatment for Major Depression. 2011 , 46, 96	
1870	Second-generation antipsychotics in major depressive disorder: update and clinical perspective. 2011 , 24, 10-7	53
1869	Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder. 2011 , 27, 805-10	9
1868	Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. 2011 , 73, 127-33	108

1867	Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. 2011 , 31, 187-93	28
1866	Clinical and pharmacologic perspectives on the treatment of major depressive disorder. 2011 , 16, 191-203	4
1865	Antidepressant augmentation and combination in unipolar depression: strong guidance, weak foundations. 2011 , 28, i-ix	2
1864	Long-term impact of residual symptoms in treatment-resistant depression. 2011 , 56, 549-57	7
1863	Pharmacogenetics of antidepressants. 2011 , 2, 6	55
1862	Inflammatory mechanisms in major depressive disorder. 2011 , 24, 519-25	161
1861	Epidural cortical stimulation of the left dorsolateral prefrontal cortex for refractory major depressive disorder. 2011 , 69, 1015-29; discussion 1029	56
1860	Pharmacogenetics and the pharmacological management of depression. 2011 , 36, 14-21; quiz 21-2	3
1859	Predictors of fluoxetine remission for hospitalized patients with major depressive disorder. 2011 , 65, 510-7	6
1858	Attributes of response in depressed patients switched to treatment with duloxetine. 2011 , 65, 73-81	11
1857	Deep brain stimulation in the treatment of depression. 2011 , 123, 4-11	35
1856	Randomized trial of Internet-based relapse prevention for partially remitted depression. 2011 , 124, 285-94	80
1855	Psychiatry and the scientific fallacy. 2011 , 124, 70-2	5
1854	Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. 2011 , 16, 634-46	264
1853	The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. 2011 , 45, 64-75	34
1852	Strain-specific outcomes of repeated social defeat and chronic fluoxetine treatment in the mouse. 2011 , 97, 566-76	33
1851	Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness. 2011 , 128 Suppl 1, S11-20	24
1850	A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. 2011 , 128, 56-63	43

1849	Cognitive-emotional reactivation during deep transcranial magnetic stimulation over the prefrontal cortex of depressive patients affects antidepressant outcome. 2011 , 128, 235-42	57
1848	Electroconvulsive therapy for major depression within the Veterans Health Administration. 2011 , 130, 21-5	17
1847	Prospective evaluation of specialist inpatient treatment for refractory affective disorders. 2011 , 131, 92-103	19
1846	Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. 2011 , 132, 112-20	81
1845	Clinical effectiveness, construct and assessment. 2011 , 132 Suppl 1, S3-8	3
1844	Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. 2011 , 133, 467-76	42
1843	Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: a 52-week follow-up study. 2011 , 134, 257-65	33
1842	Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression. 2011 , 33, 1246-57	10
1841	Solving the antidepressant efficacy question: effect sizes in major depressive disorder. 2011 , 33, B49-61	43
1840	The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents. 2011 , 671, 39-44	14
1839	Efficacy of peer support interventions for depression: a meta-analysis. 2011 , 33, 29-36	234
1838	Adapting Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression: A Clinical Case Study. 2011 , 18, 362-370	41
1837	Therapeutic options in treatment-resistant depression. 2011 , 43, 512-30	58
1836	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. 2011 , 261 Suppl 3, 207-45	29
1835	[Serum-based biomarkers for psychiatric disorders]. 2011 , 82, 1395-6, 1398, 1400 passim	4
1834	Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. 2011 , 26, 643-50	45
1833	Maladaptive opioid use behaviors and psychiatric illness: what should we do with what we know?. 2011 , 15, 91-3	2
1832	Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder. 2011 , 11, 19	10

1831	Origin and consequences of brain Toll-like receptor 4 pathway stimulation in an experimental model of depression. 2011 , 8, 151		109
1830	Clinical trial design in non-invasive brain stimulation psychiatric research. 2011 , 20, e19-30		48
1829	Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. 2011 , 28, 137-44		52
1828	Cognitive and behavior therapy in the treatment and prevention of depression. 2011 , 28, 263-6		20
1827	Star-D: lessons learned and future implications. 2011 , 28, 521-4		25
1826	Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. 2011 , 28, 973-80		70
1825	Incidence and predictors of relapse during continuation treatment of major depression with SSRI, interpersonal psychotherapy, or their combination. 2011 , 28, 955-62		23
1824	Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study. 2011 , 26, 41-50		26
1823	Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study. 2011 , 26, 237-41		5
1822	Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine. 2011 , 26, 242-51		11
1821	Challenges of introducing new biomarker products for neuropsychiatric disorders into the market. 2011 , 101, 299-327		15
1820	Behavioral pharmacology: potential antidepressant and anxiolytic properties. 2011 , 96, 49-71		11
1819	Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. <i>American Journal of Psychiatry</i> , 2011 , 168, 593-602	11.9	124
1818	Theta-patterned, frequency-modulated priming stimulation enhances low-frequency, right prefrontal cortex repetitive transcranial magnetic stimulation (rTMS) in depression: a randomized, sham-controlled study. 2011 , 23, 348-57		17
1817	T3 augmentation in major depressive disorder: safety considerations. <i>American Journal of Psychiatry</i> , 2011 , 168, 1035-40	11.9	20
1816	Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. <i>American Journal of Psychiatry</i> , 2011 , 168, 689-701	11.9	266
1815	Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. <i>American Journal of Psychiatry</i> , 2011 , 168, 751-2	11.9	52
1814	Combination of noninvasive brain stimulation with pharmacotherapy. 2011 , 8, 31-9		9

1813	Chronic 5-HT transporter blockade reduces DA signaling to elicit basal ganglia dysfunction. 2011 , 31, 15742-50		37
1812	Electroconvulsive therapy: how effective is it?. 2011 , 17, 217-8		5
1811	Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression. <i>American Journal of Psychiatry</i> , 2011 , 168, 356-64	11.9	115
1810	A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase. 2011 , 7, 431-9		63
1809	The future of psychiatric pharmacogenomics. 2011 , 12, 927-9		2
1808	Unipolar depression and the progression of coronary artery disease: toward an integrative model. 2011 , 80, 264-74		44
1807	Contrasting patterns of deficits in visuospatial memory and executive function in patients with major depression with and without ECT referral. 2011 , 41, 983-95		12
1806	Participants' Perceptions of Deep Brain Stimulation Research for Treatment-Resistant Depression: Risks, Benefits, and Therapeutic Misconception. 2011 , 2, 33-41		25
1805	The clinical impact of ABCB1 polymorphisms on the treatment of psychiatric diseases. 2011 , 17, 2843-51		16
1804	Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. 2011 , 31, 6008-18		144
1803	Anti-inflammatory drugs as moderators of antidepressant effects, especially those of the selective serotonin-reuptake inhibitor class. 2011 , 4, 575-8		3
1802	Targeting treatment-resistant depression. 2011 , 24, 520-33		12
1801	Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. <i>American Journal of Psychiatry</i> , 2011 , 168, 502-10	11.9	376
1800	Community, Constituency, and Morbidity: Applying Chervenak and McCullough's Criteria. 2011 , 11, 57-60		6
1799	Adherence to guidelines and effectiveness of inpatient treatment for unipolar depression. 2012 , 16, 103-12		5
1798	Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. 2012 , 26, 1525-39		54
1797	Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. 2012 , 9, e1001326		94
1796	Past, Present and Future Psychiatric Trends in USA: Lessons for All. 2012 , 22, 205-209		

1795	Mood and Global Symptom Changes among Psychotherapy Clients with Depressive Personality. 2012 , 2012, 208435	
1794	Role of repetitive transcranial magnetic stimulation in maintenance treatment of resistant depression. 2012 , 34, 286-9	4
1793	Differences in FKBP51 regulation following chronic social defeat stress correlate with individual stress sensitivity: influence of paroxetine treatment. 2012 , 37, 2797-808	42
1792	Metyrapone in treatment-resistant depression. 2012 , 2, 139-49	27
1791	Next-generation treatments for mental disorders. 2012 , 4, 155ps19	111
1790	Revolution stalled. 2012 , 4, 155cm11	167
1789	Approaches to decrease the prevalence of depression in later life. 2012 , 25, 451-6	10
1788	Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. 2012 , 32, 487-91	147
1787	Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies. 2012 , 27, 298-309	19
1786	PHQ-9 Response Curve: Rate of Improvement for Depression Treatment With Collaborative Care Management. 2012 , 3, 155-8	6
1785	Genetics and personalized medicine in antidepressant treatment. 2012 , 18, 5853-78	18
1784	A randomized trial to reduce the prevalence of depression and self-harm behavior in older primary care patients. 2012 , 10, 347-56	41
1783	Nature against depression. 2012 , 19, 2229-41	13
1782	Pharmacological treatment of unipolar depression. 2013 , 14, 263-89	5
1781	Bioenergetics for depression: something different for depression. <i>American Journal of Psychiatry</i> , 2012 , 169, 891-3	11.9 8
1780	Abstract. 2012 , 16, 1-55	
1779	3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders. 2012 , 109, 1713-8	39
1778	Deep brain stimulation of the subcallosal cingulate gyrus: further evidence in treatment-resistant major depression. 2012 , 15, 121-33	138

1777	L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. <i>American Journal of Psychiatry</i> , 2012 , 169, 1267-74	11.9	183
1776	Early switch strategy in patients with major depressive disorder. 2012 , 12, 1185-8		7
1775	Use and treatment modalities for SSRI and SNRI antidepressants in Italy during the period 2003-2009. 2012 , 28, 1475-84		16
1774	Depression and coronary heart disease. 2012 , 2012, 743813		35
1773	Relabeling the medications we call antidepressants. 2012 , 2012, 965908		9
1772	Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. 2012 , 42, 967-80		229
1771	The efficacy of mindfulness-based cognitive therapy in recurrent depressed patients with and without a current depressive episode: a randomized controlled trial. 2012 , 42, 989-1001		175
1770	The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial. 2012 , 32, 56-60		11
1769	Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. 2012 , 37, 1013-25		71
1768	Long-term effects of nucleus accumbens deep brain stimulation in treatment-resistant depression: evidence for sustained efficacy. 2012 , 37, 1975-85		243
1767	Real-time self-regulation of emotion networks in patients with depression. 2012 , 7, e38115		277
1766	Diffusion tensor imaging to aid subgenual cingulum target selection for deep brain stimulation in depression. 2012 , 90, 225-32		22
1765	Mindfulness-based cognitive therapy: theory and practice. 2012 , 57, 63-9		92
1764	Reducing major depression in children at high risk: opportunities for prevention. 2012 , 44, 271-90		3
1763	Update on Deep Brain Stimulation for Treatment-Resistant Depression. 2012 , 8, 175-182		
1762	Residual sleep disturbances in patients remitted from major depressive disorder: a 4-year naturalistic follow-up study. 2012 , 35, 1153-61		53
1761	Für jeden Patienten den optimalen Wirkstoff finden. 2012 , 23, 26-38		1
1760	The Long-Term Management of Major Depressive Disorders. 2012 , 10, 434-441		2

1759	Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. 2012 , 27, 27-39	24
1758	Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. 2012 , 17, 107-20	41
1757	Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. 2012 , 10, 492-505	1
1756	Acupuncture for depression: a review of clinical applications. 2012 , 57, 397-405	58
1755	Cognitive and Behavior Therapy in the Treatment and Prevention of Depression. 2012 , 10, 506-509	
1754	Selegiline transdermal system in major depressive disorder. 2012 , 2, 125-134	2
1753	Major depressive disorder: new clinical, neurobiological, and treatment perspectives. 2012 , 379, 1045-55	538
1752	Using a pharmacogenomic algorithm to guide the treatment of depression. 2012 , 2, e172	119
1751	Effect of obstructive sleep apnea on response to cognitive behavior therapy for depression after an acute myocardial infarction. 2012 , 72, 276-81	9
1750	New insights into BDNF signaling: relevance to major depression and antidepressant action. <i>American Journal of Psychiatry</i> , 2012 , 169, 1137-40	11.9 22
1749	Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good. 2012 , 3, 117	76
1748	Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. 2012 , 2, e199	159
1747	P.2.g.007 Effects of induced thyroid hormone deficiency during differentiated thyroid cancer treatment in anxiety and depression. 2012 , 22, S299-S300	
1746	P.2.g.008 Efficacy and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. 2012 , 22, S300	1
1745	P.2.g.009 One year follow-up of repetitive TMS efficacy in treatment-resistant major depression: report of two cases. 2012 , 22, S300-S301	
1744	C.04.02 What are the next steps? Combating inadequate response in MDD. 2012 , 22, S444-S445	
1743	C.04.03 Gazing into the crystal ball: what does the future hold for MDD?. 2012 , 22, S445	
1742	C.05.01 Defining success in antipsychotic treatment. 2012 , 22, S445	

1741	Intravenous ketamine for treatment-resistant major depressive disorder. 2012 , 46, 117-23	35
1740	Emerging drugs for major depressive disorder. 2012 , 17, 105-26	60
1739	Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants. 2012 , 7, 2093-100	8
1738	Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review. 2012 , 83, 371-83	21
1737	Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: an open preliminary study. 2012 , 22, 132-6	7
1736	Does prior antidepressant treatment of major depression impact brain function during current treatment?. 2012 , 22, 711-20	12
1735	European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings. 2012 , 22, 453-68	91
1734	The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data. 2012 , 27, 522-7	11
1733	Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. 2012 , 27, 114-28	27
1732	An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery. 2012 , 46, 1553-63	48
1731	The role of single nucleotide polymorphism of D2 dopamine receptor gene on major depressive disorder and response to antidepressant treatment. 2012 , 200, 1047-50	21
1730	Recovery from depression. 2012 , 35, 37-49	14
1729	Efficacy of extended release quetiapine in affective symptoms. 2012 , 5 Suppl 1, 3-19	2
1728	Combined treatment of depression. 2012 , 35, 165-79	11
1727	Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. 2012 , 200, 52-9	324
1726	Strategies to improve the management of depression in primary care. 2012 , 39, 415-31	107
1725	The varieties of depressive experience: diagnosing mood disorders. 2012 , 35, 73-86	22
1724	[Integral Care Guide for Early Detection and Diagnosis of Depressive Episodes and Recurrent Depressive Disorder in Adults. Integral Attention of Adults with a Diagnosis of Depressive Episodes and Recurrent Depressive Disorder: Part II: General Aspects of Treatment, Management of the Acute Phase, Continuation and Maintenance of Patients with a Depression Diagnosis]. 2012 , 41, 740-79	2

1723	Predicting outcomes of mood, anxiety and somatoform disorders: the Leiden routine outcome monitoring study. 2012 , 142, 122-31	20
1722	Choice of treatment with antidepressants: influencing factors. 2012 , 18, 5958-75	13
1721	Review of pharmacological treatment in mood disorders and future directions for drug development. 2012 , 37, 77-101	86
1720	Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. 2012 , 2, e79	214
1719	Studies of long-term use of antidepressants: how should the data from them be interpreted?. 2012 , 26, 97-109	27
1718	Ketamine for treatment-resistant unipolar depression: current evidence. 2012 , 26, 189-204	170
1717	Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. 2012 , 22, 29-36	23
1716	The hidden third: improving outcome in treatment-resistant depression. 2012 , 26, 587-602	49
1715	A framework to avoid irrational polypharmacy in psychiatry. 2012 , 26, 1507-11	8
1714	Impact of integrated and measurement-based depression care: clinical experience in an HIV clinic. 2012 , 53, 51-7	17
1713	Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. 2012 , 36, 147-54	27
1712	Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine. 2012 , 38, 223-7	2
1711	Is there anything really novel on the antidepressant horizon?. 2012 , 14, 643-9	52
1710	Somatic treatments for mood disorders. 2012 , 37, 102-16	86
1709	Older adults with severe, treatment-resistant depression. 2012 , 308, 909-18	29
1708	Maintenance of a positive outlook during acute stress protects against pro-inflammatory reactivity and future depressive symptoms. 2012 , 26, 346-52	78
1707	Agenten statt Patienten. 2012 , 55, 4-6	1
1706	Self-report and clinician-rated measures of depression severity: can one replace the other?. 2012 , 29, 1043-9	123

1705	Efficacy of a systematic depression management program in high utilizers of primary care: a randomized trial. 2012 , 12, 298	13
1704	Comparison of health-related quality of life among patients using atypical antipsychotics for treatment of depression: results from the National Health and Wellness Survey. 2012 , 10, 81	10
1703	Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care. 2012 , 11, 22	7
1702	Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. 2012 , 32, 373-85	16
1701	CHAPTER 10:Glutamate Approaches Towards the Treatment of Mood Disorders. 2012 , 258-275	
1700	Deep brain stimulation for intractable psychiatric disorders. 2012 , 63, 511-24	68
1699	Brain stimulation therapies for psychiatric disorders: The first decade of the new millennium--A review. 2012 , 5, 3-10	7
1698	[Costs and associated factors with optimal and suboptimal responses to the treatment of major depressive disorder]. 2012 , 44, 667-75	5
1697	Is deep brain stimulation able to make antidepressants effective in resistant obsessive-compulsive disorder?. 2012 , 71, e43-4	3
1696	Potential utility of optogenetics in the study of depression. 2012 , 71, 1068-74	47
1695	Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. 2012 , 39, 355-7	17
1694	Methoxetamine: from drug of abuse to rapid-acting antidepressant. 2012 , 79, 504-7	32
1693	A "SMART" design for building individualized treatment sequences. 2012 , 8, 21-48	315
1692	Ketamine as a novel antidepressant: from synapse to behavior. 2012 , 91, 303-9	129
1691	Stress-related depression: neuroendocrine, genetic, and therapeutical aspects. 2012 , 13, 556-68	25
1690	Uncoupling the dopamine D1-D2 receptor complex: a novel target for antidepressant treatment. 2012 , 91, 298-302	8
1689	The complexities of depression. 2012 , 14, 608-9	2
1688	How should primary care doctors select which antidepressants to administer?. 2012 , 14, 360-9	15

1687	The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. 2012 , 28, 27-39	20
1686	Use of a Second Generation Antipsychotic among Patients Diagnosed with Major Depressive Disorder in the United States. 2012 , 26, 235-241	
1685	Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment. 2012 , 12, 143	21
1684	The use of cognitive behavioral therapy in the treatment of resistant depression in adolescents. 2012 , 3, 95-104	1
1683	Optimal treatment of social phobia: systematic review and meta-analysis. 2012 , 8, 203-15	39
1682	Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. 2012 , 8, 123-30	13
1681	Evidence-based pharmacotherapy of major depressive disorder. 53-72	
1680	A tale of 2s: optimizing maternal-child health in the context of antenatal maternal depression and antidepressant use. 2012 , 57, 519-22	6
1679	Deep Brain Stimulation for Treatment-Resistant Depression: A State-of-the-Art Review. 2012 ,	
1678	Citalopram. 70-74	
1677	Management commentary. 231-233	2
1676	Pharmacogenetics in psychiatry. 53-68	2
1675	CNS drug development [Phase III. 92-99	
1674	Effect of triiodothyronine (T(3)) augmentation of acute milnacipran administration on monoamine levels: an in vivo microdialysis study in rats. 2012 , 8, 501-7	1
1673	Internalization of serotonin 5-HT1A autoreceptors as an imaging biomarker of antidepressant response. 2012 , 1, 239-245	2
1672	Are two antidepressants always better than one?. 2012 , 16, 5-8	1
1671	Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant. 2012 , 32, 234-43	14
1670	Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. 2012 , 13, 441-64	37

1669	Neurodevelopmental outcomes following prenatal exposure to serotonin reuptake inhibitor antidepressants: a "social teratogen" or moderator of developmental risk?. 2012 , 94, 651-9	28
1668	Enrolling in deep brain stimulation research for depression: influences on potential subjects' decision making. 2012 , 29, 139-46	25
1667	Predicting outcome of depression using the depressive symptom profile: the Leiden Routine Outcome Monitoring Study. 2012 , 29, 523-30	18
1666	Symptom profiles of DSM-IV-defined remission, recovery, relapse, and recurrence of depression: the role of the core symptoms. 2012 , 29, 638-45	25
1665	Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (TMS) in treatment-resistant depression. 2012 , 29, 883-90	35
1664	Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. 2012 , 29, 587-96	188
1663	Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: effects of fluoxetine and MK-801. 2012 , 62, 503-17	39
1662	Interleukin-1 β causes fluoxetine resistance in an animal model of epilepsy-associated depression. 2012 , 9, 477-85	70
1661	Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. 2012 , 165, 289-312	135
1660	Neuromuscular blocking agents for electroconvulsive therapy: a systematic review. 2012 , 56, 3-16	28
1659	Behavioral and neurobiological characteristics of social stress versus depression in nonhuman primates. 2012 , 233, 87-94	57
1658	Effect of communicating depression severity on physician prescribing patterns: findings from the Clinical Outcomes in MEasurement-based Treatment (COMET) trial. 2012 , 34, 105-12	22
1657	Staging methods for treatment resistant depression. A systematic review. 2012 , 137, 35-45	133
1656	Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. 2012 , 136, 1164-73	76
1655	Low dietary or supplemental zinc is associated with depression symptoms among women, but not men, in a population-based epidemiological survey. 2012 , 136, 781-8	60
1654	Gender-specific role of the protein tyrosine phosphatase receptor type R gene in major depressive disorder. 2012 , 136, 591-8	12
1653	Low trait anxiety, high resilience, and their interaction as possible predictors for treatment response in patients with depression. 2012 , 137, 61-9	52
1652	Does differential drop-out explain the influence of study design on antidepressant response? A meta-analysis. 2012 , 140, 57-65	10

1651	The ethics of research on deep brain stimulation for depression: decisional capacity and therapeutic misconception. 2012 , 1265, 69-79	41
1650	Antidepressant effects on emotional temperament: toward a biobehavioral research paradigm for major depressive disorder. 2012 , 18, 441-51	30
1649	Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. 2012 , 46, 64-71	62
1648	Facing depression with botulinum toxin: a randomized controlled trial. 2012 , 46, 574-81	127
1647	Contribution of spontaneous improvement to placebo response in depression: a meta-analytic review. 2012 , 46, 697-702	56
1646	Overview of glutamatergic neurotransmission in the nervous system. 2012 , 100, 656-64	175
1645	Novel glutamatergic agents for major depressive disorder and bipolar disorder. 2012 , 100, 678-87	65
1644	Bringing back melancholia. 2012 , 14, 1-5	15
1643	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. 2012 , 262, 13-22	17
1642	Comparable seizure characteristics in magnetic seizure therapy and electroconvulsive therapy for major depression. 2013 , 23, 1541-50	28
1641	Manipulating melatonin in managing mood. 2013 , 128, 16-23	17
1640	Bipolar disorder diagnosis: challenges and future directions. 2013 , 381, 1663-71	339
1639	Behavioral Neurobiology of Depression and Its Treatment. 2013 ,	3
1638	Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. 2013 , 719, 25-33	88
1637	Treatment resistant depression: strategies for primary care. 2013 , 15, 370	13
1636	What is the role of brain stimulation therapies in the treatment of depression?. 2013 , 15, 368	19
1635	Depression in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): The Mediating Role of Cognitive-Behavioral Factors. 2013 , 37, 1220-1232	39
1634	Neural Correlates of Three Neurocognitive Intervention Strategies: A Preliminary Step Towards Personalized Treatment for Psychological Disorders. 2013 , 37, 657-672	34

1633	Classification of methods in transcranial electrical stimulation (tES) and evolving strategy from historical approaches to contemporary innovations. 2013 , 219, 297-311	145
1632	Utility of the Berlin questionnaire for predicting obstructive sleep apnea in individuals with treatment-resistant depression. 2013 , 17, 1221-7	10
1631	Optimizing outcomes in major depressive disorder via augmentation therapy--focus on the role of atypical antipsychotics. Foreword. 2013 , 27 Suppl 1, S3-4	2
1630	Clinical issues in use of atypical antipsychotics for depressed patients. 2013 , 27 Suppl 1, S39-45	18
1629	Management of chronic depressive patients with residual symptoms. 2013 , 27 Suppl 1, S53-7	11
1628	mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. 2013 , 66, 40-52	94
1627	Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. 2013 , 13, 851-70	65
1626	Percentage reduction of depression severity versus absolute severity after initial weeks of treatment to predict final response or remission. 2013 , 67, 265-72	6
1625	Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. 2013 , 151, 209-19	51
1624	The economic burden of treatment-resistant depression. 2013 , 35, 512-22	84
1623	Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. 2013 , 73, 147-59	88
1622	Involvement of prolactin and somatostatin in depression and the mechanism of action of antidepressant drugs. 2013 , 65, 1640-6	25
1621	P.2.b.016 Effectiveness of duloxetine monotherapy compared to combination therapy with other antidepressants in patients with depression. 2013 , 23, S328	
1620	Trajectories of individual symptoms in remitters versus non-remitters with depression. 2013 , 151, 506-513	28
1619	Beyond serotonin: new approaches to the management of depression. 2013 , 17, 23-25	5
1618	Surgery for psychiatric disorders. 2013 , 80, S31.e17-28	42
1617	Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. 2013 , 6, 631-40	107
1616	Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. 2013 , 38, 2467-74	135

1615	Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. 2013 , 27, 703-16	204
1614	The treatment of depressive disorders in epilepsy: what all neurologists should know. 2013 , 54 Suppl 1, 3-12	79
1613	Deep brain stimulation for major depression. 2013 , 116, 235-43	38
1612	Depression treatment and short-term healthcare expenditures among elderly Medicare beneficiaries with chronic physical conditions. 2013 , 12, 15	3
1611	Seizures during antidepressant treatment in psychiatric inpatients--results from the transnational pharmacovigilance project "Arzneimittelsicherheit in der Psychiatrie" (AMSP) 1993-2008. 2013 , 230, 191-201	12
1610	Ketamine, sleep, and depression: current status and new questions. 2013 , 15, 394	51
1609	Study protocol for the randomised controlled trial: antigluco-corticoid augmentation of anti-Depressants in Depression (The ADD Study). 2013 , 13, 205	6
1608	The economic burden of depression in Switzerland. 2013 , 31, 237-50	24
1607	The impact of neurochemical mediators on antidepressant effectiveness. 2013 , 4, 1245-8	1
1606	Acute and long-term treatment outcome in depressed inpatients with vs. without anxious features: results of a one-year follow-up study. 2013 , 150, 1055-61	9
1605	The sertraline versus electrical current therapy for treating depression clinical study (select-TDCS): results of the crossover and follow-up phases. 2013 , 30, 646-53	58
1604	Antidepressant combination for major depression in incomplete responders--a systematic review. 2013 , 144, 1-6	17
1603	Medicare patient experience with vagus nerve stimulation for treatment-resistant depression. 2013 , 16, 62-74	30
1602	A machine learning approach using EEG data to predict response to SSRI treatment for major depressive disorder. 2013 , 124, 1975-85	100
1601	Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment. 2013 , 25, 572-8	14
1600	Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy. 2013 , 13, 1183-200	6
1599	Multi-modality: a new approach for the treatment of major depressive disorder. 2013 , 16, 1433-1442	29
1598	Prophylactic effects of duloxetine on post-stroke depression symptoms: an open single-blind trial. 2013 , 69, 336-43	22

1597	The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: data from multicenter, prospective, longitudinal clinic practice. 2013 , 47, 8-14	47
1596	Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. 2013 , 74, 250-6	498
1595	Challenging sequential approach to treatment resistant depression: cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR(?)D) trial. 2013 , 23, 1739-46	8
1594	Modeling predictors, moderators and mediators of treatment outcome and resistance in depression. 2013 , 74, 2-4	22
1593	The relationship between mood instability and depression: implications for studying and treating depression. 2013 , 81, 459-62	21
1592	Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression. 2013 , 150, 17-22	12
1591	Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. 2013 , 21, 769-84	31
1590	C.03.02 From hopelessness to hope: a patient-centred approach. 2013 , 23, S632	
1589	Trigeminal nerve stimulation in major depressive disorder: acute outcomes in an open pilot study. 2013 , 28, 221-6	60
1588	Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach. 2013 , 2, 171-180	5
1587	Quetiapine add-on therapy improves the depressive behaviors and hippocampal neurogenesis in fluoxetine treatment resistant depressive rats. 2013 , 253, 206-11	15
1586	The role of electrode location and stimulation polarity in patient response to cortical stimulation for major depressive disorder. 2013 , 6, 254-60	13
1585	The clinical utility of different quantitative methods for measuring treatment resistance in major depression. 2013 , 150, 231-6	9
1584	Neurophysiologic effects of repeated exposure to antidepressant medication: are brain functional changes during antidepressant administration influenced by learning processes?. 2013 , 81, 1004-11	6
1583	P.2.b.015 iNOS gene expression correlates with cognitive impairment in recurrent depressive disorder. 2013 , 23, S327-S328	
1582	Hippocampal volume and total cell numbers in major depressive disorder. 2013 , 47, 299-306	93
1581	NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test. 2013 , 73, 232-40	6
1580	Practical considerations in the development and refinement of subcallosal cingulate white matter deep brain stimulation for treatment-resistant depression. 2013 , 80, S27.e25-34	26

1579	The societal cost of depression: evidence from 10,000 Swedish patients in psychiatric care. 2013 , 150, 790-7	67
1578	Relation between structural and functional connectivity in major depressive disorder. 2013 , 74, 40-7	145
1577	C.04.01 Protecting patients from the long-term consequences of schizophrenia. 2013 , 23, S632-S633	
1576	Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. 2013 , 105, 41-50	179
1575	Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS). 2013 , 151, 854-9	10
1574	Treatment of depression in individuals living with HIV/AIDS. 2013 , 54, 336-44	22
1573	Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). 2013 , 151, 899-905	43
1572	C.03.03 New pharmacotherapeutic opportunities for the treatment of depression. 2013 , 23, S632	
1571	P.2.b.017 Distribution pattern of activity shifts in accordance with improvement of depressive symptoms in patients with depressive episode. 2013 , 23, S328-S329	
1570	Antidepressants from a public health perspective: re-examining effectiveness, suicide, and carcinogenicity. 2013 , 127, 89-93	9
1569	Centralized, stepped, patient preference-based treatment for patients with post-acute coronary syndrome depression: CODIACS vanguard randomized controlled trial. 2013 , 173, 997-1004	89
1568	Total sleep deprivation followed by sleep phase advance and bright light therapy in drug-resistant mood disorders. 2013 , 144, 28-33	46
1567	Ketamine as an alternative treatment for treatment-resistant depression. 2013 , 49, 2-4	9
1566	Definitions and Predictors of Treatment-resistant Depression. 2013 , 1-20	4
1565	Is There a Role for Switching Antidepressants in Treatment-resistant Depression?. 2013 , 91-105	
1564	The Role of Atypical Antipsychotics in Inadequate-response and Treatment-resistant Depression. 2013 , 107-128	2
1563	The Role of Psychotherapy in the Management of Treatment-resistant Depression. 2013 , 183-208	
1562	Neuroimaging Approaches to the Understanding of Depression and the Identification of Novel Antidepressants. 2013 , 343-411	1

1561	Serotonin and beyond: therapeutics for major depression. 2013 , 368, 20120536	149
1560	How might circadian rhythms control mood? Let me count the ways. 2013 , 74, 242-9	302
1559	What can fear and reward learning teach us about depression?. 2013 , 14, 223-42	3
1558	Monoamine neurocircuitry in depression and strategies for new treatments. 2013 , 45, 54-63	313
1557	Rapid effects of deep brain stimulation for treatment-resistant major depression. 2013 , 73, 1204-12	403
1556	Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics? 2013 , 81, 10-4	3
1555	Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. 2013 , 18, 231-41	31
1554	Learned helplessness: unique features and translational value of a cognitive depression model. 2013 , 354, 171-8	87
1553	Identifying brain imaging correlates of clinical response to repetitive transcranial magnetic stimulation (rTMS) in major depression. 2013 , 6, 54-61	36
1552	Rapid antidepressant effects: moving right along. 2013 , 18, 856-63	26
1551	Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. 2013 , 246, 199-229	601
1550	Gene therapy for psychiatric disorders. 2013 , 80, S32.e11-8	19
1549	Antidepressant-like effects of curcumin in WKY rat model of depression is associated with an increase in hippocampal BDNF. 2013 , 239, 27-30	75
1548	Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543. 2013 , 40, 213-20	32
1547	Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy. 2013 , 40, 306-11	24
1546	How do we re-engage the pharmaceutical industry in research on serotonin and psychiatric disorders?. 2013 , 4, 9-12	4
1545	Evidence for the management of adolescent depression. 2013 , 132, e996-e1009	49
1544	Borderline personality disorder, bipolar disorder, depression, attention deficit/hyperactivity disorder, and narcissistic personality disorder: Practical differential diagnosis. 2013 , 77, 1-22	55

1543	Desvenlafaxina, un nuevo IRSN para el tratamiento de la depresi3n mayor: Revisi3n de la literatura. 2013 , 20, 2-7		1
1542	Teaching all the evidence bases: reintegrating psychodynamic aspects of prescribing into psychopharmacology training. 2013 , 41, 13-37		4
1541	ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients. 2013 , 14, 1723-30		20
1540	Serotonin receptors involved in antidepressant effects. 2013 , 137, 119-31		208
1539	Disrupted-in-schizophrenia-1 Gln31Leu polymorphism results in social anhedonia associated with monoaminergic imbalance and reduction of CREB and μ -arrestin-1,2 in the nucleus accumbens in a mouse model of depression. 2013 , 38, 423-36		43
1538	A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. 2013 , 70, 31-41		1049
1537	Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. 2013 , 18, 1119-24		137
1536	[Individualized treatment with antidepressants]. 2013 , 81, 104-16; quiz 117-8		5
1535	A model of placebo response in antidepressant clinical trials. <i>American Journal of Psychiatry</i> , 2013 , 170, 723-33	11.9	168
1534	Psychotherapy: a paradox. <i>American Journal of Psychiatry</i> , 2013 , 170, 712-5	11.9	15
1533	Motivational pharmacotherapy: combining motivational interviewing and antidepressant therapy to improve treatment adherence. 2013 , 76, 203-9		22
1532	Neurogenesis and increase in differentiated neural cell survival via phosphorylation of Akt1 after fluoxetine treatment of stem cells. 2013 , 2013, 582526		17
1531	Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. 2013 , 27, 424-34		42
1530	[Not Available]. 2013 , 102, 515-21		0
1529	Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: a randomized, open-label study. 2013 , 17, 35-43		7
1528	Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. <i>American Journal of Psychiatry</i> , 2013 , 170, 1134-42	11.9	725
1527	Implications and limitations of cellular reprogramming for psychiatric drug development. 2013 , 45, e59		9
1526	Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. 2013 , 29, 3-12		55

1525	Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. 2013 , 23, 535-48		128
1524	EEG alpha power as an intermediate measure between brain-derived neurotrophic factor Val66Met and depression severity in patients with major depressive disorder. 2013 , 30, 261-7		35
1523	Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study. 2013 , 28, 322-9		8
1522	Imaging the serotonin 1A receptor using [11C]WAY100635 in healthy controls and major depression. 2013 , 368, 20120004		43
1521	Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study. 2013 , 36, 157-61		12
1520	Ketamine for treatment-resistant depression: ready or not for clinical use?. <i>American Journal of Psychiatry</i> , 2013 , 170, 1079-81	11.9	20
1519	Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice. 2013 , 18, 322-32		23
1518	Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. <i>American Journal of Psychiatry</i> , 2013 , 170, 207-17	11.9	181
1517	Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: a meta-analysis of randomized, double-blind and sham-controlled trials. 2013 , 38, 543-51		184
1516	Use of mental health telemetry to enhance identification and predictive value of early changes during augmentation treatment of major depression. 2013 , 33, 775-81		13
1515	A systematic review and meta-analysis on the efficacy and acceptability of bilateral repetitive transcranial magnetic stimulation (rTMS) for treating major depression. 2013 , 43, 2245-54		72
1514	Future Directions of Cytokine Hypothesis in Depression: NLRP3 inflammasome 2013 , 23, 280-288		7
1513	NMDA Receptor Antagonists for Treatment of Depression. 2013 , 6, 480-99		39
1512	Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data. 2013 , 47, 933-45		10
1511	Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study. 2013 , 46, 69-76		23
1510	Early improvement and serum concentrations of citalopram to predict antidepressant drug response of patients with major depression. 2013 , 46, 261-6		15
1509	Prevalence of treatment-resistant depression in primary care: cross-sectional data. 2013 , 63, e852-8		80
1508	Antidepressant treatment and emotional processing: can we dissociate the roles of serotonin and noradrenaline?. 2013 , 27, 719-31		19

1507	Prediction and structural equation model of sertraline treatment response in Japanese patients with major depressive disorder. 2013 , 28, 576-85	4
1506	A review of current evidence for vilazodone in major depressive disorder. 2013 , 17, 160-9	23
1505	RNAi-mediated serotonin transporter suppression rapidly increases serotonergic neurotransmission and hippocampal neurogenesis. 2013 , 3, e211	41
1504	Synaptic synopsis. 2013 , 6, 1153-1153	
1503	A Critical Perspective on the Role of Psychotropic Medications in Mental Health Courts. 2013 , 57, 244-265	7
1502	[Mindfulness-based cognitive therapy : current status and future applications]. 2013 , 38, 65-82	2
1501	Detecting critical decision points in psychotherapy and psychotherapy + medication for chronic depression. 2013 , 81, 783-92	22
1500	A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. 2013 , 70, 1241-7	109
1499	A neuroscientific update on monoamine oxidase and its inhibitors. 2013 , 18 Suppl 1, 25-32; quiz 33	26
1498	Mechanisms of antidepressant resistance. 2013 , 4, 146	71
1497	Novel glutamatergic drugs for the treatment of mood disorders. 2013 , 9, 1101-12	68
1496	Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. 2013 , 74, 1101-7	95
1495	Incentive salience: novel treatment strategies for major depression. 2013 , 18, 307-14	16
1494	A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. 2013 , 6, 17-35	46
1493	Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy. 2013 , 5, 49-57	9
1492	Physical activity in depressed elderly. A systematic review. 2013 , 9, 125-35	71
1491	Possible associations of NTRK2 polymorphisms with antidepressant treatment outcome: findings from an extended tag SNP approach. 2013 , 8, e64947	16
1490	Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. 2013 , 8, e76882	87

- 1489 Treating depression and depression-like behavior with physical activity: an immune perspective. **2013**, 4, 3 81
- 1488 Combining medication and psychotherapy in the treatment of depression. 299-310
- 1487 Ketamine in treatment-resistant depression. 345-357 1
- 1486 Cognitive behavior therapy. 258-269
- 1485 Electroconvulsive therapy. 311-324
- 1484 The Pharmacological Frontiers in Treatment Resistant Major Depression. **2013**,
- 1483 Antidepressants: current mechanisms and new hopes. **2014**, 12, 38-42 2
- 1482 Comparative efficacy and acceptability of seven augmentation agents for treatment-resistant depression: A multiple-treatments meta-analysis. **2014**, 20, 6
- 1481 Antidepressants: current mechanisms and new hopes. **2014**, 3, 23-27
- 1480 A Comparison of Pharmacotherapy in Inpatients with Major Depressive Disorders Between Patients With Single Episodes and Patients With Recurrent Episodes. **2014**, 5, 5-10
- 1479 Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES). **2014**, 75, e1428-32 99
- 1478 Tracking functional brain changes in patients with depression under psychodynamic psychotherapy using individualized stimuli. **2014**, 9, e109037 30
- 1477 Striatal dopamine D2/3 receptor availability in treatment resistant depression. **2014**, 9, e113612 8
- 1476 High dosage of hypnotics predicts subsequent sleep-related breathing disorders and is associated with worse outcomes for depression. **2014**, 37, 803-9, 809A-809B 13
- 1475 Antidepressants and the Placebo Effect. **2014**, 222, 128-134 69
- 1474 EMSAM (deprenyl patch): how a promising antidepressant was underutilized. **2014**, 10, 1911-23 13
- 1473 Early Life Stress in Depressive Patients: HPA Axis Response to GR and MR Agonist. **2014**, 5, 2 31
- 1472 The role of ketamine in treatment-resistant depression: a systematic review. **2014**, 12, 444-61 107

1471	Networks in Mood and Anxiety Disorders. 2014 , 327-334	3
1470	Role of corticosteroids in the antidepressant response. 2014 , 87	1
1469	A failure to confirm the effectiveness of a brief group psychoeducational program for mothers of children with high-functioning pervasive developmental disorders: a randomized controlled pilot trial. 2014 , 10, 1141-53	10
1468	Chronic and treatment resistant depression: diagnosis and stepwise therapy. 2014 , 111, 766-75; quiz 775	36
1467	Predicting depression outcome in mental health treatment: a recursive partitioning analysis. 2014 , 24, 675-86	7
1466	Optimization of Treatment Algorithms for Clinical Depression: Glutamate Antagonists and Transcranial Magnetic Stimulation as Case Examples. 2014 , 12, 146-151	1
1465	Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy. 2014 , 68, 1301-8	4
1464	Depression: Therapieleitlinien der WFSBP 2013. 2014 , 15, 17-18	
1463	Depression im Alter – Strategien für Diagnostik und Therapie. 2014 , 15, 33-42	
1462	Decisional conflict among women considering antidepressant medication use in pregnancy. 2014 , 17, 493-501	42
1461	ADHS im Erwachsenenalter. 2014 , 15, 18-19	
1460	Epigenetics of depression. 2014 , 128, 103-37	22
1459	Modulation of early stress-induced neurobiological changes: a review of behavioural and pharmacological interventions in animal models. 2014 , 4, e390	42
1458	Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. 2014 , 39, 2549-59	30
1457	Association of depressive symptoms with hippocampal volume in 1936 adults. 2014 , 39, 770-9	45
1456	Personalized Medicine in ADHD and Depression: Use of Pharmaco-EEG. 2014 , 21, 345-70	11
1455	Optimizing the management of depression: primary care experience. 2014 , 220 Suppl 1, S45-57	27
1454	Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials. 2014 , 48, 663-71	26

1453	Stepped collaborative depression care: primary care results before and after implementation of a stepped collaborative depression programme. 2014 , 31, 180-92		6
1452	Empirically supported methods of short-term psychodynamic therapy in depression - towards an evidence-based unified protocol. 2014 , 169, 128-43		50
1451	Benefit of slow titration of paroxetine to treat depression in the elderly. 2014 , 29, 544-51		4
1450	Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers. 2014 , 29, 129-41		24
1449	Ketamine for Treatment-Resistant Depression: Ready or Not for Clinical Use?. 2014 , 12, 244-245		
1448	Eye Movement Desensitization and Reprocessing as an Adjunctive Treatment of Unipolar Depression: A Controlled Study. 2014 , 8, 103-112		35
1447	[Chronic depression--epidemiological data and therapeutic options]. 2014 , 82, 155-71; quiz 172-3		4
1446	[MAO-inhibitors--a treatment option for treatment resistant depression: application, efficacy and characteristics]. 2014 , 82, 228-36; quiz 237-8		7
1445	Toward personalizing treatment for depression: predicting diagnosis and severity. 2014 , 21, 1069-75		67
1444	Psychoanalysis or cognitive-behavioral therapy for bulimia nervosa: the specificity of psychological treatments. <i>American Journal of Psychiatry</i> , 2014 , 171, 13-6	11.9	5
1443	Etiological classification of depression based on the enzymes of tryptophan metabolism. 2014 , 14, 372		18
1442	Tiefe Hirnstimulation bei therapieresistenter Depression. 2014 , 45, 113-117		7
1441	Major Depressive Disorder: New Clinical, Neurobiological, and Treatment Perspectives. 2014 , 12, 217-228		2
1440	Electrophysiology and Psychophysiology in Psychiatry and Psychopharmacology. 2014 ,		1
1439	Cognitive-emotional training as an intervention for major depressive disorder. 2014 , 31, 699-706		41
1438	Depression: current approaches to assessment and treatment. 2014 , 25, 16-20		2
1437	Emotion recognition processing as early predictor of response to 8-week citalopram treatment in late-life depression. 2014 , 29, 1132-9		73
1436	Clinical relevance of fatigue as a residual symptom in major depressive disorder. 2014 , 31, 250-7		83

1435	Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression. 2014 , 70, 173-80	4
1434	A therapeutic application of the experience sampling method in the treatment of depression: a randomized controlled trial. 2014 , 13, 68-77	144
1433	Biomarker studies and the future of personalized treatment for depression. 2014 , 31, 902-5	30
1432	Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. 2014 , 39, 1388-98	53
1431	Melatonin synergizes with citalopram to induce antidepressant-like behavior and to promote hippocampal neurogenesis in adult mice. 2014 , 56, 450-61	31
1430	H-coil repetitive transcranial magnetic stimulation for treatment resistant major depressive disorder: An 18-week continuation safety and feasibility study. 2014 , 15, 298-306	62
1429	Comparative efficacies of fluoxetine and paroxetine in major depression across varying acute-phase treatment periods: a meta-analysis. 2014 , 6, 353-62	1
1428	Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. 2014 , 71, 1157-64	114
1427	Addressing suicide risk in emergency department patients. 2014 , 312, 298	3
1426	Deep Brain Stimulation for Treatment-Refractory DepressionPart I. 2014 , 36, 1-5	
1425	The role of ECT in suicide prevention. 2014 , 30, 5-9	90
1424	The extent and correlates of same class versus multiclass polypharmacy among Egyptian psychiatric inpatients. 2014 , 21, 3-10	1
1423	The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study. 2014 , 29, 26-35	13
1422	A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. <i>American Journal of Psychiatry</i> , 2014 , 171, 44-53	11.9 38
1421	Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment. 2014 , 29, 16-25	3
1420	Real-world disparities between patient- and clinician-reported outcomes: results from a disease-specific program in depression and anxiety. 2014 , 19, 63-74	5
1419	Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder. 2014 , 36, 730-3	20
1418	Sociodemographic characterization of ECT utilization in Hawaii. 2014 , 30, 43-6	6

1417	Functional neuroimaging changes subsequent to electroconvulsive therapy in unipolar depression: a review of the literature. 2014 , 30, 265-74	12
1416	Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial. 2014 , 29, 332-8	4
1415	Antidepressant pharmacogenetics. 2014 , 27, 43-51	35
1414	Deep Brain Stimulation for Treatment-Refractory DepressionPart I. 2014 , 36, 6	
1413	Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder. 2014 , 4, 123-9	6
1412	Proposed DSM-5 mixed features are associated with greater likelihood of remission in out-patients with major depressive disorder. 2014 , 44, 1361-7	17
1411	Relevance of the anti-inflammatory properties of curcumin in neurodegenerative diseases and depression. 2014 , 19, 20864-79	54
1410	Addressing suicide risk in emergency department patients. 2014 , 312, 297-8	1
1409	Leukocyte Gene Expression in Patients with Medication Refractory Depression before and after Treatment with ECT or Isoflurane Anesthesia: A Pilot Study. 2014 , 2014, 582380	10
1408	Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder. 2014 , 83, 298-307	43
1407	Instability of depression severity at intake as a moderator of outcome in the treatment for major depressive disorder. 2014 , 83, 382-3	3
1406	Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression. 2014 , 61-76	1
1405	Antidepressant treatment response is modulated by genetic and environmental factors and their interactions. 2014 , 13, 17	13
1404	Deep Brain Stimulation for Treatment-Refractory DepressionPart II. 2014 , 36, 1-5	
1403	Deep Brain Stimulation for Treatment-Refractory DepressionPart II. 2014 , 36, 6	
1402	Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder. 2014 , 34, 57-65	16
1401	Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review. 2014 , 19, 496-508	62
1400	Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy. 2014 , 19, 528-34	11

1399	Default mode network mechanisms of transcranial magnetic stimulation in depression. 2014 , 76, 517-26	365
1398	Serotonin 2A receptor clustering in peripheral lymphocytes is altered in major depression and may be a biomarker of therapeutic efficacy. 2014 , 163, 47-55	25
1397	Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. 2014 , 231, 2299-310	11
1396	Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium. 2014 , 32, 479-93	14
1395	[Deep brain stimulation as possible alternative for therapy resistant depression]. 2014 , 85, 156-61	2
1394	A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression. 2014 , 231, 685-93	54
1393	Optogenetics to study the circuits of fear- and depression-like behaviors: a critical analysis. 2014 , 122, 144-57	45
1392	Sex differences in stress-related psychiatric disorders: neurobiological perspectives. 2014 , 35, 303-19	364
1391	Personality dimensions and deep repetitive transcranial magnetic stimulation (DTMS) for treatment-resistant depression: a pilot trial on five-factor prediction of antidepressant response. 2014 , 563, 144-8	14
1390	Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: a multi-center, naturalistic study. 2014 , 49, 75-82	16
1389	Transcranial Magnetic Stimulation. 2014 ,	27
1388	Biomarkers of epileptogenesis: psychiatric comorbidities (?). 2014 , 11, 358-72	70
1387	Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. 2014 , 28, 536-44	124
1386	Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. 2014 , 121, 907-24	92
1385	Stratified medicine for mental disorders. 2014 , 24, 5-50	121
1384	Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. 2014 , 54, 119-39	116
1383	Neuromodulation for treatment resistant depression: state of the art and recommendations for clinical and scientific conduct. 2014 , 27, 12-9	16
1382	A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. 2014 , 156, 24-35	129

1381	Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model. 2014 , 22, 311-24	13
1380	Neuromodulation for depression: invasive and noninvasive (deep brain stimulation, transcranial magnetic stimulation, trigeminal nerve stimulation). 2014 , 25, 103-16	37
1379	Classics in Chemical Neuroscience: Fluoxetine (Prozac). 2014 , 5, 14-23	51
1378	B vitamins to enhance treatment response to antidepressants in middle-aged and older adults: results from the B-VITAGE randomised, double-blind, placebo-controlled trial. 2014 , 205, 450-7	39
1377	Noncontinuous use of antidepressant in adults with major depressive disorders - a retrospective cohort study. 2014 , 4, 390-7	15
1376	Vagus nerve stimulation therapy in treatment-resistant depression: a series report. 2014 , 68, 606-11	16
1375	Patient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the STAR*D trial. 2014 , 31, 707-16	16
1374	Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review. 2014 , 16, 447	15
1373	Sleepiness and Human Impact Assessment. 2014 ,	9
1372	Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. 2014 , 39, 1399-408	72
1371	Advancements of Mass Spectrometry in Biomedical Research. 2014 ,	4
1370	Adjunctive triple chronotherapy (combined total sleep deprivation, sleep phase advance, and bright light therapy) rapidly improves mood and suicidality in suicidal depressed inpatients: an open label pilot study. 2014 , 59, 101-7	47
1369	Deep brain stimulation of the human reward system for major depression--rationale, outcomes and outlook. 2014 , 39, 1303-14	102
1368	A phase-specific neuroimmune model of clinical depression. 2014 , 54, 265-74	48
1367	Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. 2014 , 171, 4255-72	43
1366	Psychopharmacology in Oncology and Palliative Care. 2014 ,	4
1365	Drug safety evaluation of olanzapine/fluoxetine combination. 2014 , 13, 1133-41	3
1364	Exercise or basic body awareness therapy as add-on treatment for major depression: a controlled study. 2014 , 168, 98-106	54

1363	Possible involvement of rumination in gray matter abnormalities in persistent symptoms of major depression: an exploratory magnetic resonance imaging voxel-based morphometry study. 2014 , 168, 229-35	29
1362	Major depression. 2014 , 98, 981-1005	37
1361	An update on the interaction between the serotonin transporter promoter variant (5-HTTLPR), stress and depression, plus an exploration of non-confirming findings. 2014 , 273, 89-105	120
1360	Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-naïve patients, in combination therapy and after treatment switch. 2014 , 18, 86-96	5
1359	Web-based Mindfulness-based Cognitive Therapy for reducing residual depressive symptoms: An open trial and quasi-experimental comparison to propensity score matched controls. 2014 , 63, 83-9	55
1358	Neural Predictors of Treatment Response in Depression. 2014 , 1, 125-133	4
1357	The common inflammatory etiology of depression and cognitive impairment: a therapeutic target. 2014 , 11, 151	108
1356	Mice genetically depleted of brain serotonin do not display a depression-like behavioral phenotype. 2014 , 5, 908-19	38
1355	Ketamine administration in depressive disorders: a systematic review and meta-analysis. 2014 , 231, 3663-76	216
1354	Perfusion deficits, inflammation and aging precipitate depressive behaviour. 2014 , 15, 439-48	49
1353	Stem cell therapy: a new approach to the treatment of refractory depression. 2014 , 121, 1221-32	7
1352	Antidepressant effects of resveratrol in an animal model of depression. 2014 , 268, 1-7	117
1351	Rational use of antidepressant drugs. 2014 , 83, 197-204	64
1350	Biomarkers in major depressive disorder: the role of mass spectrometry. 2014 , 806, 545-60	12
1349	Role of lithium augmentation in the management of major depressive disorder. 2014 , 28, 331-42	74
1348	Vagus Nerve Stimulation. 2014 , 1, 64-73	179
1347	Ways forward for treating depressed patients with cancer. 2014 , 1, 332	1
1346	Trigeminal nerve stimulation (TNS) protocol for treating major depression: an open-label proof-of-concept trial. 2014 , 39, 6-9	26

1345	Depression symptom clusters and their predictive value for treatment outcomes: results from an individual patient data meta-analysis of duloxetine trials. 2014 , 53, 54-61	10
1344	Effectiveness and acceptability of deep brain stimulation (DBS) of the subgenual cingulate cortex for treatment-resistant depression: a systematic review and exploratory meta-analysis. 2014 , 159, 31-8	70
1343	[A phenomenological approach of treatment-resistant depressions]. 2014 , 40, 168-73	
1342	Deep brain stimulation for treatment-resistant depression: systematic review of clinical outcomes. 2014 , 11, 475-84	147
1341	Are there meaningful biomarkers of treatment response for depression?. 2014 , 19, 539-61	47
1340	Influence of BCL2 gene in major depression susceptibility and antidepressant treatment outcome. 2014 , 155, 288-94	26
1339	Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. 2014 , 215, 355-61	86
1338	Is there a role for palmitoylethanolamide in the treatment of depression?. 2014 , 82, 507-11	8
1337	Antidepressant treatment history as a predictor of response to scopolamine: clinical implications. 2014 , 162, 39-42	27
1336	Rare copy number variation in treatment-resistant major depressive disorder. 2014 , 76, 536-41	54
1335	Does comorbid subthreshold anxiety predict treatment response in depression? Results from a naturalistic cohort study (the CRESCEND study). 2014 , 152-154, 352-9	9
1334	Rapid mood-elevating effects of low field magnetic stimulation in depression. 2014 , 76, 186-93	50
1333	[Ketamine in acute and severe major depressive disorder]. 2014 , 43, 492-500	5
1332	Handbook of Depression. 2014 ,	1
1331	Patients? perspectives on how treatment can impede their recovery from depression. 2014 , 167, 153-9	17
1330	The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS. 2014 , 167, 333-5	35
1329	How treatable is refractory depression?. 2014 , 167, 148-52	6
1328	The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. 2014 , 19, 165-75	45

1327	Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy. 2014 , 20, 76-85	16
1326	Mechanisms underlying the antidepressant response and treatment resistance. 2014 , 8, 208	58
1325	A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. 2014 , 3, 10-9	30
1324	The treatment of nonmelancholic depression: when antidepressants fail, does psychotherapy work?. 2014 , 59, 358-65	1
1323	Treatment-resistant depression in primary care across Canada. 2014 , 59, 349-57	83
1322	Researching Depression in Prostate Cancer Patients: Factors, Timing, and Measures. 2014 , 11, 145-156	2
1321	The Effects of Computerized Cognitive Control Training on Community Adults with Depressed Mood. 2015 , 43, 578-89	59
1320	Neurobiological mechanisms of repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex in depression: a systematic review. 2015 , 45, 3411-32	64
1319	Treating to target in major depressive disorder: response to remission to functional recovery. 2015 , 20 Suppl 1, 20-30; quiz 31	24
1318	Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study). 2015 , 15, 257	10
1317	P.1.h.016 Impact of stress on neuronal plasticity in rats. 2015 , 25, S289-S290	
1316	Quel bilan ? Quelles ^ valuations ?. 2015 , 30, S21-S22	
1315	A Review of Brain Stimulation Treatments for Late-Life Depression. 2015 , 2, 413-421	40
1314	Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group. 2015 , 5, e00318	5
1313	Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study. 2015 , 69, 34-42	20
1312	Patients' perspective on self-management in the recovery from depression. 2015 , 18, 1339-48	29
1311	L'EMDR (d^ sensibilisation et retraitement par les mouvements oculaires) comme traitement d'appoint de la d^ pression unipolaire : une ^ tude contr� e. 2015 , 9, 94-104	
1310	Antidepressant Research Controversies. 2015 , 1-6	

1309	Depressive Disorders: Major Depressive Disorder and Persistent Depressive Disorder. 2015 , 902-965	
1308	Epidural Cortical Stimulation. 2015 , 255-269	
1307	Introduction to Brain Stimulation. 2015 , 1-12	1
1306	Psychiatric Epidemiology. 2015 , 407-434	1
1305	The STAR*D Trial: It Is Time to Reexamine the Clinical Beliefs That Guide the Treatment of Major Depression. 2015 , 60, 9-13	24
1304	Pharmacological Management of Treatment-Resistant Unipolar Depression. 2015 , 2311-2330	1
1303	Somatoform disorders in litigation: causation and prognosis. 2015 , 4, 41-43	0
1302	Integrative and Complementary Medicine in Psychiatry. 2015 , 2261-2290	0
1301	C. 02.01 Inadequate responses to antidepressant treatments in MDD are frequent and associated with poor functional outcomes. 2015 , 25, S662	
1300	Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial. 2015 , 16, 410	29
1299	Serotonin transporter clustering in blood lymphocytes predicts the outcome on anhedonia scores in naïve depressive patients treated with antidepressant medication. 2015 , 14, 45	11
1298	Lessons from a pilot and feasibility randomised trial in depression (Blood pressure Rapid Intensive Lowering And Normal Treatment for Mood and cognition in persistent depression (BRILiANT mood study)). 2015 , 1, 44	4
1297	[Cognitive dysfunction in major depression]. 2015 , 157, 63-4	
1296	Botulinumtoxin B ein Neuromodulator zur effektiven Therapie von Depression?. 2015 , 16, 24-32	
1295	Implementing measurement-based care (iMBC) for depression in community mental health: a dynamic cluster randomized trial study protocol. 2015 , 10, 127	39
1294	ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis. 2015 , 168B, 274-83	42
1293	A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder. 2015 , 35, 319-23	11
1292	P.1.h.014 Time dependent sensitisation exaggerates depressive-like symptoms in Flinders sensitive line (FSL) rats, a genetic animal model of depression. 2015 , 25, S288-S289	

1291	Usage and cost of first-line drugs for patients referred to inpatient anthroposophic integrative care or inpatient conventional care for stress-related mental disorders--a register based study. 2015 , 15, 354	2
1290	Targeting inflammation to influence mood following spinal cord injury: a randomized clinical trial. 2015 , 12, 204	41
1289	THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS' PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS. 2015 , 32, 605-13	25
1288	Antidepressants. 2015 , 1-4	
1287	Smoking and Cellular Telephone Use Among Pregnant Women Seeking Prenatal Care: Opportunities for Intervention. 2015 , 14, 203-210	2
1286	Augmentation Therapy With Serial Intravenous Ketamine Over 18 Months in a Patient With Treatment Resistant Depression. 2015 , 38, 212-6	6
1285	Depression. 2015 , 21, 756-71	7
1284	. 2015 ,	
1283	Levomilnacipran for the treatment of major depressive disorder: a review. 2015 , 11, 125-35	18
1282	Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy. 2015 , 10, 49-62	15
1281	Major depressive disorder: mechanism-based prescribing for personalized medicine. 2015 , 11, 875-88	57
1280	Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. 2015 , 51, 66-80	11
1279	Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report. 2015 , 13, 150-6	82
1278	Current applications and perspectives of neurologic and psychiatric disorders therapy with repetitive transcranial magnetic stimulation. 2015 , 4, 267-273	
1277	Transcranial magnetic stimulation for the treatment of major depression. 2015 , 11, 1549-60	64
1276	Management of the Suicidal Patient. 2015 , 2492-2505	
1275	The Escitalopram versus Electric Current Therapy for Treating Depression Clinical Study (ELECT-TDCS): rationale and study design of a non-inferiority, triple-arm, placebo-controlled clinical trial. 2015 , 133, 252-63	44
1274	Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action. 2015 , 12, 155-63	22

1273	Antidepressant efficacy and side-effect burden: a quick guide for clinicians. 2015 , 4, 212290	80
1272	Patients' Perspective on the Value of Medication Management Appointments. 2015 , 3, 284-95	2
1271	Toward an online cognitive and emotional battery to predict treatment remission in depression. 2015 , 11, 517-31	13
1270	Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study. 2015 , 11, 3031-40	3
1269	Treatment-resistant Late-life Depression: Challenges and Perspectives. 2015 , 13, 577-91	31
1268	Investigating subtypes of reward processing deficits as trait markers for depression. 2015 , 3, 27517	2
1267	Pre-stress performance in an instrumental training predicts post-stress behavioral alterations in chronically stressed rats. 2015 , 9, 119	2
1266	Systematic Review of the Neurobiological Relevance of Chemokines to Psychiatric Disorders. 2015 , 9, 357	94
1265	Nuevos enfoques para tratar la depresi3n resistente [translation of New approaches to treating resistant depression] by Rodolfo Zaratiegui. 2015 , 21,	
1264	Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. 2015 , 11, 1193-212	13
1263	Acute Treatment with a Novel TRPC4/C5 Channel Inhibitor Produces Antidepressant and Anxiolytic-Like Effects in Mice. 2015 , 10, e0136255	34
1262	Severity of Depression Predicts Remission Rates Using Transcranial Magnetic Stimulation. 2015 , 6, 114	13
1261	Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology. 2015 , 6, 116	72
1260	. 2015 ,	12
1259	Somatotherapy, History of. 2015 , 16-21	
1258	Rational Polypharmacy in Psychiatry. 2015 ,	
1257	A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. 2015 , 45, 693-704	236
1256	No support for replication of the genetic variants identified by a recent mega-analysis of the treatment response to antidepressants. 2015 , 60, 343-4	

1255	Deep brain stimulation for psychiatric disorders: where we are now. 2015 , 38, E2	50
1254	The relative influence of patients' self-reported depressive symptoms of cognitive deficit and cognitive bias on total depression in prostate cancer patients: implications for psychotherapy interventions. 2015 , 6, 70-79	
1253	Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression. 2015 , 85, 291-4	6
1252	Frontal alpha asymmetry as a pathway to behavioural withdrawal in depression: Research findings and issues. 2015 , 292, 56-67	49
1251	Retaining Part D's comprehensive coverage of antidepressants: not a silver bullet. 2015 , 72, 201-2	2
1250	Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. 2015 , 17, 50	55
1249	Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. 2015 , 95, 81-97	145
1248	Curcumin as a putative antidepressant. 2015 , 15, 269-80	27
1247	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. 2015 , 29, 459-525	381
1246	Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study. 2015 , 66-67, 84-94	28
1245	Emerging role of synaptic actin-regulatory pathway in the pathophysiology of mood disorders. 2015 , 19, 283-288	10
1244	Improving the assessment of depression remission with the Remission Evaluation and Mood Inventory Tool. 2015 , 50, 383-97	3
1243	Commercialisation of Biomarker Tests for Mental Illnesses: Advances and Obstacles. 2015 , 33, 712-723	14
1242	Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. 2014 , 18,	27
1241	Adjunctive treatment with asenapine augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic neurotransmission in the medial prefrontal cortex of the rat. 2014 , 18,	9
1240	Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?. 2015 , 7, 2385-406	26
1239	Influence of circadian disruption on neurotransmitter levels, physiological indexes, and behaviour in rats. 2015 , 32, 1449-57	23
1238	Refractory depression: mechanisms and evaluation of radically open dialectical behaviour therapy (RO-DBT) [REFRAMED]: protocol for randomised trial. 2015 , 5, e008857	19

1237	Psychiatry Under the Influence. 2015 ,	95
1236	Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. 2015 , 49, 1087-206	461
1235	Deconstructing Chronic Low Back Pain in the Older Adult: Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment: Part IV: Depression. 2015 , 16, 2098-108	33
1234	Cut points on the Patient Health Questionnaire (PHQ-9) that predict response to cognitive-behavioral treatments for depression. 2015 , 37, 470-5	8
1233	Biological determinants of depression following bereavement. 2015 , 49, 171-81	14
1232	Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: an open label trial. 2015 , 173, 216-20	60
1231	Do depressed patients on adjunctive atypical antipsychotics demonstrate a better quality of life compared to those on antidepressants only? A comparative cross-sectional study of a nationally representative sample of the US population. 2015 , 11, 228-40	3
1230	Optimizing the Exercise Prescription for Depression: The Search for Biomarkers of Response. 2015 , 4, 43-47	18
1229	The cognitive neuropsychological model of antidepressant response. 2015 , 4, 124-130	4
1228	The poly(I:C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery. 2015 , 149, 213-26	137
1227	What to do when a psychotherapy fails. 2015 , 2, 186-90	15
1226	Developing cognitive-emotional training exercises as interventions for mood and anxiety disorders. 2015 , 30, 75-81	15
1225	Magnetic Resonance Imaging Measures of Brain Structure to Predict Antidepressant Treatment Outcome in Major Depressive Disorder. 2015 , 2, 37-45	41
1224	Toward sophisticated basal ganglia neuromodulation: Review on basal ganglia deep brain stimulation. 2015 , 58, 186-210	42
1223	Rapid antidepressants stimulate the decoupling of GABA(B) receptors from GIRK/Kir3 channels through increased protein stability of 14-3-3. 2015 , 20, 298-310	34
1222	Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. 2015 , 37, 178-84	67
1221	Somatostatin, neuronal vulnerability and behavioral emotionality. 2015 , 20, 377-87	103
1220	The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. 2015 , 61, 1-12	90

1219	Behavioral activation therapy for return to work in medication-responsive chronic depression with persistent psychosocial dysfunction. 2015 , 57, 140-7	16
1218	Effect of a 10-day trigeminal nerve stimulation (TNS) protocol for treating major depressive disorder: a phase II, sham-controlled, randomized clinical trial. 2015 , 44, 23-6	38
1217	A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant Depression. 2015 , 78, 240-8	303
1216	Sleep Disturbances in Depression. 2015 , 10, 17-23	132
1215	Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. 2015 , 22, 394-9	61
1214	[Electroconvulsive therapy for the treatment of major depression]. 2015 , 86, 549-56	11
1213	Maintained superiority of chronotherapeutics vs. exercise in a 20-week randomized follow-up trial in major depression. 2015 , 131, 446-57	22
1212	Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. 2015 , 1344, 66-77	84
1211	A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. 2015 , 232, 2061-70	66
1210	Ablative Surgery for Depression. 2015 , 87-94	1
1209	Ketamine: a growing global health-care need. 2015 , 115, 491-3	19
1208	Using a matrix-analytical approach to synthesizing evidence solved incompatibility problem in the hierarchy of evidence. 2015 , 68, 1251-60	23
1207	Development and impact of computerised decision support systems for clinical management of depression: A systematic review. 2015 , 8, 157-66	5
1206	Development and impact of computerised decision support systems for clinical management of depression: A systematic review. 2015 , 8, 157-166	
1205	What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?. 2015 , 2, 756-764	11
1204	Daily life stress reactivity in remitted versus non-remitted depressed individuals. 2015 , 30, 441-7	41
1203	Persistent decrease in alpha current density in fully remitted subjects with major depressive disorder treated with fluoxetine: A prospective electric tomography study. 2015 , 96, 191-200	3
1202	Transcranial direct current stimulation (tDCS) in the treatment of depression: Systematic review and meta-analysis of efficacy and tolerability. 2015 , 57, 46-62	131

1201	Transcranial focused ultrasound as a possible treatment for major depression. 2015 , 84, 381-3	30
1200	Innovative designs of point-of-care comparative effectiveness trials. 2015 , 45, 61-8	14
1199	Models for treating depression in specialty medical settings: a narrative review. 2015 , 37, 315-22	7
1198	Docosahexaenoic acid alters Gs β localization in lipid raft and potentiates adenylate cyclase. 2015 , 31, 1025-30	5
1197	Suggestibility as a predictor of response to antidepressants: A preliminary prospective trial. 2015 , 185, 8-11	8
1196	A two-factor model of relapse/recurrence vulnerability in unipolar depression. 2015 , 124, 38-53	44
1195	Decreased Resting-State Connectivity between Neurocognitive Networks in Treatment Resistant Depression. 2015 , 6, 28	39
1194	Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. 2015 , 20, 1142-50	80
1193	Anhedonia and the brain reward circuitry in depression. 2015 , 2, 146-153	115
1192	Deep Brain Stimulation Modulates Gamma Oscillations and Theta-Gamma Coupling in Treatment Resistant Depression. 2015 , 8, 1033-42	27
1191	Differences in the Prevalence, Severity and Symptom Profiles of Depression in Boys and Adolescents with an Autism Spectrum Disorder versus Normally Developing Controls. 2015 , 62, 158-167	29
1190	A rest-activity biomarker to predict response to SSRIs in major depressive disorder. 2015 , 64, 19-22	15
1189	Antidepressant-like effect of geniposide on chronic unpredictable mild stress-induced depressive rats by regulating the hypothalamus-pituitary-adrenal axis. 2015 , 25, 1332-41	85
1188	In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature. 2015 , 1344, 50-65	65
1187	A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women. 2015 , 24, 281-90	17
1186	Altered fecal microbiota composition in patients with major depressive disorder. 2015 , 48, 186-94	1033
1185	The Modern Concept of Remission in Nonpsychotic Depressive Disorders. 2015 , 45, 384-392	
1184	Vagus nerve stimulation for treatment-resistant mood disorders: a long-term naturalistic study. 2015 , 15, 64	18

1183	Cognitive disruptions in stress-related psychiatric disorders: A role for corticotropin releasing factor (CRF). 2015 , 76, 125-35	28
1182	Pilot study of feasibility of the effect of treatment with tDCS in patients suffering from treatment-resistant depression treated with escitalopram. 2015 , 126, 1185-1189	77
1181	Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. 2015 , 5, e513	12
1180	Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks?. 2015 , 350, h569	6
1179	Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. 2015 , 16, 541-53	36
1178	Pharmacogenomics in practice: a case report of personalized inpatient psychiatric care. 2015 , 16, 433-9	11
1177	Homer1/mGluR5 activity moderates vulnerability to chronic social stress. 2015 , 40, 1222-33	44
1176	Minority Primary Care Patients With Depression: Outcome Disparities Improve With Collaborative Care Management. 2015 , 53, 32-7	29
1175	Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders. 2015 , 233-271	2
1174	Pharmacogenetics and analgesic effects of antidepressants in chronic pain management. 2015 , 12, 163-175	4
1173	Mindfulness-based cognitive therapy vs. psycho-education for patients with major depression who did not achieve remission following antidepressant treatment. 2015 , 226, 474-83	44
1172	CNS drug development: lessons learned part 2. Symptoms, not syndromes as targets consistent with the NIMH research domain approach. 2015 , 21, 60-6	7
1171	Effects of electroconvulsive therapy and magnetic seizure therapy on acute memory retrieval. 2015 , 31, 13-9	26
1170	Does ketamine have anti-suicidal properties? Current status and future directions. 2015 , 29, 181-8	34
1169	Pyridinic analog of the natural product (-)-spectaline as potential adjuvant for the treatment of central nervous system disorders. 2015 , 25, 2247-50	4
1168	Brain Activation During Emotional Memory Processing Associated with Subsequent Course of Depression. 2015 , 40, 2454-63	15
1167	Immediate cerebral metabolic changes induced by discontinuation of deep brain stimulation of subcallosal cingulate gyrus in treatment-resistant depression. 2015 , 173, 159-62	17
1166	Late-Life Depression and Antidepressants. 2015 , 23, 995-8	

1165	Vilazodone: a review in major depressive disorder in adults. 2015 , 75, 1915-23	18
1164	New approaches to treating resistant depression. 2015 , 21, 315-323	9
1163	Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report. 2015 , 25, 1981-90	22
1162	Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up. 2015 , 131, 51-60	57
1161	A randomized clinical trial of a telephone depression intervention to reduce employee presenteeism and absenteeism. 2015 , 66, 570-7	27
1160	Translating depression biomarkers for improved targeted therapies. 2015 , 59, 1-15	17
1159	Development of New Psychopharmacological Agents for Depression and Anxiety. 2015 , 38, 379-93	12
1158	Managing inadequate antidepressant response in depressive illness. 2015 , 115, 183-201	13
1157	The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition. 2015 , 355, 76-85	77
1156	Treatment-resistant depression: are animal models of depression fit for purpose?. 2015 , 232, 3473-95	87
1155	Pharmacotherapeutic strategies for patients treated for depression in UK primary care: a database analysis. 2015 , 31, 795-807	3
1154	Deep brain stimulation for depression: Scientific issues and future directions. 2015 , 49, 967-78	12
1153	RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response. 2015 , 5, e538	29
1152	Antidepressant treatment history and drug-placebo separation in a placebo-controlled trial in major depressive disorder. 2015 , 232, 3833-40	8
1151	Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials. 2015 , 18,	16
1150	A neurocognitive model for understanding treatment action in depression. 2015 , 370, 20140213	42
1149	Treatment-resistant depression: experience of the first repetitive transcranial magnetic stimulation clinic in the UK. 2015 , 10, 211-215	1
1148	A brief history of the development of antidepressant drugs: from monoamines to glutamate. 2015 , 23, 1-21	216

1147	C.01.03 How to use anxiety, irritability, and agitation (AIA) for diagnosing mania with depressive symptoms [patient cases. 2015 , 25, S661-S662	
1146	C.02.02 Augmentation therapies in MDD [what are the unmet needs?. 2015 , 25, S662-S663	
1145	Theta-burst stimulation: a new form of TMS treatment for depression?. 2015 , 32, 182-92	88
1144	What is important in being cured from: does discordance between physicians and patients matter? (2). 2015 , 174, 372-7	12
1143	Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation. 2015 , 47, 193-200	47
1142	Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression. 2015 , 31, 75-86	31
1141	Developments in the field of antidepressants, where do we go now?. 2015 , 25, 657-70	63
1140	Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. 2015 , 66, 509-23	247
1139	Neurosurgical Treatments for Psychiatric Disorders. 2015 ,	2
1138	Textbook of Neuromodulation. 2015 ,	7
1137	An adaptationist perspective on the etiology of depression. 2015 , 172, 315-23	84
1136	A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. 2015 , 57, 11-6	69
1135	Neuromodulation for mood and memory: from the engineering bench to the patient bedside. 2015 , 30, 38-43	14
1134	Pharmacokinetics, metabolism and excretion of [(14)C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects. 2015 , 45, 244-55	5
1133	Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression. 2015 , 125, 336-43	7
1132	A functional MRI marker may predict the outcome of electroconvulsive therapy in severe and treatment-resistant depression. 2015 , 20, 609-14	120
1131	Risk factors for treatment resistance in unipolar depression: a systematic review. 2015 , 171, 137-41	74
1130	A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment. 2015 , 122, 465-75	3

1129	The effectiveness of prefrontal theta cordance and early reduction of depressive symptoms in the prediction of antidepressant treatment outcome in patients with resistant depression: analysis of naturalistic data. 2015 , 265, 73-82	21
1128	Repetitive Transcranial Magnetic Stimulation in Major Depression. 2016 , 07,	
1127	Implementing treatment strategies for different types of depression. 2016 , 77 Suppl 1, 9-15	4
1126	Effects of Δ -Tetrahydrocannabinol, Synthetic Cannabinoids, and Fatty Acid Amide Hydrolase Inhibitors on Mood and Serotonin Neurotransmission. 2016 , 815-826	
1125	Effective Treatment of Depressive Disorders in Medical Clinics for Adolescents and Young Adults Living With HIV: A Controlled Trial. 2016 , 71, 38-46	22
1124	A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression. 2016 , 12, 1151-6	2
1123	Identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder. 2016 , 12, 2533-2538	1
1122	Transcranial magnetic stimulation and transcranial direct current stimulation appear to be safe neuromodulatory techniques useful in the treatment of anxiety disorders and other neuropsychiatric disorders. 2016 , 74, 829-835	17
1121	Novel Targets in the Glutamate and Nitric Oxide Neurotransmitter Systems for the Treatment of Depression. 2016 , 81-113	5
1120	Editorial (Thematic Issue:Classic and New Agents to the Treatment of Affective Disorders: Some Concerns and Perspectives. 2016 , 4, 68-69	
1119	Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data. 2016 , 12, 2755-2764	6
1118	Comparison between neurostimulation techniques repetitive transcranial magnetic stimulation vs electroconvulsive therapy for the treatment of resistant depression: patient preference and cost-effectiveness. 2016 , 10, 1481-7	17
1117	Developing the language of futility in psychiatry with care. 2016 , 22, 978	3
1116	Vilazodone for the Treatment of Depression: An Update. 2016 , 52, 91-100	24
1115	Efficacy of Adjunctive Brexpiprazole in Patients with Major Depressive Disorder: A Clinical Overview. 2016 , 12, 291-301	6
1114	Overview of Short-Term and Long-Term Safety of Brexpiprazole in Patients with Major Depressive Disorder and Inadequate Response to Antidepressant Treatment. 2016 , 12, 278-290	18
1113	Probiotics as an Adjuvant Therapy in Major Depressive Disorder. 2016 , 14, 952-958	27
1112	Affect Following First Exercise Session as a Predictor of Treatment Response in Depression. 2016 , 77, 1036-42	12

1111	. 2016,	1
1110	Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute Neuropathologies. 2016, 2016, 2701526	80
1109	Trazodone Addition to Paroxetine and Mirtazapine in a Patient with Treatment-Resistant Depression: The Pros and Cons of Combining Three Antidepressants. 2016, 2016, 5362485	2
1108	Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review. 2016, 17,	47
1107	Longitudinal Changes in Depressive Circuitry in Response to Neuromodulation Therapy. 2016, 10, 50	44
1106	Cortico-Striatal-Thalamic Loop Circuits of the Salience Network: A Central Pathway in Psychiatric Disease and Treatment. 2016, 10, 104	228
1105	Antidepressant and Abuse Potential of Ketamine. 2016, 639-648	
1104	Erythropoietin Pathway: A Potential Target for the Treatment of Depression. 2016, 17,	34
1103	Helpful Factors in the Treatment of Depression from the Patient's, Carer's and Professional's Perspective: A Concept Map Study. 2016, 11, e0167719	2
1102	The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials. 2016, 12, 523-31	5
1101	Switching and stopping antidepressants. 2016, 39, 76-83	32
1100	The effect of knowledge and expectations on adherence to and persistence with antidepressants. 2016, 10, 761-8	13
1099	Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. 2016 , 52, 159-72	36
1098	The Treatment with Exercise Augmentation for Depression (TREAD) study. 96-108	1
1097	Effectiveness of Duloxetine Monotherapy Compared to Combination Therapy with Other Antidepressants in Patients with Major Depressive Disorder: A Short-Term, Retrospective Study. 2016, 13, 447-52	
1096	Effects of Restricted Time in Bed on Antidepressant Treatment Response: A Randomized Controlled Trial. 2016, 77, e1218-e1225	7
1095	Molecular serum signature of treatment resistant depression. 2016, 233, 3051-9	13
1094	An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. 2016, 31, 134-46	13

1093	Pregnancy and Electroconvulsive Therapy: A Multidisciplinary Approach. 2016 , 32, 104-12	62
1092	KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS. 2016 , 33, 689-97	111
1091	Role of Aspirin and Dexamethasone against Experimentally Induced Depression in Rats. 2016 , 119, 10-8	16
1090	History repeats itself: the family medication history and pharmacogenomics. 2016 , 17, 669-78	5
1089	Ketamine for Treatment-Resistant Depression. 2016 ,	11
1088	Metabolomic biosignature differentiates melancholic depressive patients from healthy controls. 2016 , 17, 669	25
1087	Hypothalamus-pituitary-adrenal-axis associations with self- vs. parental ratings of depression in boys with an autism spectrum disorder. 2016 , 15,	2
1086	Is treatment-resistant depression a useful concept?. 2016 , 19, 1-3	20
1085	The Discovery of the Antidepressant Vortioxetine and the Research that Uncovered Its Potential to Treat the Cognitive Dysfunction Associated with Depression. 2016 , 189-214	1
1084	The Relationship Between Cortical Inhibition and Electroconvulsive Therapy in the Treatment of Major Depressive Disorder. 2016 , 6, 37461	9
1083	Antidepressant treatment response in bipolar II disorder. 2016 , 18, 706-707	
1082	Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders. 2016 , 31-42	1
1081	Ketamine's Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies. 2016 , 99-121	1
1080	"Torpedo" for the brain: perspectives in neurostimulation. 2016 , 123, 1119-20	2
1079	PC-FACS. 2016 , 52, 920-926	
1078	Patient functioning and health-related quality of life (HRQoL) should be prioritised in the treatment of schizophrenia. 2016 , 26, S762-S763	
1077	Stepping up our expectations around major depressive disorder (MDD) and schizophrenia treatment. 2016 , 26, S763	
1076	Depression: Current Conceptual Trends. 2016 , 1-21	

1075	Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression. 2016 , 70, 117-26		36
1074	Pushing the threshold: How NMDAR antagonists induce homeostasis through protein synthesis to remedy depression. 2016 , 1647, 94-104		11
1073	¿Cómo cambiar de antidepresivo?. 2016 , 23, 286-289		
1072	Suicidality and Activation of the Kynurenine Pathway of Tryptophan Metabolism. 2017 , 31, 269-284		14
1071	Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior. 2016 , 18, 61		15
1070	Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. 2016 , 80, 424-431		225
1069	Orbitofrontal cortex 5-HT2A receptor mediates chronic stress-induced depressive-like behaviors and alterations of spine density and Kalirin7. 2016 , 109, 7-17		24
1068	What we know, what we do not know, and where are we heading? Efficacy and acceptability of psychological interventions for depression. 2016 , 25, 301-8		8
1067	Electroconvulsive therapy for depression in Parkinson's disease: systematic review of evidence and recommendations. 2016 , 6, 161-76		49
1066	MAOIs - does the evidence warrant their resurrection?. 2016 , 24, 371-3		12
1065	Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient Outcomes) trial. 2016 , 365, 190-8		14
1064	A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , 2016 , 173, 816-26	11.9	276
1063	Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for Treatment-Resistant Depression: A Randomized Clinical Trial. 2016 , 73, 456-64		165
1062	The Association Between Social Responsivity and Depression in High-Functioning Boys with an Autism Spectrum Disorder. 2016 , 28, 317-331		7
1061	Long-Term Efficacy of Repeated Daily Prefrontal Transcranial Magnetic Stimulation (TMS) In Treatment-Resistant Depression. 2016 , 14, 277-282		
1060	Major Depressive Disorder: New Clinical, Neurobiological, and Treatment Perspectives. 2016 , 14, 266-276		7
1059	Plasticity-augmented psychotherapy for refractory depressive and anxiety disorders. 2016 , 70, 134-47		4
1058	Combining Antidepressants in Acute Treatment of Depression: A Meta-Analysis of 38 Studies Including 4511 Patients. 2016 , 61, 29-43		34

1057	An Individualized Approach to Treatment-Resistant Bipolar Disorder: A Case Series. 2016 , 12, 237-45	2
1056	Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. 2016 , 78, 11-23	153
1055	Adjunctive Therapy With Second-Generation Antipsychotics: The New Standard for Treatment-Resistant Depression?. 2016 , 14, 180-183	4
1054	Evaluating the economic impact of screening and treatment for depression in the workplace. 2016 , 26, 1004-13	30
1053	Self-compassion enhances the efficacy of explicit cognitive reappraisal as an emotion regulation strategy in individuals with major depressive disorder. 2016 , 82, 1-10	57
1052	Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review. 2016 , 240, 421-430	94
1051	Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. 2016 , 46, 1459-72	210
1050	Transcranial Magnetic Stimulation. 2016 , 165-186	2
1049	Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder. 2016 , 200, 156-8	12
1048	Subgenual cingulate cortical activity predicts the efficacy of electroconvulsive therapy. 2016 , 6, e789	49
1047	Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial. 2016 , 26, 705-16	30
1046	NMDAR inhibition-independent antidepressant actions of ketamine metabolites. 2016 , 533, 481-6	903
1045	Pharmacogenomics. 2016 , 121-135	
1044	Antidepressants. 2016 , 205-245	
1043	[Short-Term Psychodynamic Therapy in Depression - An Evidence-Based Unified Protocol]. 2016 , 66, 9-20	3
1042	Modulatory Effects of Antidepressant Classes on the Innate and Adaptive Immune System in Depression. 2016 , 49, 85-96	44
1041	Electrical stimulation of the vmPFC serves as a remote control to affect VTA activity and improve depressive-like behavior. 2016 , 283, 255-63	17
1040	Models for Evaluating Therapeutic Resistance of Depression. 2016 , 46, 539-543	0

1039	Antidepressant-like effects and cognitive enhancement of the total phenols extract of <i>Hemerocallis citrina</i> Baroni in chronic unpredictable mild stress rats and its related mechanism. 2016 , 194, 819-826	33
1038	Deep transcranial magnetic stimulation (dTMS) - beyond depression. 2016 , 13, 987-1000	28
1037	Traditional herbal formula Sini Powder extract produces antidepressant-like effects through stress-related mechanisms in rats. 2016 , 14, 590-8	6
1036	Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies. 2016 , 206, 151-160	12
1035	Person-centered measurement-based care for depression. 2016 , 15, 238-239	5
1034	Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require "next-step" treatments: A VAST-D report. 2016 , 206, 232-240	15
1033	Role of Neuro-Immunological Factors in the Pathophysiology of Mood Disorders: Implications for Novel Therapeutics for Treatment Resistant Depression. 2017 , 31, 339-356	33
1032	Five-Year Follow-Up of Bilateral Epidural Prefrontal Cortical Stimulation for Treatment-Resistant Depression. 2016 , 9, 897-904	26
1031	In cognitive therapy for depression, early focus on maladaptive beliefs may be especially efficacious for patients with personality disorders. 2016 , 84, 353-64	22
1030	Right patient, right treatment, right time: biosignatures and precision medicine in depression. 2016 , 15, 237-238	12
1029	Major depressive disorder. 2016 , 2, 16065	635
1028	Art therapy for patients with depression: expert opinions on its main aspects for clinical practice. 2016 , 25, 527-535	6
1027	Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants. 2016 , 17, 1835-7	10
1026	Further Investigation of Ketamine. <i>American Journal of Psychiatry</i> , 2016 , 173, 761-2	11.9 8
1025	Efficacy and cost-effectiveness of a specialist depression service versus usual specialist mental health care to manage persistent depression: a randomised controlled trial. 2016 , 3, 821-31	17
1024	Predisposition to treatment response in major depressive episode: A peripheral blood gene coexpression network analysis. 2016 , 81, 119-26	22
1023	Antidepressants Accumulate in Lipid Rafts Independent of Monoamine Transporters to Modulate Redistribution of the G Protein, Gβ. 2016 , 291, 19725-19733	32
1022	Predictors of readmission after successful electroconvulsive therapy for depression: a chart review study. 2016 , 20, 260-4	4

1021	Beneficial effect of aspirin against interferon- β -induced depressive behavior in Sprague Dawley rats. 2016 , 43, 1208-1215	6
1020	Collaborative care for depression symptoms in an outpatient cardiology setting: A randomized clinical trial. 2016 , 219, 164-71	8
1019	TPH-2 Polymorphisms Interact with Early Life Stress to Influence Response to Treatment with Antidepressant Drugs. 2016 , 19,	18
1018	The Controversial Issue of Euthanasia in Patients With Psychiatric Illness. 2016 , 316, 656-7	20
1017	The Dutch Measure for quantification of Treatment Resistance in Depression (DM-TRD): an extension of the Maudsley Staging Method. 2016 , 205, 365-371	33
1016	Increased BDNF levels after electroconvulsive therapy in patients with major depressive disorder: A meta-analysis study. 2016 , 83, 47-53	73
1015	Breaking Sad: Unleashing the Breakthrough Potential of Ketamine's Rapid Antidepressant Effects. 2016 , 77, 489-494	7
1014	Prolactin and Somatostatin Responses to Antidepressant Therapy. 2016 , 655-666	
1013	[Knowledge regarding Proper Use Guidelines for Benzodiazepines]. 2016 , 136, 73-7	
1012	Treatment of depression with low-strength transcranial pulsed electromagnetic fields: A mechanistic point of view. 2016 , 71, 137-43	13
1011	Antinociceptive and Anti-Inflammatory Effects of Ketamine and the Relationship to Its Antidepressant Action and GSK3 Inhibition. 2016 , 119, 562-573	13
1010	Does Diet Matter? The Use of Polyunsaturated Fatty Acids (PUFAs) and Other Dietary Supplements in Inflammation-Associated Depression. 2017 , 31, 321-338	8
1009	Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. 2016 , 91, 897-907	51
1008	Alpha oscillations and their impairment in affective and post-traumatic stress disorders. 2016 , 68, 794-815	15
1007	Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation?. 2017 , 31, 303-319	22
1006	Proliferation rates and gene expression profiles in human lymphoblastoid cell lines from patients with depression characterized in response to antidepressant drug therapy. 2016 , 6, e950	10
1005	Treatment-Resistant Depression in the Elderly: Diagnostic and Treatment Approaches. 2016 , 5, 241-247	2
1004	Psychedelics in the treatment of unipolar mood disorders: a systematic review. 2016 , 30, 1220-1229	70

1003	Melatonin Induces Antidepressant-Like Behavior by Promotion of Adult Hippocampal Neurogenesis. 2016 , 129-136	
1002	Combination Strategies in Treatment-Resistant Depression. 2016 , 421-444	1
1001	Step-wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression. 2016 , 18, 563-570	10
1000	Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications. 2017 , 31, 173-198	67
999	Improving outcomes for patients with medication-resistant anxiety: effects of collaborative care with cognitive behavioral therapy. 2016 , 33, 1099-1106	8
998	Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies. 2016 , 30, 1169-1189	12
997	Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning. 2017 , 20, 22-30	11
996	The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPAR α -mediated alteration of microglial activation phenotypes. 2016 , 13, 259	77
995	Understanding in vivo modelling of depression in non-human animals: a systematic review protocol. 2016 , 3, e00024	4
994	Gambling on treatment is not an option. 2016 , 20, 29-34	
993	Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors. 2016 , 4, e00275	23
992	Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil. 2016 ,	1
991	Ketamine for depression relapse prevention following electroconvulsive therapy: protocol for a randomised pilot trial (the KEEP-WELL trial). 2016 , 2, 38	3
990	A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. 2016 , 233, 3259-67	22
989	Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial. 2016 , 36, 436-44	24
988	Electroconvulsive therapy. 2016 , 429-453	1
987	RISK OF NEW ONSET TYPE II DM IN MDD PATIENTS RECEIVING SECOND-GENERATION ANTIPSYCHOTICS TREATMENT: A NATIONWIDE COHORT STUDY. 2016 , 33, 435-43	2
986	Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. 2016 , 204, 40-7	12

985	Are Sensory Processing Features Associated with Depressive Symptoms in Boys with an ASD?. 2016 , 46, 242-252	17
984	Cytokine production capacity in depression and anxiety. 2016 , 6, e825	95
983	The association between aspects of psychological resilience and subtypes of depression: implications for focussed clinical treatment models. 2016 , 20, 151-6	8
982	Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder: Sequencing Analysis of SLC6A4. 2016 , 36, 27-31	8
981	The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits. 2016 , 358, 71-82	67
980	The Current Situation on Major Depressive Disorder in China: Research on Mechanisms and Clinical Practice. 2016 , 32, 389-97	19
979	Current Trends in Identifying Rapidly Acting Treatments for Depression. 2016 , 3, 185-191	10
978	Long-Term Outcome and Non-Response in Psychotherapy: Are We Short-Sighted. 2016 , 85, 235-7	8
977	Herbal Medicine in Depression. 2016 ,	3
976	Traditional and Novel Possible Targets for Antidepressant Drugs. 2016 , 43-73	1
975	Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain. 2016 , 9, 87-96	
974	Pioglitazone, a PPAR α agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice. 2016 , 3, 114-121	23
973	Patient-reported functioning in major depressive disorder. 2016 , 7, 160-9	31
972	A patient decision aid for antidepressant use in pregnancy: study protocol for a randomized controlled trial. 2016 , 17, 110	16
971	The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence. 2016 , 34, 901-12	6
970	Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression. 2016 , 133-144	1
969	Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients. 2016 , 13, 51	47
968	An overview on clinical aspects in magnetic seizure therapy. 2016 , 123, 1139-46	9

967	Pathogenesis of depression: Insights from human and rodent studies. 2016 , 321, 138-162	238
966	The potential use of histone deacetylase inhibitors in the treatment of depression. 2016 , 64, 320-4	53
965	Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. 2016 , 3, 117-27	25
964	Role of neuro-immunological factors in the pathophysiology of mood disorders. 2016 , 233, 1623-36	91
963	The clinical effectiveness of concise cognitive behavioral therapy with or without pharmacotherapy for depressive and anxiety disorders; a pragmatic randomized controlled equivalence trial in clinical practice. 2016 , 47, 131-8	8
962	Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea. 2016 , 16, 629-638	9
961	Cortico-Basal Ganglia Circuit Function in Psychiatric Disease. 2016 , 78, 327-50	73
960	Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder. 2016 , 32, 351-66	18
959	The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder. 2016 , 11, 515-23	41
958	Indicators for Remission of Suicidal Ideation Following Magnetic Seizure Therapy in Patients With Treatment-Resistant Depression. 2016 , 73, 337-45	72
957	[Other therapeutic strategies]. 2016 , 45, 350-9	1
956	[Switching and combining strategies of antidepressant medications]. 2016 , 45, 329-37	3
955	Comparative analysis of affective temperament in patients with difficult-to-treat and easy-to-treat major depression and bipolar disorder: Possible application in clinical settings. 2016 , 66, 71-8	9
954	Association of thalamic hyperactivity with treatment-resistant depression and poor response in early treatment for major depression: a resting-state fMRI study using fractional amplitude of low-frequency fluctuations. 2016 , 6, e754	41
953	Depression in pregnancy. 2016 , 352, i1547	63
952	Psychiatric Neurotherapeutics. 2016 ,	5
951	Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder: A nonrandomized controlled pilot study. 2016 , 195, 172-9	115
950	Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2016 , 173, 499-508	11.9 123

949	Antidepressant, antioxidant and neurotrophic properties of the standardized extract of <i>Cocos nucifera</i> husk fiber in mice. 2016 , 70, 510-21	15
948	Computational psychiatry as a bridge from neuroscience to clinical applications. 2016 , 19, 404-13	439
947	Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders. 2016 ,	2
946	Critical appraisal of selegiline transdermal system for major depressive disorder. 2016 , 13, 659-65	9
945	Discriminating Between Bipolar Disorder and Major Depressive Disorder. 2016 , 39, 1-10	32
944	Antidepressant treatment response: 'I want it all, and I want it now!' 2016 , 208, 101-3	9
943	Practical guidance for prescribing trazodone extended-release in major depression. 2016 , 17, 433-41	5
942	Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression. 2016 , 233, 1077-86	8
941	Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study. 2016 , 9, 251-7	38
940	Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression. <i>American Journal of Psychiatry</i> , 2016 , 173, 107-119	45
939	Electroconvulsive therapy increases temporal gray matter volume and cortical thickness. 2016 , 26, 506-17	67
938	<i>Rhodiola rosea</i> L. as a putative botanical antidepressant. 2016 , 23, 770-83	60
937	A hospital for the mentally ill in the Middle Ages--psychiatry in history. 2016 , 208, 103	2
936	Genome-wide linkage on chromosome 10q26 for a dimensional scale of major depression. 2016 , 191, 123-31	13
935	Genomic Studies of Treatment Resistance in Major Depressive Disorder. 2016 , 55-65	1
934	[Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain]. 2016 , 9, 87-96	2
933	Role of neuroinflammation in neurodegenerative diseases (Review). 2016 , 13, 3391-6	442
932	Acute Continuation and Maintenance Treatment of Major Depressive Episodes With Transcranial Magnetic Stimulation. 2016 , 9, 313-319	14

931	Increased Default Mode Network Connectivity in Individuals at High Familial Risk for Depression. 2016 , 41, 1759-67	56
930	NMDA antagonist treatment of depression. 2016 , 36, 112-7	43
929	The role of inflammation in depression: from evolutionary imperative to modern treatment target. 2016 , 16, 22-34	1623
928	Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis. 2016 , 25, 464-72	7
927	Trauma, personality disorders and chronic depression ¶the role of the conversational model of psychodynamic psychotherapy in treatment resistant depression. 2016 , 30, 23-41	6
926	Microglial dysfunction connects depression and Alzheimer's disease. 2016 , 55, 151-165	65
925	Major depression treatment in Germany-descriptive analysis of health insurance fund routine data and assessment of guideline-adherence. 2016 , 189, 246-53	16
924	Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine. 2016 , 21, 1298-308	109
923	Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial. 2016 , 73, 56-63	134
922	Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration. 2016 , 21, 328-38	35
921	Modulation of Limbic and Prefrontal Connectivity by Electroconvulsive Therapy in Treatment-resistant Depression: A Preliminary Study. 2016 , 9, 65-71	28
920	Moving to Second-Stage Treatments Faster: Identifying Midtreatment Tailoring Variables for Youth with Anxiety Disorders. 2016 , 45, 457-68	11
919	Frontal Cortex Stimulation Reduces Vigilance to Threat: Implications for the Treatment of Depression and Anxiety. 2016 , 79, 823-830	83
918	Vascular endothelial growth factor: Potential predictor of treatment response in major depression. 2017 , 18, 575-585	18
917	Ketamine modulates hippocampal neurogenesis and pro-inflammatory cytokines but not stressor induced neurochemical changes. 2017 , 112, 210-220	50
916	Psychiatric disorders biochemical pathways unraveled by human brain proteomics. 2017 , 267, 3-17	26
915	Low-Level Laser Irradiation Improves Depression-Like Behaviors in Mice. 2017 , 54, 4551-4559	34
914	Investigational drugs in recent clinical trials for treatment-resistant depression. 2017 , 17, 593-609	46

913	Resting-state brain alteration after a single dose of SSRI administration predicts 8-week remission of patients with major depressive disorder. 2017 , 47, 438-450	22
912	Computer tool to evaluate the cue reactivity of chemically dependent individuals. 2017 , 140, 139-149	
911	Bitemporal v. high-dose right unilateral electroconvulsive therapy for depression: a systematic review and meta-analysis of randomized controlled trials. 2017 , 47, 518-530	75
910	Predicting relapse after antidepressant withdrawal - a systematic review. 2017 , 47, 426-437	39
909	Early Symptom Trajectories as Predictors of Treatment Outcome for Citalopram Versus Placebo. 2017 , 25, 654-661	5
908	Co-Variation of Peripheral Levels of miR-1202 and Brain Activity and Connectivity During Antidepressant Treatment. 2017 , 42, 2043-2051	30
907	Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. 2017 , 78, 105-113	118
906	The fibrinolytic system: A new target for treatment of depression with psychedelics. 2017 , 100, 46-53	20
905	Transcranial direct current stimulation for the treatment of post-stroke depression: results from a randomised, sham-controlled, double-blinded trial. 2017 , 88, 170-175	48
904	Glial GLT-1 blockade in infralimbic cortex as a new strategy to evoke rapid antidepressant-like effects in rats. 2017 , 7, e1038	40
903	Clinical Use of Curcumin in Depression: A Meta-Analysis. 2017 , 18, 503-508	97
902	Overview of the NMDA Receptor. 2017 , 1-18	0
901	Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. 2017 , 252, 277-283	31
900	The use of adjunctive antipsychotics to treat depression in UK primary care. 2017 , 33, 891-898	5
899	61% of unmedicated treatment resistant depression patients who did not respond to acute TMS treatment responded after four weeks of twice weekly deep TMS in the Brainsway pivotal trial. 2017 , 10, 847-849	41
898	Rapid and stable changes in maturation-related phenotypes of the adult hippocampal neurons by electroconvulsive treatment. 2017 , 10, 8	22
897	Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach. 2017 , 74, 370-378	135
896	Deep brain stimulation to the medial forebrain bundle for depression- long-term outcomes and a novel data analysis strategy. 2017 , 10, 664-671	87

895	Statistical Analysis Plan for Stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) Study. 2017 , 6, 22-30	17
894	Frontal and temporal cortical functional recovery after electroconvulsive therapy for depression: A longitudinal functional near-infrared spectroscopy study. 2017 , 91, 26-35	35
893	Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. 2017 , 89, 97-104	10
892	Using cluster analysis of anxiety-depression to identify subgroups of prostate cancer patients for targeted treatment planning. 2017 , 26, 1846-1851	3
891	A randomised controlled trial of Intensive Short-Term Dynamic Psychotherapy for treatment resistant depression: the Halifax Depression Study. 2017 , 214, 15-25	32
890	The Double Burden of Work Stress and Depression. 2017 , 147-167	1
889	The Role of Noncompetitive Antagonists of the N-Methyl-d-aspartate (NMDA) Receptors in Treatment-Resistant Depression. 2017 , 293-311	
888	The multiple diagnoses of comorbid anxiety disorders and higher interpersonal sensitivity predict treatment-resistant depression. 2017 , 26, 131-135	5
887	Randomized controlled trial of repetitive transcranial magnetic stimulation combined with paroxetine for the treatment of patients with first-episode major depressive disorder. 2017 , 254, 18-23	16
886	mGlu2/3 Receptor Antagonists as Novel Antidepressants. 2017 , 38, 569-580	51
885	The Comparison of Effectiveness of Various Potential Predictors of Response to Treatment With SSRIs in Patients With Depressive Disorder. 2017 , 205, 618-626	9
884	Wake and light therapy for moderate-to-severe depression - a randomized controlled trial. 2017 , 136, 559-570	14
883	Influence of sleep disorders on somatic symptoms, mental health, and quality of life in patients with chronic constipation. 2017 , 96, e6093	12
882	Key updates in the clinical application of electroconvulsive therapy. 2017 , 29, 54-62	62
881	A study of time- and sex-dependent effects of vortioxetine on rat sexual behavior: Possible roles of direct receptor modulation. 2017 , 121, 89-99	8
880	Alcohol Use Disorder as a Possible Predictor of Electroconvulsive Therapy Response. 2017 , 33, 117-121	6
879	Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression I: bio-behavioural validation and response to imipramine. 2017 , 29, 193-206	12
878	Transient Receptor Potential Canonical Channels and Brain Diseases. 2017 ,	2

877	Clinical predictors of acute response to transcranial direct current stimulation (tDCS) in major depression. 2017 , 219, 25-30	38
876	Factor structure and longitudinal measurement invariance of PHQ-9 for specialist mental health care patients with persistent major depressive disorder: Exploratory Structural Equation Modelling. 2017 , 219, 1-8	34
875	Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom. 2017 , 218, 291-298	8
874	Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. 2017 , 218, 277-283	30
873	Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications. 2017 , 7, 1450	14
872	Hippocampal neurogenesis of Wistar Kyoto rats is congenitally impaired and correlated with stress resistance. 2017 , 329, 148-156	12
871	Repetitive Transcranial Magnetic Stimulation (5 and 10 Hz) With Modified Parameters in the Treatment of Resistant Unipolar and Bipolar Depression in a Private Practice Setting. 2017 , 23, 92-100	3
870	Improving Outcomes for Patients With Medication-Resistant Anxiety: Effects of Collaborative Care With Cognitive Behavioral Therapy. 2017 , 15, 211-218	
869	Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data. 2017 , 234, 2453-2461	33
868	Gut microbiota and depression: from pathogenesis to new therapeutic strategies. 2017 , 28, 56-62	4
867	How effective is repetitive transcranial magnetic stimulation for bipolar depression?. 2017 , 209, 270-272	16
866	Therapeutic Potential of Conjugated siRNAs for the Treatment of Major Depressive Disorder. 2017 , 42, 371	8
865	Double-blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment-resistant depression. 2017 , 71, 204-211	10
864	Whole-body hyperthermia and a subthreshold dose of citalopram act synergistically to induce antidepressant-like behavioral responses in adolescent rats. 2017 , 79, 162-168	7
863	TRPC Channels and Mental Disorders. 2017 , 976, 137-148	3
862	Oral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case Series. 2017 , 37, 464-467	18
861	Trichotillomania in Attention-Deficit/Hyperactivity Disorder Under Methylphenidate Treatment. 2017 , 37, 484	5
860	Loss of Eyebrows (Madarosis) After Use of Long-Acting Methylphenidate: Case Report. 2017 , 37, 485-486	1

859	HCN Channel Targets for Novel Antidepressant Treatment. 2017 , 14, 698-715		22
858	Engaging Depressed Patients: An Essential Step in Optimizing Care. <i>American Journal of Psychiatry</i> , 2017 , 174, 506-507	11.9	3
857	Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial. 2017 , 51, 829-840		57
856	Effects of Transcranial Magnetic Stimulation on the Cognitive Control of Emotion: Potential Antidepressant Mechanisms. 2017 , 33, 73-80		26
855	Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. 2017 , 69, 200-235		324
854	A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality. <i>American Journal of Psychiatry</i> , 2017 , 174, 640-648	11.9	171
853	Modulation of motor cortex excitability predicts antidepressant response to prefrontal cortex repetitive transcranial magnetic stimulation. 2017 , 10, 787-794		21
852	Deep brain stimulation in the bed nucleus of the stria terminalis and medial forebrain bundle in a patient with major depressive disorder and anorexia nervosa. 2017 , 5, 679-684		43
851	Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. 2017 , 4, 419-426		92
850	Increased dopamine receptor expression and anti-depressant response following deep brain stimulation of the medial forebrain bundle. 2017 , 217, 80-88		27
849	Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. 2017 , 7, e1065		102
848	Intrinsic disruption of white matter microarchitecture in first-episode, drug-naïve major depressive disorder: A voxel-based meta-analysis of diffusion tensor imaging. 2017 , 76, 179-187		42
847	Targeting treatments for depression: what can our patients tell us?. 2017 , 26, 37-39		3
846	Two Versus One High-Frequency Repetitive Transcranial Magnetic Stimulation Session per Day for Treatment-Resistant Depression: A Randomized Sham-Controlled Trial. 2017 , 33, 190-197		21
845	Adjunctive yoga v. health education for persistent major depression: a randomized controlled trial. 2017 , 47, 2130-2142		35
844	Default mode and task-positive networks connectivity during the N-Back task in remitted depressed patients with or without emotional residual symptoms. 2017 , 38, 3491-3501		8
843	Abnormal self-schema in semantic memory in major depressive disorder: Evidence from event-related brain potentials. 2017 , 126, 41-47		14
842	Associations Between Medication Class and Subsequent Augmentation of Depression Treatment in Privately Insured US Adults. 2017 , 37, 323-331		1

841	Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial. 2017 , 4, 365-377	54
840	Effects of hyperthermic baths on depression, sleep and heart rate variability in patients with depressive disorder: a randomized clinical pilot trial. 2017 , 17, 172	20
839	New Trends in Antidepressant Drug Research. 2017 , 21-52	
838	A Preliminary Study of Genetic Variation in the Dopaminergic and Serotonergic Systems and Genome-wide Additive Genetic Effects on Depression Severity and Treatment Response. 2017 , 5, 158-165	2
837	Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial. 2017 , 7, e00628	16
836	Targeting glutamate signalling in depression: progress and prospects. 2017 , 16, 472-486	234
835	Prevalence of depressed mood versus anhedonia in older persons: implications for clinical practice. 2017 , 8, 3-14	2
834	Potential Use of MicroRNA for Monitoring Therapeutic Response to Antidepressants. 2017 , 31, 253-262	25
833	The Global ECT-MRI Research Collaboration (GEMRIC): Establishing a multi-site investigation of the neural mechanisms underlying response to electroconvulsive therapy. 2017 , 14, 422-432	37
832	The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor. 2017 , 42, 2052-2063	123
831	Gene expression and proliferation biomarkers for antidepressant treatment resistance. 2017 , 7, e1061	15
830	Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence. 2017 , 27, 423-441	15
829	Inflammation-Associated Depression: Evidence, Mechanisms and Implications. 2017 ,	17
828	Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. 2017 , 33, 701-711	44
827	Total depression and subtypes in prostate cancer survivors 10 years after treatment. 2017 , 26, e12630	4
826	Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies. 2017 , 29, 207-221	9
825	Updated Review on the Clinical Use of Repetitive Transcranial Magnetic Stimulation in Psychiatric Disorders. 2017 , 33, 747-756	34
824	Major Depressive Disorder in Patients With Doctoral Degrees: Patient-reported Depressive Symptom Severity, Functioning, and Quality of Life Before and After Initial Treatment in the STAR*D Study. 2017 , 23, 328-341	2

823 Reward Processing in Depression. **2017**, 57-71

822 Peripheral blood microRNA and VEGFA mRNA changes following electroconvulsive therapy: implications for psychotic depression. **2017**, 136, 594-606 22

821 Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood. **2019**, 253, 337-358 24

820 Efficacy of adding nutritional supplements in unipolar depression: A systematic review and meta-analysis. **2017**, 27, 1090-1109 67

819 Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder. **2017**, 37, 555-561 6

818 Impact of depression treatment on health-related quality of life among adults with cancer and depression: a population-level analysis. **2017**, 11, 624-633 12

817 [French Society for Biological Psychiatry and Neuropsychopharmacology and Fondation FondaMental task force: Formal Consensus for the management of treatment-resistant depression]. **2017**, 43, S1-S24 7

816 Nonremission and time to remission among remitters in major depressive disorder: Revisiting STAR*D. **2017**, 34, 1123-1133 11

815 A randomized, sham-controlled study of maintenance rTMS for treatment-resistant depression (TRD). **2017**, 258, 226-233 24

814 Maintenance efficacy designs in psychiatry: Randomized discontinuation trials - enriched but not better. **2017**, 1, 198-204 9

813 Backing into the future: pharmacological approaches to the management of resistant depression. **2017**, 47, 2569-2577 21

812 Prediction of Primary Care Depression Outcomes at Six Months: Validation of DOC-6^r. **2017**, 30, 281-287 8

811 A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy. **2017**, 31, 1190-1203 7

810 Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial. **2017**, 31, 1166-1175 77

809 Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis. **2017**, 31, 1137-1148 70

808 Prediction of human efficacious antidepressant doses using the mouse forced swim test. **2017**, 161, 22-29 9

807 Low medical morbidity and mortality after acute courses of electroconvulsive therapy in a population-based sample. **2017**, 136, 583-593 26

806 Can Cognitive Behavioral Therapy for Anxiety and Depression Be Improved with Pharmacotherapy? A Meta-analysis. **2017**, 40, 715-738 14

805	Ketamine metabolites with antidepressant effects: Fast, economical, and eco-friendly enantioselective separation based on supercritical-fluid chromatography (SFC) and single quadrupole MS detection. 2017 , 146, 410-419	22
804	Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: an application of the parametric g-formula. 2017 , 27, 783-789.e2	8
803	Simple Enantioselective Syntheses of (2R,6R)-Hydroxynorketamine and Related Potential Rapid-Onset Antidepressants. 2017 , 19, 5224-5227	8
802	Methoxetamine produces rapid and sustained antidepressant effects probably via glutamatergic and serotonergic mechanisms. 2017 , 126, 121-127	13
801	Beta-hydroxybutyrate, an endogenous NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses. 2017 , 7, 7677	92
800	Acute change in anterior cingulate cortex GABA, but not glutamine/glutamate, mediates antidepressant response to citalopram. 2017 , 269, 9-16	25
799	The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder. 2017 , 12, 1067-1081	4
798	Neurobehavioral comorbidities of epilepsy: Role of inflammation. 2017 , 58 Suppl 3, 48-56	51
797	Lateralized hippocampal volume increase following high-frequency left prefrontal repetitive transcranial magnetic stimulation in patients with major depression. 2017 , 71, 747-758	22
796	Clinical and demographic predictors of response to rTMS treatment in unipolar and bipolar depressive disorders. 2017 , 128, 1961-1970	38
795	Initiation of Behavioral Response to Antidepressants by Cholecystokinin Neurons of the Dentate Gyrus. 2017 , 95, 564-576.e4	31
794	Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection. 2017 , 66, 103-110	47
793	What big data can do for treatment in psychiatry. 2017 , 18, 34-42	62
792	Differing antidepressant maintenance methodologies. 2017 , 61, 87-95	7
791	Computer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy. 2017 , 33, 52-57	10
790	Analysis of Patient-reported Outcomes of Quality of Life and Functioning Before and After Treatment of Major Depressive Disorder Comorbid With Alcohol Use Disorders. 2017 , 11, 47-54	3
789	A comparative study of quality of life and marital satisfaction in patients with depression and their spouses. 2017 , 30, 65-70	7
788	Does psychological resilience buffer against the link between the 5-HTTLPR polymorphism and depression following stress. 2017 , 180, 53-59	4

- 787 The History and Future of Ablative Neurosurgery for Major Depressive Disorder. **2017**, 95, 216-228 26
- 786 Citalopram is less effective for patients with neurological disorder and/or post-traumatic stress disorder. **2017**, 4-6, 32-38 1
- 785 Editorial. **2017**, 29, 51-53
- 784 Actigraphy in Patients With Major Depressive Disorder Undergoing Repetitive Transcranial Magnetic Stimulation: An Open Label Pilot Study. **2017**, 33, 36-42 7
- 783 Effect of Metabolic Syndrome on Late-Life Depression: Associations with Disease Severity and Treatment Resistance. **2017**, 65, 2651-2658 18
- 782 Efficacy of levomilnacipran extended release in treating major depressive disorder. **2017**, 18, 2017-2024 5
- 781 Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix) to Guide Treatment of Patients with Depression and/or Anxiety. **2017**, 35, 1297-1310 5
- 780 Mood Disorders. **2016**, 233-244
- 779 Electroconvulsive Therapy. **2016**, 79-97
- 778 Depressive Störungen. **2016**, 1-107
- 777 Prevention of CVD in Depression. **2016**, 509-517
- 776 Electroencephalographic changes following trigeminal nerve stimulation for major depressive disorder: study protocol for a randomized sham-controlled trial. **2016**, 1, 164
- 775 A 35-Year-Old Man with Depressed Mood, Insomnia, and Suicidal Ideation. **2016**, 46, 216-218
- 774 Some issues of antidepressant efficacy and tolerability relevant for routine clinical practice. **2016**, 17, 48-52 1
- 773 Ricerca e impiego degli psicofarmaci. **2016**, 23-42
- 772 Pharmacoresistant depression - what is the next step?. **2016**, 17, 92-95
- 771 Neuromodulation in Neuropsychiatric Disorders. **2016**, 46, 626-628
- 770 Praxis der tiefen Hirnstimulation. **2017**, 391-402

- 769 Antidepressive Pharmakotherapie bei leichten Depressionen [Pro und Contra. **2017**, 309-315
- 768 Cancer Drug Delivery. **2017**, 185-228
- 767 Resilience in the First Episode of Major Depressive Disorder. **2017**, 06, 115-125 1
- 766 Deep Brain Stimulation: A Promising Therapeutic Approach to the Treatment of Severe Depressed Patients [Current Evidence and Intrinsic Mechanisms. **2017**, 251-264
- 765 Prinzipien der Methodik empirischer Forschung in der Psychiatrie. **2017**, 463-490
- 764 Des techniques de neurostimulation ^ l'immuno-psychiatrie. **2017**, 201, 833-844
- 763 Treating Chronic, Severe, or Complex Disorders. **2017**,
- 762 Psychotherapy, Psychopharmacotherapy, and Neuromodulation. **2018**, 513-529
- 761 Encapsulated stem cells ameliorate depressive-like behavior via growth factor secretion. **2018**, 4, 128-132 2
- 760 Complementary and Alternative Therapies for Treatment-Resistant Depression: A Clinical Perspective. **2018**, 123-142 1
- 759 D^e pression. **2018**, 83-99
- 758 The Rise of Ketamine in Clinical Practice. **2018**, 48, 167-168
- 757 Actualit^e s de l'efficacit^e de la tDCS dans le traitement de la d^e pression. **2018**, 1, S64-S65
- 756 The Influence of Pharmaceutical Companies and Restoring Integrity to Psychiatric Research and Practice. **2019**, 71-96 1
- 755 Psychopharmacology and Psychotherapy Research. **2019**, 1192, 313-329
- 754 Effect of Somatostatin-Expressing Interneuron Deficits in Depression. **2019**, 09, 1767-1777
- 753 Transcranial Magnetic Stimulation for Depression. **2019**, 56, 38-43
- 752 Continuation Therapies After Successful Treatment with Electroconvulsive Therapy in Major Depressive Disorder. **2019**, 49, 164-168

751	Which kinds of work stress are related with which types of depression? Workplace satisfaction and subtypes of depression in rural Australians. 2019 , 5, 034-041	
750	Introductory Chapter: Antidepressants - Preclinical, Clinical and Translational Aspects.	
749	La d ^e pression caract ^{er} is ^e e st : que faire en cas d ^e chec th ^{er} apeutique?. 2019 , 1, S3	
748	Redefining Therapeutic Outcomes of Depression Treatment. 2019 , 5, 1-8	1
747	Trajectories of Psychiatric Disorders and the Challenge of Relapse and Recurrence: A Network Perspective. 2020 , 50, 134-135	
746	Toward a New Model of Understanding, Preventing, and Treating Adolescent Depression Focusing on Exhaustion and Stress. 2020 , 11, 412	3
745	Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial. 2020 , 17, 796-803	1
744	The Emerging Role of Magnetic Resonance Imaging-Guided Focused Ultrasound in Functional Neurosurgery. 2020 , 12, e9820	3
743	Deep brain stimulation as a treatment for depressive disorder. 2020 , 42, 342-343	1
742	Investigating the Role of Leukocyte Telomere Length in Treatment-Resistant Depression and in Response to Electroconvulsive Therapy. 2021 , 11,	0
741	Transdiagnostic and functional predictors of depression severity and trajectory in the Penn state psychiatry clinical assessment and rating evaluation system (PCARES) registry. 2022 , 298, 86-94	0
740	Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial).. 2020 , 3, 90	1
739	Molecular Imaging of Depressive Disorders. 2021 , 85-207	0
738	Comparison of venlafaxine alone versus venlafaxine plus late partial sleep deprivation therapy combination for major depressive disorder. 2021 , 38, 378-386	0
737	Effects of Discontinuation of Drugs Used for Augmentation Therapy on Treatment Outcomes in Depression: A Systematic Review and Meta-analysis. 2021 , 54, 106-116	0
736	Repeated Digitized Assessment of Risk and Symptom Profiles During Inpatient Treatment of Affective Disorder: Observational Study. 2020 , 7, e24066	1
735	Evaluating the efficacy and moderators of algorithm-guided antidepressant treatments of major depressive disorder. 2022 , 297, 68-75	
734	A pilot study on effect of adjunctive transcranial direct current stimulation on symptom domains of depression in patients with depressive disorder.. 2021 , 30, 305-309	

- 733 Depression in Older Adults: Principles of Diagnosis and Management. **2020**, 213-221 1
- 732 Site of Ketamine Action on the NMDA Receptor. **2020**, 47-67
- 731 tDCS in Depressive Disorders. **2020**, 225-238
- 730 Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study. **2020**, 52, 79-85 1
- 729 Traditional Plant Compounds for the Treatment of Neuropsychiatric Disorders. **2020**, 435-459
- 728 Peripheral Nerve Stimulation. **2020**, 187-204
- 727 Ketamina, un nuevo agente terapéutico para la depresión. **2020**, 63, 6-13 2
- 726 Computational psychiatry: A new perspective on research and clinical applications in depression. **2020**, 28, 111
- 725 Esketamine Nasal Spray. **2020**, 13, 13-15
- 724 Developing Predictive Biomarkers Goes Alongside Diagnostic Biotypes in Major Depressive Disorder. **2020**, 87, 386-387
- 723 A Glimpse Into the Sexual Dimorphisms in Major Depressive Disorder Through Epigenetic Studies. **2021**, 15, 768571
- 722 Effect of tetrahedral DNA nanostructures on LPS-induced neuroinflammation in mice. **2021**, 4
- 721 Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST): study protocol for a randomized non-inferiority trial of magnetic seizure therapy versus electroconvulsive therapy. **2021**, 22, 786 1
- 720 Clinical Features and Outcomes of 124 Italian Patients With Treatment Resistant Depression: A Real-World, Prospective Study. **2021**, 12, 769693 1
- 719 Vitamin D and the risk of treatment-resistant and atypical depression: A Mendelian randomization study. **2021**, 11, 561 0
- 718 Adherence to Desvenlafaxine Versus Usual Care and Its Impact on Health Outcomes: A Comparative Real-world Clinical Study. **2021**, 41, 1055-1066
- 717 Effect of pharmacogenomic testing on pharmacotherapy decision making in patients with symptoms of depression in an interprofessional primary care clinic. **2021**, 0
- 716 Electroacupuncture Ameliorates Depression-Like Behaviour in Rats by Enhancing Synaptic Plasticity via the GluN2B/CaMKII/CREB Signalling Pathway. **2021**, 2021, 2146001 0

715 Cancer Drug Delivery. 52-95

714 Late-Life Depression Treatment: the State of the Art. **2020**, 18, 95-107

713 Methylome-wide association study of antidepressant use in Generation Scotland and the Netherlands Twin Register implicates the innate immune system. 0

712 Repetitive Transcranial Magnetic Stimulation With and Without Internet-Delivered Cognitive-Behavioral Therapy for the Treatment of Resistant Depression: Protocol for Patient-Centered Randomized Controlled Pilot Trial. **2020**, 9, e18843 3

711 Twelve-Month Follow-Up to a Fully Automated Internet-Based Cognitive Behavior Therapy Intervention for Rural Adults With Depression Symptoms: Single-Arm Longitudinal Study. **2020**, 22, e21336 3

710 Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders. **2020**, 35, 1

709 Temperament and Defense Mechanism Patterns of Patients with Depressive Disorder: In Comparison with or without Anxiety Symptom. **2020**, 31, 70-80 0

708 Repeated Digitized Assessment of Risk and Symptom Profiles During Inpatient Treatment of Affective Disorder: Observational Study (Preprint).

707 Pharmacological Targets and Active Components of Gastrodiae rhizoma Against Depression: Findings of Network Pharmacology. **2020**, 16, 500-513

706 Development of Innovative Diagnostic and Therapeutic Methods for Psychiatric Disorders by Applying Sleep Science and Chronobiology to Psychiatry. **2020**, 79, 309-312

705 Translating evidence on depression and physical symptoms into effective clinical practice. **2007**, 9, 295-302 1

704 Review of olanzapine in the management of bipolar disorders. **2007**, 3, 579-87 20

703 Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. **2009**, 34, 175-80 87

702 Analysis of Classes Used in the Treatment of Depression by Physician-reported Severity. **2010**, 7, 17-23

701 Augmentation and combination strategies to treat the residual symptoms of major depressive disorder. **2007**, 4, 16-8 1

700 L-methylfolate Plus SSRI or SNRI from Treatment Initiation Compared to SSRI or SNRI Monotherapy in a Major Depressive Episode. **2011**, 8, 19-28 21

699 Are antidepressants effective in the acute and long-term treatment of depression? Sic et Non. **2012**, 9, 31-40 2

698 Depression remission after six months of collaborative care management: role of initial severity of depression in outcome. **2012**, 9, 99-106 10

697	Biomarkers and the future of treatment for depression. 2012 , 2012, 6	5
696	Collaborative care for depression in primary care: how psychiatry could "troubleshoot" current treatments and practices. 2013 , 86, 139-46	21
695	PDLIM5 gene polymorphisms and short term antidepressant response in Chinese major depressive disorders. 2013 , 6, 677-82	3
694	Sparse generalized functional linear model for predicting remission status of depression patients. 2014 , 364-75	2
693	A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder. 2014 , 11, 10-22	10
692	Use of personalized Dynamic Treatment Regimes (DTRs) and Sequential Multiple Assignment Randomized Trials (SMARTs) in mental health studies. 2014 , 26, 376-83	3
691	Relapse prevention after index electroconvulsive therapy in treatment-resistant depression. 2014 , 26, 288-96	11
690	Effective Vortioxetine Dose Varies with Extent of Antidepressant Use Across Countries. 2018 , 48, 26-39	2
689	Major Depression Comorbid with Medical Conditions: Analysis of Quality of Life, Functioning, and Depressive Symptom Severity. 2018 , 48, 8-25	1
688	Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations. 2013 , 16, 113-22	16
687	Major Depression and Obsessive-compulsive Disorder Treated with Deep Brain Stimulation of Bilateral Nucleus Accumbens: The First Case of Turkey. 2018 , 13, 842-844	1
686	The Impact of Completing Medication Reconciliation and Depression Treatment History in an Outpatient Depression Clinic. 2019 , 49, 44-55	2
685	Citalopram and metacognitive therapy for depressive symptoms and cognitive emotion regulation in patients with major depressive disorder: A randomized controlled trial. 2020 , 9, 6	1
684	[decoction produces antidepressant-like effects sirt1-p53 signaling pathway]. 2021 , 41, 399-405	
683	Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment. 2021 , 21, 1-214	
682	Applying Pharmacogenomics in Drug Therapy of Neurologic and Psychiatric Disorders. 2021 ,	
681	A piece of the puzzle: Does bipolarity partly explain the high prevalence of treatment resistance in depression?. 2021 , 307, 114275	0
680	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. 2021 , 55, 86-95	3

679	Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium. 2021 , 1	0
678	PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression. 2021 ,	0
677	Post-weaning Social Isolated Flinders Sensitive Line Rats Display Bio-Behavioural Manifestations Resistant to Fluoxetine: A Model of Treatment-Resistant Depression. 2021 , 12, 688150	1
676	Rostral anterior cingulate network effective connectivity in depressed adolescents and associations with treatment response in a randomized controlled trial. 2021 ,	0
675	Transcranial Magnetic Stimulation (TMS) for Geriatric Depression. 2021 , 74, 101531	3
674	A Patient With Electroconvulsive Therapy-resistant Major Depressive Disorder With a Full Response to Heated Yoga: A Case Report. 2021 , 27, 486-491	
673	Treatment selection using prototyping in latent-space with application to depression treatment. 2021 , 16, e0258400	0
672	A Breakthrough in Understanding the Rapid Antidepressant Effect of Ketamine Based on Structural Analysis. 2021 , 1	0
671	Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: preliminary findings based on a systematic review and dose-effect meta-analysis.. 2021 , 1-8	1
670	Novel drug developmental strategies for treatment-resistant depression. 2021 ,	3
669	Associations between sensory processing and depression in autistic girls. 2021 , 89, 101881	0
668	The Role of Neutrophil Extracellular Traps in Lipopolysaccharide-Induced Depression-like Behaviors in Mice. 2021 , 11,	1
667	Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment-free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design. 2021 , e2826	1
666	Ketamine Anesthesia in Electroconvulsive Therapy.	
665	Oscillatory Brain Network Changes after Transcranial Magnetic Stimulation Treatment in Patients with Major Depressive Disorder. 2021 , 100277	
664	Health care utilisation in treatment-resistant depression: a Swedish population-based cohort study. 2021 , 1-8	3
663	3 T MRI of rapid brain activity changes driven by subcallosal cingulate deep brain stimulation.. 2021 ,	6
662	Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy. 2021 , 24, 1299-1308	

- 661 Inflammation-related microRNAs are involved in stressful life events exposure and in trauma-focused psychotherapy in treatment-resistant depressed patients.. **2021**, 12, 1987655 0
- 660 Lower Antidepressant Response to Fluoxetine Is Associated With Anxiety-Like Behavior, Hippocampal Oxidative Imbalance, and Increase on Peripheral IL-17 and IFN- γ Levels. 0
- 659 Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants. **2021**, 26, 317-347 0
- 658 Die Wirkung von Hypnose auf Parameter des Immunsystems. **2021**, 50, 1-9 0
- 657 Rh-Catalyzed Diastereoselective Addition of Arylboronic Acids to β -Keto N-tert-Butanesulfinyl Aldimines: Synthesis of β -Amino Ketones. 2
- 656 Clinical research challenges posed by difficult-to-treat depression.. **2022**, 1-14 1
- 655 The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort.. **2021**, 299, 335-343 0
- 654 More treatment but no less depression: The treatment-prevalence paradox.. **2021**, 91, 102111 7
- 653 Serum amyloid P component level is associated with clinical response to escitalopram treatment in patients with major depressive disorder.. **2021**, 146, 172-178 0
- 652 Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder.. **2021**, 308, 114354 0
- 651 Treatment of anxiety symptoms in patients receiving rTMS for treatment resistant depression. **2022**, 2, 100014 1
- 650 Health-related quality of life burden associated with treatment-resistant depression in UK patients: Quantitative results from a mixed-methods non-interventional study.. **2021**, 0
- 649 Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review.. **2022**, 55, 112-157 2
- 648 Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.. **2021**, 434, 120096 0
- 647 Long-Term Outcomes of Repeated Ketamine Infusions in Patients with Unipolar and Bipolar Depression: A Naturalistic Follow-Up Study.. **2021**, 300, 172-172 1
- 646 Mechanisms of Ketamine and its Metabolites as Antidepressants.. **2021**, 114892 7
- 645 When depression is difficult to treat.. **2022**, 56, 89-91 1
- 644 Daily steps and depressive symptoms: A longitudinal evaluation of patients with major depressive disorder in the precision medicine in mental health care study.. **2022**, 300, 334-340 0

- 643 Longitudinal associations between adolescents' individualised risk for depression and inflammation in a UK cohort study.. **2022**, 101, 78-83 2
- 642 Electroconvulsive therapy in treatment resistant depression.. **2021**, 434, 120095 1
- 641 Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression.. **2021**, 115, 110507 1
- 640 Chapitre 2. Dépression unipolaire majeure : définition, prévalence, incidence, évolution et traitement. **2015**, 14-23
- 639 Major depression and obsessive-compulsive disorder treated with deep brain stimulation of bilateral nucleus accumbens: The first case of Turkey. **2018**, 13, 842 1
- 638 Duloxetine. **2020**, 263-268
- 637 Imipramine. **2020**, 367-374
- 636 Paliperidone. **2020**, 581-592
- 635 Molindone. **2020**, 527-532
- 634 Diphenhydramine. **2020**, 235-238
- 633 Citalopram. **2020**, 159-164
- 632 Aripiprazole. **2020**, 53-64
- 631 Acamprosate. **2020**, 1-4
- 630 Atomoxetine. **2020**, 79-84
- 629 Carbamazepine. **2020**, 131-136
- 628 Flunitrazepam. **2020**, 297-300
- 627 Lumateperone. **2020**, 451-456
- 626 Galantamine. **2020**, 337-342

625 Flumazenil. **2020**, 293-296

624 Oxcarbazepine. **2020**, 575-580

623 Flupenthixol. **2020**, 307-312

622 Asenapine. **2020**, 71-78

621 Clozapine. **2020**, 191-200

620 Lofepramine. **2020**, 421-426

619 Armodafinil. **2020**, 65-70

618 Amoxapine.

617 Diazepam. **2020**, 229-234

616 Brexanolone. **2020**, 99-102

615 Escitalopram. **2020**, 269-274

614 Chlordiazepoxide. **2020**, 147-152

613 Lurasidone. **2020**, 457-464

612 Deutetrabenazine. **2020**, 221-224

611 Disulfiram. **2020**, 239-242

610 Nefazodone. **2020**, 545-550

609 Dothiepin. **2020**, 249-254

608 Lemborexant.

607 Mianserin. **2020**, 495-498

606 Moclobemide. **2020**, 515-520

605 Buspirone. **2020**, 123-126

604 Agomelatine.

603 Oxazepam. **2020**, 569-574

602 Naltrexone/Bupropion. **2020**, 541-544

601 Lithium. **2020**, 415-420

600 Introduction. **2020**, xi-xiv

599 Haloperidol. **2020**, 347-354

598 Desvenlafaxine. **2020**, 215-220

597 Desipramine. **2020**, 207-214

596 Memantine.

595 Olanzapine. **2020**, 559-568

594 Isocarboxazid. **2020**, 375-382

593 Nalmefene. **2020**, 533-536

592 Ketamine. **2020**, 383-386

591 Dextromethorphan. **2020**, 225-228

590 Clonazepam. **2020**, 173-178

589 Methylphenidate (D,L). **2020**, 487-494

588 Naltrexone. **2020**, 537-540

587 Levomilnacipran. **2020**, 403-408

586 loperidone. **2020**, 359-366

585 Nortriptyline. **2020**, 551-558

584 Blonanserin. **2020**, 89-94

583 Gabapentin. **2020**, 331-336

582 Maprotiline. **2020**, 465-472

581 Amphetamine (D,L). **2020**, 45-52

580 Buprenorphine. **2020**, 111-116

579 Doxepin. **2020**, 255-262

578 Methylphenidate (D). **2020**, 481-486

577 Guanfacine. **2020**, 343-346

576 Methylfolate (L). **2020**, 477-480

575 Levetiracetam. **2020**, 399-402

574 Brexpiprazole.

573 Hydroxyzine. **2020**, 355-358

572 Esketamine. **2020**, 275-280

571 Cariprazine. **2020**, 137-146

1

570 Alprazolam. **2020**, 11-16

569 Estazolam. **2020**, 281-284

568 Lisdexamfetamine.

567 Donepezil. **2020**, 243-248

566 Bupropion. **2020**, 117-122

565 Flurazepam. **2020**, 321-324

564 Cyamemazine. **2020**, 201-206

563 Amphetamine (D). **2020**, 39-44

562 Amitriptyline. **2020**, 25-32

561 Clorazepate. **2020**, 185-190

560 Clonidine. **2020**, 179-184

559 Caprylidene. **2020**, 127-130

558 Fluoxetine. **2020**, 301-306

557 Eszopiclone. **2020**, 285-288

556 Bremelanotide. **2020**, 95-98

555 Mirtazapine. **2020**, 509-514

554 Midazolam. **2020**, 499-502

553 Milnacipran. **2020**, 503-508

552 Chlorpromazine. **2020**, 153-158

551 Flibanserin. **2020**, 289-292

550 Loxapine. **2020**, 443-450

549 Fluphenazine. **2020**, 313-320

548 Clomipramine. **2020**, 165-172

547 Fluvoxamine. **2020**, 325-330

546 Modafinil. **2020**, 521-526

545 Lorazepam. **2020**, 437-442

544 Amisulpride. **2020**, 17-24

543 Benztropine. **2020**, 85-88

542 Lamotrigine. **2020**, 387-394

541 Lofexidine. **2020**, 427-430

540 The Modulatory Effects of 2-Hz rTMS Treatment on the Prefrontal Cortex in Patients with Major Depressive Disorder: An fNIRS Study.

539 Psychopathology of Depression in the Spectrum of Mood Disorders. **2021**, 31-46

538 Analysis of Antidepressant-like Effects and Action Mechanisms of GSB-106, a Small Molecule, Affecting the TrkB Signaling.. **2021**, 22, 0

537 Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.. **2022**, 3

536 Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial). 3, 90

535	Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression.. 2022 , 12, 12	1
534	A neural network approach to optimising treatments for depression using data from specialist and community psychiatric services in Australia, New Zealand and Japan.. 2022 , 1-20	1
533	The neurobiology of treatment-resistant depression: a systematic review of neuroimaging studies. 2021 , 132, 433-433	4
532	Optogenetic stimulation of ventral tegmental area dopaminergic neurons in a female rodent model of depression: The effect of different stimulation patterns.. 2022 ,	1
531	Efficacy of polysaccharide in adolescents with subthreshold depression: interim analysis of a randomized controlled study.. 2022 , 17, 1582-1587	1
530	Risks of Antidepressant induced psychotic events in patients with depression and psychosis.	
529	Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression.. 2022 , 1-9	
528	Antidepressant response and stress resilience are promoted by CART peptides in GABAergic neurons of the anterior cingulate cortex. 2022 ,	1
527	Computational Approaches to Treatment Response Prediction in Major Depression Using Brain Activity and Behavioral Data: A Systematic Review. 1-52	0
526	A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder.. 2022 , 1-25	0
525	Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report.. 2022 , 22, 46	
524	Distinct Effects of Antidepressants in Association With Mood Stabilizers and/or Antipsychotics in Unipolar and Bipolar Depression.. 2022 , 42,	0
523	Antidepressant-like effects of cinnamamide derivative M2 via D receptors in the mouse medial prefrontal cortex.. 2022 ,	0
522	Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.. 2022 ,	5
521	Bilateral Habenula deep brain stimulation for treatment-resistant depression: clinical findings and electrophysiological features.. 2022 , 12, 52	1
520	Comparison between Atomoxetine and OROS Methylphenidate as an Adjunctive to SSRIs in Attention-deficit/Hyperactivity Disorder Adults with Comorbid Partially Responsive Major Depressive Disorder: A Head-to-head, 12-week, Randomized, Rater-blinded Clinical Trial.. 2022 , 20, 143-153	1
519	The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines.. 2022 , 20, 37-50	2
518	Depression: why drugs and electricity are not the answer.. 2022 , 1-10	4

517	Differences in Cerebral Distribution between Imipramine and Paroxetine via Membrane Transporters at the Rat Blood-Brain Barrier.. 2022 , 39, 223	0
516	Setting Up a Successful Vagus Nerve Stimulation Service for Patients With Difficult-to-Treat Depression.. 2022 ,	
515	Safety and Feasibility of Tele-Supervised Home-Based Transcranial Direct Current Stimulation for Major Depressive Disorder.. 2021 , 13, 765370	0
514	Accelerated Intermittent Theta Burst Stimulation: Expediting and Enhancing Treatment Outcomes in Treatment-Resistant Depression.. <i>American Journal of Psychiatry</i> , 2022 , 179, 85-87	11.9 0
513	Dopamine D3 Receptor in the Nucleus Accumbens Alleviates Neuroinflammation in a Mouse Model of Depressive-Like Behavior.. 2021 , 101, 165-165	0
512	Predictors of suicidal ideation trajectories in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.. 2022 , 148, 9-13	0
511	Augmentation Strategies For Treatment Resistant Major Depression: A Systematic Review And Network Meta-Analysis.. 2022 ,	7
510	High-resolution Virtual Brain Modeling Personalizes Deep Brain Stimulation for Treatment-Resistant Depression: Spatiotemporal Response Characteristics Following Stimulation of Neural Fiber Pathways.. 2021 , 249, 118848	0
509	Combination of Spontaneous Regional Brain Activity and HTR1A/1B DNA Methylation to Predict Early Responses to Antidepressant Treatments in MDD.. 2022 , 302, 249-249	0
508	Deep Brain Stimulation for Treatment-Resistant Depression. 2022 , 357-372	
507	Predictors of 4-week antidepressant outcome in patients with first-episode major depressive disorder:An ROC curve analysis.. 2022 ,	0
506	rTMS combined with CBT as a next step in antidepressant non-responders: a study protocol for a randomized comparison with current antidepressant treatment approaches.. 2022 , 22, 88	
505	Concerns About Psychiatric Neurosurgery and How They Can Be Overcome: Recommendations for Responsible Research. 2022 , 15, 1	
504	Transdiagnostic Symptom Subtypes to Predict Response to Therapeutic Transcranial Magnetic Stimulation in Major Depressive Disorder and Posttraumatic Stress Disorder.. 2022 , 12,	
503	Impact of serotonergic medication on interoception in major depressive disorder.. 2022 , 108286	2
502	Is It Time to Try Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Again?. 2022 ,	0
501	Development of a model to predict psychotherapy response for depression among Veterans.. 2022 , 1-10	
500	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study.. 2022 , 56, 100-111	2

499	Corticomotor Plasticity as a Predictor of Response to High Frequency Transcranial Magnetic Stimulation Treatment for Major Depressive Disorder.. 2022,	1
498	The Emerging Role of SPECT Functional Neuroimaging in Schizophrenia and Depression.. 2021, 12, 716600	
497	Prescriber's Guide. 2020,	7
496	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.. 2021,	10
495	Targeting epigenetics as future treatments of trauma- and stress-or-related disorders. Epidrugs and epinutraceuticals. 2022, 317-392	
494	Static and treatment-responsive brain biomarkers of depression relapse vulnerability following prophylactic psychotherapy: Evidence from a randomized control trial.. 2022, 34, 102969	0
493	Depression and epigenetics: Epidemiology, pathophysiology, diagnosis, and assessment. 2022, 51-65	
492	Sex differences in responses to antidepressant augmentations in treatment-resistant depression.. 2022,	0
491	Depression management and pharmacoepigenetics. 2022, 67-84	
490	Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.. 2022, e2836	0
489	Microglia Loss and Astrocyte Activation Cause Dynamic Changes in Hippocampal [F]DPA-714 Uptake in Mouse Models of Depression.. 2022, 16, 802192	0
488	Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study.. 2022, 12,	1
487	Psychometric and Clinical Evaluation of the Clinician (VQIDS-C) and Self-Report (VQIDS-SR) Versions of the Very Quick Inventory of Depressive Symptoms.. 2022, 18, 289-302	0
486	Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme.. 2022, 1-11	0
485	Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing.. 2022, 36, 239	0
484	Characteristics of platelet-associated parameters and their predictive values in Chinese patients with affective disorders.. 2022, 22, 150	0
483	Fecal Microbiota Transplantation (FMT) as an Adjunctive Therapy for Depression-Case Report.. 2022, 13, 815422	2
482	[The efficacy of esketamine in resistant major depressive disorder: A systematic review of the literature].. 2022,	

481	Common network effect-patterns after monoamine reuptake inhibition in dissociated hippocampus cultures.. 2022 , 129, 261	
480	BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model.. 2022 , 22, 182	1
479	Low omega-3 polyunsaturated fatty acids predict reduced response to standard antidepressants in patients with major depressive disorder.. 2022 ,	0
478	The syndemic effects of adverse mental health conditions and polysubstance use on being at risk of clinical depression among marginally housed and homeless transitional age youth living in San Francisco, California.. 2022 , 17, e0265397	1
477	Carnitine and Depression.. 2022 , 9, 853058	1
476	Machine learning models to predict neuropsychiatric disorders in various brain tumors.. 2022 , 1-26	
475	DNA Methylation as a Therapeutic and Diagnostic Target in Major Depressive Disorder.. 2022 , 16, 759052	1
474	[Cytochrome pharmacogenetics applied to the prescription of antidepressants: Instructions for use].. 2022 ,	0
473	BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression.. 2022 , 13, 836771	
472	Clinical Guidelines of the Egyptian Psychiatric Association for the Management of Treatment-Resistant Unipolar Depression in Egypt.. 2022 , 13, 797150	
471	Molecular Signaling Mechanisms for the Antidepressant Effects of NLX-101, a Selective Cortical 5-HT Receptor Biased Agonist.. 2022 , 15,	0
470	BDNF blood levels after electroconvulsive therapy in patients with mood disorders: an updated systematic review and meta-analysis.. 2022 , 1-29	1
469	Time for united action on depression: a Lancet-World Psychiatric Association Commission.. 2022 , 399, 957-1022	23
468	The Effect of High Frequency Versus Theta-Burst Repetitive Transcranial Magnetic Stimulation on Suicidality in Patients with Treatment Resistant Depression.. 2022 ,	0
467	Antioxidant Biomolecules and Their Potential for the Treatment of Difficult-to-Treat Depression and Conventional Treatment-Resistant Depression.. 2022 , 11,	2
466	A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression.. 2022 ,	0
465	Suicidality and Quality of Life in Treatment-Resistant Depression Patients in Latin America: Secondary Interim Analysis of the TRAL Study.. 2022 , 13, 812938	0
464	Uso de la farmacogenética como herramienta de precisión en psiquiatría: hacia una medicina personalizada. 2022 , 33, 163-173	

463	Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial.. 2022 , 12, 101	3
462	Longitudinal Stability of SCORS-G Dimensional Ratings, Score Ranges, and Narrative "Blandness" in a Clinical Sample.. 2022 ,	
461	Predicting Medication Nonadherence in Older Adults With Difficult-to-Treat Depression in the IRL-GRey Randomized Controlled Trial.. 2022 ,	
460	The Legacy of the TTASAAN Report-Premature Conclusions and Forgotten Promises: A Review of Policy and Practice Part I.. 2021 , 12, 749579	1
459	Socioeconomic Indicators of Treatment Prognosis for Adults With Depression: A Systematic Review and Individual Patient Data Meta-analysis.. 2022 ,	2
458	Ppp4r3a deficiency leads to depression-like behaviors in mice by modulating the synthesis of synaptic proteins.. 2022 ,	
457	Treatment-Resistant Depression in Portugal: Perspective From Psychiatry Experts.. 2022 , 13, 824919	
456	Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways.. 2022 , 23,	0
455	Psychostimulant use and clinical outcome of repetitive transcranial magnetic stimulation treatment of major depressive disorder.. 2022 ,	
454	Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.. 2022 ,	0
453	Beyond the neuron: Role of non-neuronal cells in stress disorders.. 2022 ,	2
452	Recent advances in the psychopharmacology of major depressive disorder. 1-14	1
451	The concentration of MMP-9 and the effects of intravenous anaesthetics on the efficacy of electroconvulsive therapy in patients with drug-resistant depression. 2022 ,	
450	Is the JAK-STAT Signaling Pathway Involved in the Pathogenesis of Depression?. 2022 , 11,	0
449	Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study.. 2022 ,	0
448	Increased Prefrontal Activation During Verbal Fluency Task After Repetitive Transcranial Magnetic Stimulation Treatment in Depression: A Functional Near-Infrared Spectroscopy Study.. 2022 , 13, 876136	0
447	Is treatment-resistant depression really resistant?. 2022 , 58, 44-46	1
446	Allostatic load as a predictor of response to repetitive transcranial magnetic stimulation in treatment resistant depression: Research protocol and hypotheses. 2022 , 10, 100133	

- 445 Reviewing the mitochondrial dysfunction paradigm in rodent models as platforms for neuropsychiatric disease research.. **2022**, 0
- 444 LOWER ANTIDEPRESSANT RESPONSE TO FLUOXETINE IS ASSOCIATED WITH ANXIETY-LIKE BEHAVIOR, HIPPOCAMPAL OXIDATIVE IMBALANCE, AND INCREASE ON PERIPHERAL IL-17 AND IFN- γ LEVELS.. **2022**, 113815
- 443 CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efficacy and tolerability.. **2022**, 312, 114535 0
- 442 Efficiently identifying individuals at high risk for treatment resistance in major depressive disorder using electronic health records.. **2022**, 306, 254-259 1
- 441 The association of C-reactive protein with responses to escitalopram antidepressant treatment in patients with major depressive disorder.. **2022**, 0
- 440 Response to TMS treatment for depression associated with higher levels of psychological well-being.. **2022**, 150, 142-146 0
- 439 Characteristics and current standard of care among veterans with major depressive disorder in the United States: A real-world data analysis.. **2022**, 0
- 438 Immunological changes following electroconvulsive therapy in multiple sclerosis.. **2022**, 150, 180-183 1
- 437 Enhanced default mode network functional connectivity links with electroconvulsive therapy response in major depressive disorder.. **2022**, 306, 47-54 2
- 436 Knockdown of FSTL1 inhibits microglia activation and alleviates depressive-like symptoms through modulating TLR4/MyD88/NF- κ B pathway in CUMS mice.. **2022**, 353, 114060 0
- 435 Health-Related Quality of Life Over 6 Months in Patients With Major Depressive Disorder Who Started Antidepressant Monotherapy.. **2022**, 30, 127-133
- 434 Long-Term Results of Deep Brain Stimulation for Treatment-Resistant Depression: Outcome Analysis and Correlation With Lead Position and Electrical Parameters.. **2022**, 90, 72-80 0
- 433 Cognitive Behavioral Therapy for Depression. **2021**, 365-458
- 432 Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).. **2021**, 3
- 431 Impact of Comorbid Personality Disorders on Depression Treatment in Routine Outpatient Care.. **2021**, 74, 150-156
- 430 Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression. **2021**, 21, 610 1
- 429 Attenuated alpha-gamma coupling in emotional dual pathways with right-Amygdala predicting ineffective antidepressant response.. **2021**, 1
- 428 P.0567 Precision medicine in the treatment of first-episode depression [Establishing the BrainDrugs-Depression Cohort. **2021**, 53, S416-S417

427	[The right to die and assisted suicide: Review and critical analysis].. 2021 ,	1
426	Cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and Morita therapy (MT); comparison of three established psychotherapies and possible common neural mechanisms of psychotherapies. 2021 , 1	1
425	P.0367 Reduced white-matter integrity in depressed non-responders to paroxetine: a diffusion tensor imaging study. 2021 , 53, S268-S269	
424	Prevention of Stress-Induced Depressive-like Behavior by Saffron Extract Is Associated with Modulation of Kynurenine Pathway and Monoamine Neurotransmission.. 2021 , 13,	1
423	P.0882 A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. 2021 , 53, S646-S647	
422	Habitual caffeine consumption moderates the antidepressant effect of dorsomedial intermittent theta-burst transcranial magnetic stimulation. 2021 , 35, 1536-1541	1
421	Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study. 2021 , 8, e4	2
420	A new experimental design to study inflammation-related versus non-inflammation-related depression in mice.. 2021 , 18, 290	1
419	Methylome-wide association study of antidepressant use in Generation Scotland and the Netherlands Twin Register implicates the innate immune system. 2021 ,	1
418	Concomitant deep brain stimulation and vagus nerve stimulation for treatment-resistant depression: a case report. 2021 ,	
417	Preliminary Effectiveness of Group Interpersonal Psychotherapy for Young Kenyan Mothers With HIV and Depression: A Pilot Trial.. 2021 , apppsychotherapy20200050	1
416	Nuclear receptors modulate inflammasomes in the pathophysiology and treatment of major depressive disorder.. 2021 , 11, 1191-1205	0
415	Effect of repetitive transcranial magnetic stimulation on patients with severe depression: a study protocol for systematic review and meta-analysis of randomised clinical trials.. 2021 , 11, e050098	
414	CBT for Persistent Depressive Disorder. 2021 , 383-401	
413	A Clinical Case Series of Acute and Maintenance Home Administered Transcranial Direct Current Stimulation in Treatment-Resistant Depression. 2021 , Publish Ahead of Print,	0
412	Increased Asymmetric Perfusion of the Cerebral Cortices and Thalamus Indicates Individuals at Risk for Bipolar Disorder: A Family Cohort Single Photon Emission Computed Tomography Neuroimaging Study. 2022 , 13,	1
411	Loflazepate. 2020 , 431-436	
410	Antidepressant effect of buddleja cordata methanolic extract in chronic stress mouse model. 2021 , 17, 780	0

- 409 The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression. **2022**, 337-357
- 408 Non-invasive brain stimulation combined with psychosocial intervention for depression: a systematic review and meta-analysis.. **2022**, 22, 273 0
- 407 Effectiveness of Metacognitive Therapy in Patients With Depression and Comorbid Anxiety Symptoms: A Case Series From India. **2022**,
- 406 Serum Cortisol, Nesfatin-1, and IL-1 β Potential Diagnostic Biomarkers in Elderly Patients with Treatment-Resistant Depression.. **2022**, 17, 567-576 0
- 405 Efficacy and acceptability of next step treatment strategies in adults with treatment-resistant major depressive disorder: protocol for systematic review and network meta-analysis.. **2022**, 12, e056777
- 404 Glutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization.. **2022**, 13, 886918 1
- 403 The Potential Use of Ebselen in Treatment-Resistant Depression.. **2022**, 15, 0
- 402 Sub-Analysis of CYP-GUIDES Data: Assessing the Prevalence and Impact of Drug-Gene Interactions in an Ethnically Diverse Cohort of Depressed Individuals.. **2022**, 13, 884213
- 401 Efficacy of Augmentation of Cognitive Behavioral Therapy With Transcranial Direct Current Stimulation for Depression: A Randomized Clinical Trial.. **2022**, 1
- 400 Physical exercise as a form of self-management for depression. 107-137
- 399 The inpatient with depression. 21-49
- 398 Data_Sheet_1.PDF. **2018**,
- 397 DataSheet_1.docx. **2019**,
- 396 Image_1.jpeg. **2019**,
- 395 Table_1.xlsx. **2019**,
- 394 Data_Sheet_1.PDF. **2018**,
- 393 Data_Sheet_1.DOCX. **2017**,
- 392 Table_1.docx. **2019**,

391 DataSheet_1.docx. **2020**,

390 Table_1.pdf. **2020**,

389 Data_Sheet_1.docx. **2019**,

388 Data_Sheet_2.docx. **2019**,

387 Data_Sheet_1.pdf. **2020**,

386 Sleep disturbance and psychiatric disorders: a bidirectional Mendelian randomisation study.. **2022**, 31, e26 1

385 Assessment of Contributing Factors and Treatment Practices for Therapeutic Efficacy and Drug-Related Problems in Suicidal Psychotic Patients. **2022**, 12, 543

384 The burden associated with, and management of, difficult-to-treat depression in patients under specialist psychiatric care in the United Kingdom.. **2022**, 2698811221090628 0

383 Impact of fasting on stress systems and depressive symptoms in patients with major depressive disorder: a cross-sectional study.. **2022**, 12, 7642 1

382 The development of a patient decision aid to reduce decisional conflict about antidepressant use in pregnancy.. **2022**, 22, 130

381 Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders.. **2022**, 1

380 Craving and addictive potential of esketamine as side effects?. **2022**, 1-10

379 Exercise more efficiently regulates the maturation of newborn neurons and synaptic plasticity than fluoxetine in a CUS-induced depression mouse model.. **2022**, 114103 0

378 Ketamine activates adult-born immature granule neurons to rapidly alleviate depression-like behaviors in mice.. **2022**, 13, 2650 1

377 Evaluating the role of maladaptive personality traits in schema therapy and cognitive behavioural therapy for depression.. **2022**, 1-10

376 Pharmacological treatment of major depressive disorder according to severity in psychiatric inpatients: results from the AMSP pharmacovigilance program from 2001-2017.. **2022**, 1 0

375 Left DLPFC activity is associated with plasma kynurenine levels and can predict treatment response to escitalopram in major depressive disorder.. **2022**, 0

374 Efficacy and Acceptability of Remote Cognitive Behavioral Therapy for Patients With Major Depressive Disorder in Japanese Clinical Settings: A Case Series. **2022**, 0

- 373 Evaluating study designs and treatment outcomes of antidepressant pharmacogenetic clinical trials - Challenges and future perspectives. A critical review.. **2022**, 59, 68-81 1
- 372 Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review.. **2022**, 312, 114579 0
- 371 Negative cognitive schema modification as mediator of symptom improvement after electroconvulsive therapy in major depressive disorder.. **2022**, 310, 156-161
- 370 Nonremission After Electroconvulsive Therapy in Individuals With Major Depression: Role of Borderline Personality Disorder.. **2022**, 1 1
- 369 The efficacy of psilocybin in the treatment of depression and anxiety: A meta-analysis. **2022**, 18,
- 368 Polypharmacy in Australian Veterans with Post-traumatic Stress Disorder upon Admission to a Mental Health Facility: A Retrospective Chart Review.. **2022**,
- 367 Comparison of moderate and vigorous walking exercise on reducing depression in middle-aged and older adults: A pilot randomized controlled trial.. **2022**, 1-23 0
- 366 Designing and Validating a Robust Adaptive Neuromodulation Algorithm for Closed-Loop Control of Brain States.. **2022**, 0
- 365 Examining the correlation between treatment effects in clinical trials and economic modelling.. **2022**,
- 364 Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.. *American Journal of Psychiatry*, **2022**, appiajp21080800 11.9 6
- 363 Treatment of Mental Health in Patients With Chronic Liver Disease.
- 362 Efficacy and Safety of Repeated Subcutaneous Ketamine Injections for Treatment Resistant Depression - The KADS Study: A Randomised, Double-Blind, Comparator-Controlled Trial.
- 361 Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review. **2022**, 13, 1
- 360 The Location Reliability of the Resting-State fMRI FC of Emotional Regions Towards rTMS Therapy.
- 359 A Randomized Clinical Trial Comparing Two Treatment Strategies, Evaluating the Meaningfulness of HAM-D Rating Scale in Patients With Major Depressive Disorder. **2022**, 13, 2
- 358 The Development of GABAergic Network in Depression in Recent 17 Years: A Visual Analysis Based on CiteSpace and VOSviewer. **2022**, 13, 0
- 357 A study protocol for an ongoing multi-arm, randomized, double-blind, sham-controlled clinical trial with digital features, using portable transcranial electrical stimulation and internet-based behavioral therapy for major depression disorders: The PSYLECT study. 0
- 356 Changes in psychotropic polypharmacy and high-potency prescription following policy change: Findings from a large scale Japanese claims database. 0

- 355 Neuroprotective effects of dimethyl fumarate against depression-like behaviors via astrocytes and microglia modulation in mice: possible involvement of the HCAR2/Nrf2 signaling pathway. 1
- 354 Clinical, gut microbial and neural effects of a probiotic add-on therapy in depressed patients: a randomized controlled trial. **2022**, 12, 3
- 353 Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders. **2022**, 11, 1826 0
- 352 Association of serum BDNF level and Val66Met polymorphism with response to treatment in patients of major depressive disease: A step towards personalized therapy. **2022**, 430, 113931
- 351 Risk of relapse within 6 months associated with borderline personality disorder in major depressed individuals treated with electroconvulsive therapy. **2022**, 314, 114650 0
- 350 Electrophysiological and molecular effects of bilateral deep brain stimulation of the medial forebrain bundle in a rodent model of depression. **2022**, 355, 114122 0
- 349 Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: a systematic review and dose-effect meta-analysis.
- 348 Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing Psychotropics. 13, 2
- 347 Reduced nucleus accumbens functional connectivity in reward network and default mode network in patients with recurrent major depressive disorder. **2022**, 12, 0
- 346 Approaches and hurdles of implementing pharmacogenetic testing in the psychiatric clinic. **2022**, 1,
- 345 Repetitive Transcranial Magnetic Stimulation for the Treatment of Resistant Depression: A Scoping Review. **2022**, 12, 195 0
- 344 Care pathways for people with major depressive disorder: a European Brain Council Value of Treatment study. 1-21 1
- 343 Associations of dysfunctional attitudes, ruminations and metacognitive beliefs about rumination with pharmacological treatment response in patients with first episode of major depression. 1-8
- 342 Transcranial magnetic stimulation in the treatment of adolescent depression: a systematic review and meta-analysis of aggregated and individual-patient data from uncontrolled studies. 1
- 341 Slow wave sleep deficits in the flinders sensitive line rodent model of depression: effects of medial forebrain bundle deep-brain stimulation. **2022**, 0
- 340 Psychopharmacological Recovery-Oriented Treatments in Bipolar Disorders. **2022**, 199-224
- 339 Dimensions and Predictors of Personal Recovery in Major Depression. **2022**, 225-244
- 338 Associations between brain-derived neurotrophic factor val66met polymorphism, melancholic feature, and treatment refractoriness in patients with treatment-resistant depression. **2022**, 36, 68

- 337 Treatment of Depression with Botulinum Toxin. **2022**, 14, 383 ○
- 336 Repetitive transcranial magnetic stimulation may be a cost-effective alternative to antidepressant therapy after two treatment failures in patients with major depressive disorder. **2022**, 22,
- 335 Treatment Patterns During Major Depressive Episodes Among Patients with Major Depressive Disorder: A Retrospective Database Analysis. ○
- 334 Depression and suicidality severity among TRD patients after 1-year under standard of care: Findings from the TRAL study, a multicenter, multinational, observational study in Latin America. **2022**,
- 333 Emerging Roles of T Helper Cells in Non-Infectious Neuroinflammation: Savior or Sinner. 13,
- 332 Novel uses of ketamine in the emergency department. ○
- 331 Deep Brain Stimulation for Depression. ○
- 330 Inibidores da monoaminoxidase e cetamina intravenosa: uma associaçã segura?. 12, 1-20
- 329 The effect of vitamin D supplementation on depressive symptoms in adults: A systematic review and meta-analysis of randomized controlled trials. 1-18 2
- 328 Predicting Escitalopram Treatment Response from Pre-treatment and Early Response Resting State fMRI in a Multi-site Sample: A CAN-BIND-1 Report. **2022**, 103120 ○
- 327 Impact of Sevoflurane and Thiopental Used Over the Course of Electroconvulsive Therapy: Propensity Score Matching Analysis. 16,
- 326 Digital Therapeutics to Enhance Cognition in Major Depression: How Can We Make the Cognitive Gains Translate Into Functional Improvements?. *American Journal of Psychiatry*, **2022**, 179, 445-447 11.9 1
- 325 The Impact of Theta-Burst Stimulation on Cortical GABA and Glutamate in Treatment-Resistant Depression: A Surface-Based MRSI Analysis Approach. 15,
- 324 Prognostic Significance of Blood-Based Baseline Biomarkers in Treatment-Resistant Depression: A Literature Review of Available Studies on Treatment Response. **2022**, 12, 940 ○
- 323 Is Neuroplasticity Key to Treatment Response in Depression? Maybe So. *American Journal of Psychiatry*, **2022**, 179, 451-453 11.9 1
- 322 Repurposing Anti-inflammatory Agents for Mood Disorders: an Updated Review of Current Evidence. ○
- 321 Forty-eight Week Outcomes of a Site-Randomized Trial of Combined Cognitive Behavioral Therapy and Medication Management Algorithm for Treatment of Depression Among Youth with HIV in the United States. **2022**, Publish Ahead of Print,
- 320 Genetic variables of the glutamatergic system associated with treatment-resistant depression: A review of the literature. **2022**, 12, 884-896 1

- 319 Neuromodulation Treatments of Pathological Anxiety in Anxiety Disorders, Stressor-Related Disorders, and Major Depressive Disorder: A Dimensional Systematic Review and Meta-Analysis. 13,
- 318 Impaired socio-affective, but intact socio-cognitive skills in patients with treatment-resistant, recurrent depression. **2022**, 153, 206-212
- 317 C-reactive protein could predict the efficacy of SSRIs in clinical practice: A cohort study of large samples in the real world. **2022**, 313, 251-259
- 316 Adjunctive home-based transcranial direct current stimulation treatment for major depression with real-time remote supervision: An open-label, single-arm feasibility study with long term outcomes. **2022**, 153, 197-205 O
- 315 Association between peripheral inflammation and free-water imaging in Major Depressive Disorder before and after ketamine treatment [A pilot study]. **2022**, 314, 78-85 O
- 314 At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. **2022**, 314, 59-67 I
- 313 Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8 weeks. **2022**, 314, 27-33
- 312 Zolpidem. **2020**, 871-874
- 311 Pipothiazine. **2020**, 633-638
- 310 Thioridazine. **2020**, 759-764
- 309 Vortioxetine. **2020**, 853-858
- 308 Prazosin. **2020**, 643-646
- 307 Temazepam. **2020**, 755-758
- 306 Index by Drug Name. **2020**, 895-910
- 305 Quetiapine. **2020**, 667-676
- 304 Rivastigmine. **2020**, 699-704
- 303 Triiodothyronine. **2020**, 813-816
- 302 Index by Class. **2020**, 919-922

301 Zuclopenthixol. **2020**, 889-894

300 Tranylcypromine. **2020**, 787-792

299 Protriptyline. **2020**, 657-662

298 Index by Use. **2020**, 911-918

297 Reboxetine. **2020**, 681-686

296 Sulpiride. **2020**, 741-746

295 Zopiclone. **2020**, 879-882

294 Trifluoperazine. **2020**, 803-808

293 Ziprasidone. **2020**, 863-870

292 Triazolam. **2020**, 799-802

291 Perphenazine. **2020**, 607-612

290 Topiramate. **2020**, 781-786

289 Trazodone. **2020**, 793-798

288 Tiagabine. **2020**, 771-776

287 Vilazodone. **2020**, 847-852

286 Risperidone. **2020**, 687-698

285 Phenelzine. **2020**, 613-618

284 Valproate. **2020**, 829-836

283 Varenicline. **2020**, 837-840

282 Pitolisant. **2020**, 639-642

281 Sertraline. **2020**, 721-728

280 Pregabalin. **2020**, 647-652

279 Tasimelteon. **2020**, 751-754

278 Perospirone. **2020**, 601-606

277 Zonisamide. **2020**, 875-878

276 Trimipramine. **2020**, 817-824

275 Thiothixene. **2020**, 765-770

274 Valbenazine. **2020**, 825-828

273 Selegiline. **2020**, 705-714

272 Zaleplon. **2020**, 859-862

271 Tianeptine. **2020**, 777-780

270 Suvorexant. **2020**, 747-750

269 Sodium oxybate. **2020**, 733-736

268 Pimozide. **2020**, 627-632

267 solriamfetol. **2020**, 737-740

266 Zotepine. **2020**, 883-888

- 265 Pimavanserin. **2020**, 623-626
- 264 Phentermine/topiramate. **2020**, 619-622
- 263 Trihexyphenidyl. **2020**, 809-812
- 262 Propranolol. **2020**, 653-656
- 261 Venlafaxine. **2020**, 841-846
- 260 Quazepam. **2020**, 663-666
- 259 Sertindole. **2020**, 715-720
- 258 Paroxetine. **2020**, 593-600
- 257 Sildenafil. **2020**, 729-732
- 256 Ramelteon. **2020**, 677-680
- 255 Mental Activity as the Bridge between Neural Biomarkers and Symptoms of Psychiatric Illness. 155005942211124
- 254 A comprehensive approach to predicting weight gain and therapy response in psychopharmacologically treated major depressed patients: A cohort study protocol. **2022**, 17, e0271793
- 253 Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial. 13,
- 252 Zelquistinel is an orally bioavailable novel NMDA receptor allosteric modulator that exhibits rapid and sustained antidepressant-like effects. ○
- 251 Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study.
- 250 Studies of Online Cohorts for Internalizing symptoms and Language (SOCIAL) I and II: Triangulating surveys and social media data (Preprint). ○
- 249 Assessing the impact of pre-test education on patient knowledge, perceptions, and expectations of pharmacogenomic testing to guide antidepressant use.
- 248 Future of Digital Assays to Resolve Clinical Heterogeneity of Single Extracellular Vesicles. **2022**, 16, 11619-11645

247	Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. 026988112211040	0
246	Difficult-to-Treat Depression and the Role of Vagus Nerve Stimulation. 2022 , 52, 266-271	
245	Lourein C and Xanthoceraside Prevent Abnormal Behaviors Associated with Downregulation of Brain Derived Neurotrophic Factor and AKT/mTOR/CREB Signaling in the Prefrontal Cortex Induced by Chronic Corticosterone Exposure in Mice.	1
244	Association between gut microbiota and depressive symptoms: A cross-sectional population-based study in South Korea. Publish Ahead of Print,	0
243	Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine. 2022 , 239, 2735-2752	2
242	Benefits of group compassion-focused therapy for treatment-resistant depression: A pilot randomized controlled trial. 13,	
241	Single molecule long-read real-time amplicon-based sequencing of CYP2D6: a proof-of-concept with hybrid haplotypes.	0
240	Morinda officinalis oligosaccharides mitigate chronic mild stress-induced inflammation and depression-like behaviour by deactivating the MyD88/PI3K pathway via E2F2. 13,	
239	Statins in depression: a repurposed medical treatment can provide novel insights in mental health. 1-16	2
238	Behavioral Patterns of Depression Patients and Control Population. 2022 , 19, 9506	0
237	Assessment of objective and subjective cognitive function in patients with treatment-resistant depression undergoing repeated ketamine infusions.	0
236	Effect of Epigallocatechin-3-gallate on Stress-Induced Depression in a Mouse Model: Role of Interleukin-1 β and Brain-Derived Neurotrophic Factor.	1
235	Development and evaluation of the HRSD-D, an image-based digital measure of the Hamilton rating scale for depression. 2022 , 12,	
234	Cost-Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective.	1
233	Humanistic and economic burden associated with depression in the United States: a cross-sectional survey analysis. 2022 , 22,	0
232	Altered Regional Homogeneity and Amplitude of Low-Frequency Fluctuations Induced by Electroconvulsive Therapy for Adolescents with Depression and Suicidal Ideation. 2022 , 12, 1121	
231	Machine learning, pharmacogenomics, and clinical psychiatry: predicting antidepressant response in patients with major depressive disorder. 1-18	0
230	Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies. 2022 , 316, 201-208	1

- 229 Repeated intravenous esketamine treatment in patients with ECT-resistant major depressive disorder. **2022**, 10, 100400
- 228 Genetics-informed precision treatment formulation in schizophrenia and bipolar disorder. **2022**, 109, 1620-1637 ○
- 227 Transcranial magnetic stimulation and intravenous ketamine combination therapy for treatment-resistant bipolar depression: A case report. 13, ○
- 226 The association between sample and treatment characteristics and the efficacy of repetitive transcranial magnetic stimulation in depression: A meta-analysis and meta-regression of sham-controlled trials. **2022**, 141, 104848 ○
- 225 The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review. **2022**, 318, 139-149 ○
- 224 Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates. **2022**, 319, 388-396 1
- 223 Electrical brain stimulation to treat neurological disorders. **2022**, 267-302 ○
- 222 Ketamine alleviating depressive-like behaviors is associated with regulation of nNOS/APON/Dexas1 complex in chronic unpredictable mild stress rats. **2022**, 13, 309-319 ○
- 221 Evolutionary Aspects of Diverse Microbial Exposures and Mental Health: Focus on Old Friends and Stress Resilience. **2022**, 1 ○
- 220 Shape-Based Features of White Matter Fiber-Tracts Associated with Outcome in Major Depression Disorder. **2022**, 163-173 ○
- 219 Serotonergic Neurotransmission in Limbic Regions May Reflect Therapeutic Response of Depressive Patients: A PET Study with 11C-WAY-100635 and 18F-MPPF. ○
- 218 Patients' and psychiatrists' stance on the current state of pharmacological depression treatment in Serbia and prospects of introduction of personalized pharmacotherapy and its potential effects. **2022**, 72, 381-391 ○
- 217 Blending digital therapeutics within the healthcare system. **2023**, 45-64 ○
- 216 Personalized Diagnosis and Treatment for Neuroimaging in Depressive Disorders. **2022**, 12, 1403 ○
- 215 Treatment of depression in the elderly with repetitive transcranial magnetic stimulation using theta-burst stimulation: Study protocol for a randomized, double-blind, controlled trial. 16, ○
- 214 Incentivizing drug development in serious mental illness. **2022**, ○
- 213 Concordance of the treatment patterns for major depressive disorders between the Canadian Network for Mood and Anxiety Treatments (CANMAT) algorithm and real-world practice in China. 13, ○
- 212 Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study. Volume 18, 1963-1974 ○

211	Unresolved Systemic Inflammation, Long COVID, and the Common Pathomechanisms of Somatic and Psychiatric Comorbidity. 2022 , 11, 5114	1
210	Integrative multi-omics landscape of fluoxetine action across 27 brain regions reveals global increase in energy metabolism and region-specific chromatin remodelling.	0
209	Advances in optogenetic studies of depressive-like behaviors and underlying neural circuit mechanisms. 13,	0
208	Involvement of Anti-Inflammatory and Stress Oxidative Markers in the Antidepressant-like Activity of Aloysia citriodora and Verbascoside on Mice with Bacterial Lipopolysaccharide- (LPS-) Induced Depression. 2022 , 2022, 1-18	0
207	The 5-year longitudinal diagnostic profile and health services utilization of patients treated with electroconvulsive therapy in Quebec: a population-based study.	0
206	Investigation of Neurofunctional Changes Over the Course of Electroconvulsive Therapy.	0
205	Responding to the Shrinking Scope of Psychiatrists' Prescribing Practices.	0
204	Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression. 2022 , 5, e2230367	2
203	Combined repetitive transcranial magnetic stimulation and medication treatment for depression is associated with serum amyloid a level: Evidence from naturalistic clinical practice. 16,	0
202	Sucrose Preference Test as a Measure of Anhedonic Behavior in a Chronic Unpredictable Mild Stress Model of Depression: Outstanding Issues. 2022 , 12, 1287	1
201	Connectome-guided transcranial magnetic stimulation treatment in depression. 2022 , 31, 1481-1483	0
200	Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine [Implications for dose considerations.	1
199	Prediction of remission among patients with a major depressive disorder based on the resting-state functional connectivity of emotion regulation networks. 2022 , 12,	0
198	Adjunctive Bright Light Therapy for Non-Seasonal Major Depressive Disorder: A Randomized Controlled Trial. 2022 , 19, 12430	0
197	Olfactory loss is a predisposing factor for depression, while olfactory enrichment is an effective treatment for depression. 16,	0
196	La investigación sobre el tratamiento de depresión con base en registros de historia clínica: análisis de una experiencia en un hospital universitario. 2022 ,	0
195	Study protocol for evaluating the clinical efficacy and neurobiological correlates of sequential treatment with tDCS primed iTBS and ECT in treatment-resistant depression. 7, 242	0
194	The effect of the time to remission on residual symptoms and functioning among depressive patients. 2022 ,	0

- 193 Neural mechanism of the relationship between sleep efficiency and clinical improvement in major depressive disorder: A longitudinal functional magnetic resonance imaging study. 13, 0
- 192 Emulating a target trial of dynamic treatment strategies for major depressive disorder using data from the STAR*D randomized trial. **2022**, 0
- 191 Assessment of Outcome-Based Measures of Depression Care Quality in Veterans Health Administration Facilities. 0
- 190 Beneficial effects and neurobiological aspects of environmental enrichment associated to major depressive disorder and autism spectrum disorder. **2022**, 0
- 189 Characteristics of Real-World Commercially Insured Patients With Treatment-Resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States. **2022**, 1
- 188 The treatment of depression [Searching for new ideas. 13, 0
- 187 Generalizability of treatment outcome prediction in major depressive disorder using structural MRI: A NeuroPharm study. **2022**, 36, 103224 0
- 186 Mental Health Services Research and Community Psychiatry. **2022**, 411-425 0
- 185 Peripheral proteomic changes after electroconvulsive seizures in a rodent model of non-response to chronic fluoxetine. 13, 0
- 184 Efficacy of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation for Major Depressive Disorder. 2
- 183 Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis. 0
- 182 Cervical muscle stiffness and parasympathetic nervous system improvements for treatment-resistant depression. **2022**, 23, 0
- 181 Meridianins Inhibit GSK3 β In Vivo and Improve Behavioral Alterations Induced by Chronic Stress. **2022**, 20, 648 0
- 180 Chaihu-shugan-san alleviates depression-like behavior in mice exposed to chronic unpredictable stress by altering the gut microbiota and levels of the bile acids hyocholic acid and 7-ketoDCA. 13, 0
- 179 Recent innovations in non-invasive brain stimulation (NIBS) for the treatment of unipolar and bipolar depression: a narrative review. 1-12 1
- 178 Irremediability in psychiatric euthanasia: examining the objective standard. 1-19 0
- 177 Components of Behavioral Activation Therapy for Depression Engage Specific Reinforcement Learning Mechanisms in a Pilot Study. **2022**, 6, 238 0
- 176 Perspectives on the success rate of current antidepressant pharmacotherapy. 1-11 0

175	Examining the synergistic effects of a cognitive control video game and a home-based, self-administered non-invasive brain stimulation on alleviating depression: the DiSCoVeR trial protocol.	0
174	Comprehensive analysis of endoplasmic reticulum stress and immune infiltration in major depressive disorder. 13,	0
173	Evaluation of Inflammatory Response System (IRS) and Compensatory Immune Response System (CIRS) in Adolescent Major Depression. Volume 15, 5959-5976	1
172	Rates of Divergent Pharmacogenes in a Psychiatric Cohort of Inpatients with Depression Arguments for Preemptive Testing. 2022, 12, 317-328	0
171	Adjunctive accelerated repetitive transcranial magnetic stimulation for older patients with depression: A systematic review. 14,	0
170	Sex-specific effects of voluntary wheel running on behavior and the gut microbiota-immune-brain axis in mice.	0
169	Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. 2022, 387, 1637-1648	9
168	Proof-of-Principle Study on ECT Illustrates Challenges and Possible Merits of Using Polygenic Risk Scores to Predict Treatment Response in Psychiatry. 2022, 179, 794-797	1
167	Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. 2022, 9, 907-921	1
166	What outcomes matter to service users who experience persistent depression: A mixed-method narrative review and synthesis. 2022, 10, 100431	0
165	Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. 2023, 320, 353-359	1
164	Pharmakotherapie: Akuttherapie. 2023, 149-164	0
163	Electroencephalography for predicting antidepressant treatment success: A systematic review and meta-analysis. 2023, 321, 201-207	1
162	Therapieprinzipien, Therapierahmen, Therapieleitlinien. 2023, 135-142	0
161	Combination Therapies and Switching of Agents in Depression and Bipolar Disorders. 2022, 4479-4495	0
160	Psychopharmacotherapy of Depressive Disorders. 2022, 4033-4073	0
159	Current approaches to precision medicine in psychiatry: Are we just spinning our wheels?. 2023, 66, 11-13	0
158	The implication of a diversity of non-neuronal cells in disorders affecting brain networks. 16,	0

157	Serotonin-releasing agents with reduced off-target effects.	0
156	Blueberry Extract Modulates Brain Enzymes Activities and Reduces Neuroinflammation: Promising Effect on Lipopolysaccharide-Induced Depressive-Like Behavior.	0
155	Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study.	0
154	Effectiveness and safety of monoamine oxidase inhibitor treatment for bipolar depression versus unipolar depression: An exploratory case cohort study.	0
153	Evaluating cognitive disturbances as treatment target and predictor of antidepressant action in major depressive disorder: A NeuroPharm study. 2022 , 12,	1
152	A kynurenine pathway enzyme aminocarboxymuconate-semialdehyde decarboxylase may be involved in treatment-resistant depression, and baseline inflammation status of patients predicts treatment response: a pilot study. 2022 , 129, 1513-1526	0
151	Cytochromes P450 and P-Glycoprotein Phenotypic Assessment to Optimize Psychotropic Pharmacotherapy: A Retrospective Analysis of Four Years of Practice in Psychiatry. 2022 , 12, 1869	1
150	Association between electroconvulsive therapy and depressive disorder from 2012 to 2021: Bibliometric analysis and global trends. 16,	0
149	Personalised depression forecasting using mobile sensor data and ecological momentary assessment. 4,	0
148	‘I am strong and I can get on with my life’—The subjective experience of recovery of patients treated for depression. 1-15	0
147	Comparison on the clinical features in patients with or without treatment-resistant depression: A National Survey on Symptomatology of Depression report. 2023 , 319, 114972	2
146	Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials. 2023 , 144, 104965	0
145	Efficacy of an adjuvant non-face-to-face multimodal lifestyle modification program for patients with treatment-resistant major depression: A randomized controlled trial. 2023 , 319, 114975	0
144	Predicting the efficacy of escitalopram in the treatment of depression through urinary proteome. 2023 , 484, 116980	0
143	Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system. 2023 , 223, 109348	0
142	NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research. 2023 , 225, 109378	1
141	‘Drugs of Abuse’ as a ‘New Antidepressant’— A Review on Pharmacological Mechanisms, Antidepressant Effects, and Abuse Potential. 2022 , 61, 243	0
140	Positive anxiety or depression screen despite ongoing antidepressant prescription in people with epilepsy: A large cross-sectional analysis. 2022 , 20, 100572	0

- 139 Effect of Personality Traits on Sustained Remission Among Patients with Major Depression: A 12-Month Prospective Study. Volume 18, 2771-2781 ○
- 138 Client Outcomes in Graduate Trainee-Provided Psychotherapies: A Mixed Model and Exploratory Analysis. 104973152211158 ○
- 137 Salivary microRNA and Metabolic Profiles in a Mouse Model of Subchronic and Mild Social Defeat Stress. **2022**, 23, 14479 ○
- 136 A Southeast Asia Consensus on the Definition and Management of Treatment-Resistant Depression. Volume 18, 2747-2757 ○
- 135 Antidepressant effects of the traditional Chinese herbal formula Xiao-Yao-San and its bioactive ingredients. **2022**, 154558 ○
- 134 The clinical & economic burden of treatment-resistant depression in the Gulf-Cooperation Council: The Kingdom of Saudi Arabia, Kuwait and the United Arab Emirates. ○
- 133 The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine. **2022**, 23, 14605 ○
- 132 Neuroimaging-derived biomarkers of the antidepressant effects of ketamine. **2022**, ○
- 131 Effect of low-intensity focused ultrasound of right anteromedial cortico-subcortical circuits on repetitive negative and self-referential thinking in depression: a sham-controlled randomized feasibility trial. ○
- 130 Annual costs among patients with major depressive disorder and the impact of key clinical events. **2022**, 28, 1335-1343 ○
- 129 The economics of psychedelic-assisted therapies: A research agenda. 13, ○
- 128 Effect of pharmacogenomic testing on pediatric mental health outcome: a 6-month follow-up. ○
- 127 Transcranial Direct Current Stimulation as Treatment for Major Depression in a Home Treatment Setting (HomeDC Trial): Study Design and Methodology of a Double-blind, Placebo-controlled Pilotstudy. ○
- 126 Residual symptoms and their associated factors among Thai patients with depression: a multihospital-based survey. **2022**, 21, ○
- 125 Network analysis of depression in prostate cancer patients: Implications for assessment and treatment. ○
- 124 Immune cell composition in unipolar depression: a comprehensive systematic review and meta-analysis. 1
- 123 Factors associated with antidepressant responses to repetitive transcranial magnetic stimulation in antidepressant-resistant depression. 16, ○
- 122 White Matter Microstructure Associated with the Antidepressant Effects of Deep Brain Stimulation in Treatment-Resistant Depression: A Review of Diffusion Tensor Imaging Studies. **2022**, 23, 15379 ○

- 121 Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study. ○
- 120 Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases. 1
- 119 Case report: Medical student types journals during ketamine infusions for suicidal ideation, treatment-resistant depression, post-traumatic stress disorder, and generalized anxiety disorder. 13, ○
- 118 Optimal parameter determination of repetitive transcranial magnetic stimulation for treating treatment-resistant depression: A network meta-analysis of randomized controlled trials. 13, ○
- 117 Physical Inactivity and Depression: The Gloomy Dual with Rising Costs in a Large-Scale Emergency. **2023**, 20, 1603 ○
- 116 On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression. **2023**, 4, 8-9 ○
- 115 Feasibility, Acceptability, and Safety of Faecal Microbiota Transplantation in the Treatment of Major Depressive Disorder: A Pilot Randomized Controlled Trial. 070674372211505 ○
- 114 Integration of a pharmacist-led pharmacogenomic service in a geriatric clinic: Barriers and outcomes. **2023**, ○
- 113 Behavioral, cortical and autonomic effects of single-dose escitalopram on the induction and regulation of fear and disgust: Comparison with single-session psychological emotion regulation with reappraisal. 13, ○
- 112 The Precision in Psychiatry (PIP) study: Testing an internet-based methodology for accelerating research in treatment prediction and personalisation. **2023**, 23, ○
- 111 Interferon signaling and hypercytokinemia-related gene expression in the blood of antidepressant non-responders. **2023**, e13059 ○
- 110 Depression and Cancer: The Inflammatory Bridge. **2023**, ○
- 109 Structural brain plasticity and inflammation are independently related to changes in depressive symptoms six months after an index ECT course. 1-9 ○
- 108 Microglia transcriptional profiling in major depressive disorder shows inhibition of cortical grey matter microglia. ○
- 107 Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice. ○
- 106 Assessment and Management of Suicidal Risk. **2023**, 1-32 ○
- 105 Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: I. Association with change in quality of life. 1-13 ○
- 104 Associations between mortality and exposure to psychotropic medication: A population-based cohort study for depressive disorders. 000486742211453 ○

- 103 Child Maltreatment: Internalizing Characteristics. **2023**, 1-11 ○
- 102 A prospective cohort study of depression (PROUD) in China: rationale and design. **2023**, 2, ○
- 101 Effects of bilateral sequential theta-burst stimulation on functional connectivity in treatment-resistant depression: First results. **2023**, 324, 660-669 ○
- 100 The impact of early remission on disease trajectory and patient outcomes in major depression disorder (MDD): A targeted literature review and microsimulation modeling approach based on the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. **2023**, 325, 264-272 ○
- 99 Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. **2023**, 226, 109422 ○
- 98 Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States. **2022**, 28, S2-S13 ○
- 97 Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression. **2023**, 16, 31 ○
- 96 Recent advances in low-level laser therapy on depression. **2022**, 1-16 ○
- 95 Early-Onset Effectiveness of Adjunctive Aripiprazole in Patients With Depression With Inadequate Response to First-Line Antidepressants. **2022**, 52, 518-526 ○
- 94 Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial. **2023**, ○
- 93 Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy. **2023**, 41, 209-225 ○
- 92 Brain-Machine Interfaces for Closed-Loop Electrical Brain Stimulation in Neuropsychiatric Disorders. **2023**, 1317-1342 ○
- 91 Identification of drug and protein-protein interaction network among stress and depression: A bioinformatics approach. **2023**, 37, 101174 ○
- 90 AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale. **2023**, 23, ○
- 89 Non-pharmacological treatment-related changes of molecular biomarkers in major depressive disorder: A systematic review and meta-analysis. **2023**, 23, 100367 ○
- 88 Apparent Lack of Benefit of Combining Repetitive Transcranial Magnetic Stimulation with Internet-Delivered Cognitive Behavior Therapy for the Treatment of Resistant Depression: Patient-Centered Randomized Controlled Pilot Trial. **2023**, 13, 293 ○
- 87 4-F-PCP, a Novel PCP Analog Ameliorates the Depressive-Like Behavior of Chronic Social Defeat Stress Mice via NMDA Receptor Antagonism. **2023**, 31, 227-239 ○
- 86 Possible psychedelic therapeutic mechanism. **2023**, 379, 642-643 ○

- 85 Response to electroconvulsive therapy in treatment-resistant depression: nationwide observational follow-up study. **2023**, 9, ○
- 84 Pharmacotherapy for Depression and Anxiety in the Primary Care Setting. **2023**, 19, 104556 ○
- 83 Effect of Ketamine on Sleep in Treatment-Resistant Depression: A Systematic Review. **2023**, 16, 568 ○
- 82 Brain volumetric correlates of electroconvulsive therapy versus transcranial magnetic stimulation for treatment-resistant depression. **2023**, ○
- 81 Information flow and dynamic functional connectivity during electroconvulsive therapy in patients with depression. **2023**, 328, 141-152 ○
- 80 Eight-week antidepressant treatment changes intrinsic functional brain topology in first-episode drug-naïve patients with major depressive disorder. **2023**, 329, 225-234 ○
- 79 Right-side frontal-central cortical hyperactivation before the treatment predicts outcomes of antidepressant and electroconvulsive therapy responsivity in major depressive disorder. **2023**, 161, 377-385 ○
- 78 Deep TMS H1 Coil treatment for depression: Results from a large post marketing data analysis. **2023**, 324, 115179 ○
- 77 Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis. **2023**, 330, 227-238 ○
- 76 Major Depressive Disorder and Oxidative Stress: A Review of Peripheral and Genetic Biomarkers According to Clinical Characteristics and Disease Stages. **2023**, 12, 942 ○
- 75 Adaption of tele-behavioral activation to increase physical activity in depression: Protocol for iterative development and evaluation. **2023**, 33, 101103 ○
- 74 The expression of agmatinase manipulates the affective state of rats subjected to chronic restraint stress. **2023**, 229, 109476 ○
- 73 Applications of the One Health concept: Current status in the Middle East. **2023**, 5, 21-31 ○
- 72 Real world transcranial magnetic stimulation for major depression: A multisite, naturalistic, retrospective study. **2023**, 326, 26-35 ○
- 71 Development of a model to predict combined antidepressant medication and psychotherapy treatment response for depression among veterans. **2023**, 326, 111-119 ○
- 70 Systematic review of structured care pathways in major depressive disorder and bipolar disorder. **2023**, 23, ○
- 69 Stress-related reduction of hippocampal subfield volumes in major depressive disorder: A 7-Tesla study. 14, ○
- 68 Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. **2023**, 327, 120-127 ○

67	Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis. 2023 , 321, 115102	0
66	Effects of 12-week escitalopram treatment on resting-state functional connectivity of large-scale brain networks in major depressive disorder. 2023 , 44, 2572-2584	0
65	The Effectiveness of a Mobile-Based Physical Activity Program for Treating Depression Among Adults in Korea: A Pilot Study (Preprint).	0
64	Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. 2023 , 180, 241-251	2
63	Economic evaluation of interventions for treatment-resistant depression: A systematic review. 14,	0
62	Predictive capabilities of the Cloninger Temperament and Character Inventory (TCI) in evaluating the effectiveness of antidepressant pharmacotherapy. Systematic review and meta-analysis. 2023 , 15, 4-17	0
61	EEG frontal lobe asymmetry as a function of sex, depression severity, and depression subtype. 2023 , 443, 114354	0
60	Effect of Adjunctive Simvastatin on Depressive Symptoms Among Adults With Treatment-Resistant Depression. 2023 , 6, e230147	0
59	Antidepressiva State of the Art. 2023 , 56, 100-106	0
58	µOpioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine. 2023 , 43, 89-96	0
57	Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions. 2023 , 223, 173531	0
56	Machine learning prediction will be part of future treatment of depression. 000486742311582	0
55	Störungsspezifische Psychotherapien: IPT und CBASP. 2022 , 453-475	0
54	Nichtinvasive Hirnstimulationsverfahren. 2022 , 331-357	0
53	Leitlinien und Therapiealgorithmen. 2022 , 251-261	0
52	Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. 2023 , 180, 190-199	1
51	A New Option for Depressed Patients Who Do Not Respond to Antidepressant Medications. 2023 , 180, 188-189	1
50	Comparison of Efficacy and Safety of Magnetic Seizure Therapy and Electroconvulsive Therapy for Depression: A Systematic Review. 2023 , 13, 449	0

49	Plausible Role of Stem Cell Types for Treating and Understanding the Pathophysiology of Depression. 2023 , 15, 814	0
48	Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. 2023 , 388, 1067-1079	1
47	Predictive neuromodulation of cingulo-frontal neural dynamics in major depressive disorder using a brain-computer interface system: A simulation study. 17,	0
46	A Systematic Review Assessing Patient-Related Predictors of Response to Transcranial Magnetic Stimulation in Major Depressive Disorder. Volume 19, 565-577	0
45	Improvement of depressive symptoms, after a suicide attempt, with dextromethorphan/bupropion combination treatment in a patient with treatment-resistant depression and psychiatric comorbidities. 2023 , 11,	0
44	Deep phenotyping towards precision psychiatry of first-episode depression <i>The Brain Drugs-Depression cohort</i> . 2023 , 23,	0
43	Pharmacotherapy. 2023 ,	0
42	Effect of Probiotic Supplementation on Gut Microbiota in Patients with Major Depressive Disorders: A Systematic Review. 2023 , 15, 1351	2
41	Rethinking the medication management of major depression. 2023 , 23, 331-363	0
40	Partially observable collaborative model for optimizing personalized treatment selection. 2023 ,	0
39	The Role of Psychotherapy in the Management of Treatment-Resistant Depression. 2023 ,	0
38	Noninvasive Brain Stimulation Techniques for Treatment-Resistant Depression. 2023 ,	0
37	The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric Disorders. 2023 , 37-99	0
36	Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans. 2023 , 26, 422-429	0
35	Individualisation du traitement antidépresseur: suivi thérapeutique pharmacologique et tests pharmacogénétiques. 2023 ,	0
34	Life Engagement Improvement Following Initiation of Brexpiprazole Treatment in Patients with MDD: A Naturalistic, Retrospective Real-World Study. Volume 15, 195-208	0
33	Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence. 2023 , 23, 205-212	0
32	Challenging the Pleiotropic Effects of Repetitive Transcranial Magnetic Stimulation in Geriatric Depression: A Multimodal Case Series Study. 2023 , 11, 958	0

- 31 Predicting future depressive episodes from resting-state fMRI with generative embedding. **2023**, 273, 119986
- 30 Cell-liposome delivery system based on neuroinflammation to target the amygdala for ameliorating depressive-like behaviors. **2023**, 637, 122724
- 29 Repetitive Negative Thinking-Specific and Nonspecific White Matter Tracts Engaged by Historical Psychosurgical Targets for Depression. **2023**,
- 28 Efficacy and safety of theta burst versus repetitive transcranial magnetic stimulation for major depressive disorder: a meta- analysis of randomized controlled trials.
- 27 Elevated C-Reactive Protein Levels Modify the Effect of Magnesium on Depressive Symptoms: A Population-Based Study. **2023**, 15, 1560
- 26 Brain Features of Treatment-Resistant Depression. **2023**,
- 25 Pharmacotherapy for Treatment-Resistant Depression. **2023**,
- 24 Approach to Diagnosis and Management of Treatment-Resistant Depression. **2023**,
- 23 Reducing default mode network connectivity with mindfulness-based fMRI neurofeedback: a pilot study among adolescents with affective disorder history.
- 22 Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA. Volume 19, 693-707
- 21 Safety and tolerance of combination of monoamine oxidase inhibitors and direct dopamine agonists in adults and older adults with highly resistant depression. **2023**,
- 20 Clinical pharmacological innovation in the treatment of depression. **2023**, 16, 349-362
- 19 Efficacy of dynamic interpersonal therapy for major depressive disorder in China: results of a multicentered, three-arm, randomized, controlled trial. 1-13
- 18 Effectiveness of medical fee revisions for psychotropic polypharmacy in patients with mood disorders in Japan: An interrupted time-series analysis using a nationwide inpatient database. **2023**, 84, 103581
- 17 Electroconvulsive therapy induces remodeling of hippocampal co-activation with the default mode network in patients with depression. **2023**, 38, 103404
- 16 Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report Data. **2023**,
- 15 Targeting the Arginine Vasopressin V1b Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders. Volume 19, 811-828
- 14 Treatment-resistant depression begs for innovation. **2023**, 33, 5-5

- 13 Sickness Behaviour and Depression: An Updated Model of Peripheral-Central Immunity Interactions. **2023**, ○
- 12 Can Epigenetics Predict Drug Efficiency in Mental Disorders?. **2023**, 12, 1173 ○
- 11 Molecular imaging findings for treatment resistant depression. **2023**, ○
- 10 The Effect of Adding Curcumin to Sertraline in the Treatment of Severe Major Depressive Disorder: A Randomized, Double-Blind Clinical Trial. Publish Ahead of Print, ○
- 9 Unveiling behavioral and molecular neuroadaptations related to the antidepressant action of cannabidiol in the unpredictable chronic mild stress model. 14, ○
- 8 Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis. **2023**, 13, 1043 ○
- 7 Pharmacogenomics in allogeneic hematopoietic stem cell transplantation: Implications on supportive therapies and conditioning regimens. **2023**, 36, 101470 ○
- 6 Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder. 14, ○
- 5 Sex-specific effects of voluntary wheel running on behavior and the gut microbiota-immune-brain axis in mice. **2023**, 100628 ○
- 4 Deep Brain Stimulation of the Medial Forebrain Bundle for Treatment-Resistant Depression: A Systematic Review Focused on the Long-Term Antidepressive Effect. **2023**, ○
- 3 Depression as a cardiovascular disorder: central-autonomic network, brain-heart axis, and vagal perspectives of low mood. 3, ○
- 2 Effect of citicoline and transcranial direct current stimulation on depressive-like behaviors in mice & quot. **2023**, 450, 114495 ○
- 1 TDCS at home for depressive disorders: an updated systematic review and lessons learned from a prematurely terminated randomized controlled pilot study. ○